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 Abstract 
Glycosphingolipids (GSLs) are a large and heterogeneous class of lipids, whose 
function is equally versatile and complex. They consist of a membrane anchor, 
ceramide, and different kinds of sugar head groups. Glucosylceramide (GlcCer) is the 
simplest GSL and serves as a building block for the synthesis of more complex GSLs. 
GlcCer is degraded either in the lysosome by the acid beta-glucosidase GBA1 or by 
the non-lysosomal beta-glucosidase GBA2, which is associated with membranes at 
the Golgi and ER. It is not known whether their distinct localisation points towards a 
different cellular function. Accumulation of GlcCer due to the lack of GBA2 results in 
male infertility, whereas various mutations in the GBA1 gene and loss of GBA1 activity 
cause the lipid-storage disorder Gaucher disease with different clinical subtypes. 
However, no genotype-phenotype correlation has been identified so far. The role of 
GBA2 in Gaucher disease pathology and its relationship to GBA1 is not well 
understood. My results reveal a GBA1-dependent down-regulation of GBA2 activity in 
patients suffering from Gaucher disease. I show that sphingosine, the cytotoxic 
metabolite accumulating in Gaucher cells through the action of GBA2, directly binds to 
GBA2 and inhibits its activity. I propose a negative feed-back loop that inhibits GBA2 
activity in Gaucher cells through the action of sphingosine, preventing its further 
accumulation and cytotoxicity. My findings add a new chapter to the understanding of 
the complex molecular mechanism underlying Gaucher disease and the regulation of 
beta-glucosidase activity in general. 
  
 
 
 Zusammenfassung 
Glycosphingolipide (GSL) stellen eine heterogene Lipidklasse dar, deren Funktion 
gleichermaßen vielseitig und komplex ist. Sie bestehen aus einem Membrananker, 
dem Ceramid, und verschiedenen Zucker-Kopfgruppen. Glucosylceramid (GlcCer) ist 
das einfachste GSL und dient als Baustein für die Synthese von komplexeren GSL. 
Der Abbau von GlcCer findet zum einen durch die saure beta-Glucosidase GBA1 im 
Lysosom statt, und zum anderen durch die nicht-lysosomale beta-Glucosidase GBA2, 
die mit Membranen von Golgi und ER assoziiert ist. GBA1 und GBA2 befinden sich in 
verschiedenen Bereichen der Zelle. Ob ihre jeweilige Lokalisation jedoch auf eine 
unterschiedliche Funktion auf zellulärer Ebene hindeutet, ist nicht bekannt. Die 
Anreicherung von GlcCer im Fall eines Verlusts von GBA2 führt zu männlicher 
Unfruchtbarkeit, wohingegen Mutationen im GBA1-Gen und der damit verbundene 
Verlust der GBA1 Aktivität das Gaucher-Syndrom, eine lysosomale Speicherkrankheit 
mit unterschiedlichen Ausprägungen, verursachen. Bis heute konnte keine Verbindung 
zwischen dem Genotyp und dem daraus resultierenden Phänotyp der Krankheit 
hergeleitet werden. Welche Rolle GBA2 beim Gaucher-Syndrom spielt und wie ihr 
Zusammenspiel mit GBA1 ist, ist nicht bekannt. In meiner Arbeit konnte ich zeigen, 
dass die GBA2 Aktivität in Patienten, die am Gaucher-Syndrom leiden, verringert ist. 
Durch meine Versuche fand ich heraus, dass Sphingosin, ein zytotoxischer Metabolit, 
der sich durch die Aktivität von GBA2 in Gaucher Zellen anreichert, direkt an GBA2 
bindet und die Enzymaktivität inhibiert. Basierend auf diesen Ergebnissen habe ich ein 
Modell entwickelt, in dem eine negative Rückkopplung in Gaucher Zellen durch das 
von GBA2 produzierte Sphingosin die GBA2 direkt hemmt, wodurch die Anreicherung 
von zytotoxischen Mengen an Sphingosin verhindert wird. Erkenntnisse aus meinen 
Studien tragen deshalb zum Verständnis der komplexen Beschaffenheit des Gaucher-
Syndroms und auch zur Regulierung von beta-Glucosidasen im Allgemeinen bei. 
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1 Introduction 
1.1 Glycosphingolipids  
Glycosphingolipids (GSLs) are a large and heterogeneous class of lipids, whose 
function is equally versatile and complex. Present in eukaryotes and some bacteria, 
GSLs consist of a membrane anchor, ceramide, and different kinds of sugar head 
groups attached via an O-glycosidic linkage (Merrill, 2002). To date, more than 60 
different sphingoid bases and more than 300 different sugar chains have been 
identified in the field of GSLs.   
1.1.1 GSL structure and synthesis 
GSL synthesis starts with the condensation of serine and palmitoyl-CoA to 3-
ketosphinganine, catalysed by the enzyme serine palmitoyl transferase (SPT) at the 
cytoplasmic side of the endoplasmic reticulum (ER) (Figure 1) (Braun&Snell, 1968; 
Mandon et al., 1992). In the next NADPH-dependent step, 3-ketosphinganine is 
reduced to sphinganine by 3-ketosphinganine reductase (KSA-reductase, Figure 1) 
(Stoffel et al., 1968) and sphinganine is subsequently acylated to dihydro-ceramide by 
ceramide synthase (CerS) (Rother et al., 1992). Ceramides possess various acyl chain 
lengths and, up to date, six different CerS have been identified (CerS 1-6) 
(Levy&Futerman, 2010). Each CerS shows a specificity for a particular acyl chain 
length used for N-acylation of the sphingoid base (Pewzner-Jung et al., 2006). Thus, 
just like the sphingoid bases, the fatty acids used for acylation of sphinganine can also 
vary in chain length, saturation, and hydroxylation and are mostly cell-type specific 
(Rosenthal, 1987). Therefore, the presence of certain ceramide species depends on 
the activity of a certain CerS. Besides the de novo synthesis of ceramide at the ER, 
ceramide can also be synthesised from sphingosine released from complex GSLs in 
the lysosomes, a mechanism also known as the salvage pathway (Hoekstra&Kok, 
1992; Schwarzmann&Sandhoff, 1990; Tettamanti&Riboni, 1994; van 
Echten&Sandhoff, 1993). In both cases, ceramide synthesis relies on the action of 
CerS (Levy&Futerman, 2010). 
Next, the trans desaturation of dihydro-ceramide at position C4 of the sphingoid base 
is carried out by a pair of desaturases (DES1 and DES2) on the cytoplasmic side of 
the ER, converting the sphinganine part to sphingosine (Figure 1) (Geeraert et al., 
1997). Thus, free sphingosine, which is the common sphingoid backbone found in 
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GSLs, is not produced during GSL synthesis, but can be released from ceramide 
during GSL degradation. Sphingosine is the predominant sphingoid base in animals, 
which was first recognised by German biochemist Johann Thudichum in 1884, who 
described it as a substance “which is of an alkaloidal nature, and […] in 
commemoration of the many enigmas, which it presented to the inquirer” gave it the 
name “sphingosine” after the enigmatic Egyptian Sphinx (Thudichum, 1901). 
Thereafter, thousands of individual sphingolipids were discovered during the following 
century (Carter et al., 1947). Sphingosine is not only a precursor for higher-order 
glycosphingolipids, but also for glycerolipids (Figure 1). As previously mentioned, 
sphingosine is released from GSLs in the lysosome and then transported back to the 
ER, where it can be phosphorylated by sphingosine-1-phosphate (S1P) kinases to 
produce S1P (Spiegel&Milstien, 2003). S1P can be irreversibly cleaved by S1P lyase 
(SGPL1) to produce hexadecenal and phosphoethanolamine (Serra&Saba, 2010), of 
which hexadecenal enters the biosynthesis pathway for glycerolipids (Nakahara et al., 
2012).  
To produce more complex GSLs, ceramide is transported from the cytosolic leaflet of 
the ER membrane to the cytoplasmic side of the trans Golgi by ceramide transfer 
protein (CERT), which extracts ceramide from the ER membrane and targets it to the 
Golgi membrane via phosphatidylinositol-4-phosphate-rich domains (Hanada et al., 
2003). Here, ceramide serves not only as a membrane anchor for more complex GSLs, 
but also as a precursor for sphingomyelin. The latter is synthesised by transfer of 
phosphorylcholine to the 1-hydroxyl group of ceramide in the luminal part of the Golgi 
(Figure 1) (Futerman et al., 1990). Sphingomyelin is present in basically all cell types 
with higher concentrations found in neuronal cells. It is incorporated in the plasma 
membrane and especially abundant in the myelin sheath that surrounds the axon of 
neurons (Ramstedt&Slotte, 2002).   
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Figure 1: Synthesis of glycosphingolipids (GSLs). Early GSL synthesis takes place at the cytosolic 
side of the ER and is continued at both, the cytosolic and luminal side of the Golgi. Glucosylceramide 
(GlcCer) is the main precursor for more complex GSL such as the globosides and gangliosides. The 
single steps of GSL synthesis are described in the text. CoA: Coenzyme A, SPT: Serine palmitoyl 
transferase, KSA-Reductase: 3-ketosphinganine reductase, CerS: Ceramide synthase, DES: 
Desaturase, Sph-kinase: Sphingosine kinase, SGPL1: Sphingosine-1-phosphate lyase, Ethanolamine-
P: Phosphoethanolamine, UDP-glucose: Uridine diphosphate glucose, LacCerS: Lactosylceramide 
synthase, Lac: Lactose, SMS: Sphingomyelin synthase, Gb3-S: Globotriaosylceramide synthase, 
GalNacT: N-Acetylgalactosamine transferase.  
1.1.2 Glucosylceramide: The backbone of numerous glycolipids  
The complex GSL family can be divided into three sub-classes: Cerebrosides, 
gangliosides, and globosides (Figure 1). Cerebrosides are the simplest form and are 
also called monoglycosylceramides because they have either galactose 
(galatosylcerebroside) or glucose (glucosylcerebroside) attached to the 1-hydroxy 
moiety of ceramide. GSLs based on galactosylceramide (GalCer) can be found in 
specialised cells such as neurons, where GalCer, just like sphingomyelin, is part of the 
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myelin sheath around the axon (Simons&van Meer, 1988). Glucosylceramide (GlcCer), 
however, is present in most eukaryotic cells and represents the major building block 
for more complex GSLs. GlcCer is synthesised by GlcCer synthase (GlcCerS), an 
enzyme that catalyses the formation of GlcCer from ceramide and UDP-glucose (Basu 
et al., 1968) at the cytoplasmic side of the cis and medial part of the Golgi (Schweizer 
et al., 1994). GlcCerS is a 38 kDa transmembrane protein that assembles to dimers or 
oligomers with the catalytic site facing the cytoplasm (Marks et al., 1999). 
Subsequently, more complex GSLs are synthesised in the Golgi lumen (Lannert et al., 
1994). Thus, newly synthesised GlcCer has to translocate from the cytoplasmic side 
to the luminal part of the Golgi (Brade et al., 2000). It has been proposed that i) GlcCer 
reaches the lumen by either being transported back to the ER, where it is then flipped 
into the lumen via a rather non-specific phospholipid flippase (Chalat et al., 2012), or 
ii) through a yet unidentified transporter that flips GlcCer to the luminal side directly at 
the Golgi (D'Angelo et al., 2007). However, both mechanisms require the specific 
transport of GlcCer to the location sites of the proposed flippases, action that has been 
shown to rely on FAPP2 (four-phosphate-adaptor protein 2)-mediated transfer 
(D'Angelo et al., 2007).  
Once GlcCer has reached the luminal side of the Golgi, sugar molecules are added 
stepwise to its glucose head group to produce higher-order GSLs. First, 
lactosylceramide synthase (LacCerS) beta links a lactose residue to the C4-hydroxyl 
group of glucose to produce LacCer (Figure 1) (Takizawa et al., 1999). N-
acetylgalacto-saminyl-transferase then adds e.g. an N-acetylneuraminic acid residue 
to LacCer and during the following steps, gangliosides of the a-, b-, and c-series are 
synthesised (Figure 1). The term “gangliosides” generally describes all sialylated GSLs 
and was chosen by the German scientist Ernst Klenk, who isolated them from ganglion 
cells (Klenk, 1951). To date, more than 60 gangliosides are known, which mainly differ 
in the position and number of N-acetylneuraminic acid residues with the a-, b- and c-
series having one, two, or three residues attached to the galactose residue of LacCer, 
respectively. GM3 (trisialotetrahexosylganglioside), for example, represents the 
simplest ganglioside of the a-series, which contains only one sialic acid residue. Here, 
“G” stands for “ganglioside”, “M” stands for one sialic acid residue (mono), and the 
number refers to the migration of GM3 on thin layer chromatography (TLC) (e.g. GM3 
> GM2 > GM1) (according to the Svennerholm system, IUPAC-IUB Joint Commission 
on Biochemical Nomenclature 1997).  Lastly, globosides contain more than one sugar 
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as a head group of ceramide and represent the major glycolipid in the human 
erythrocyte membrane (Klenk&Lauenstein, 1952). The sugars are a mix of N-
acetylgalactosamine, D-glucose, and D-galactose. 
1.1.3 Intracellular sorting, transport, and function of GSLs 
After their synthesis is completed, GSLs are shuttled to the plasma membrane by 
vesicles that bud off from the Golgi membrane and fuse with the plasma membrane 
(Miller-Prodraza&Fishman, 1984). Via this process, the sugar moieties project into the 
extracellular space, whereas the ceramide part of GSLs is embedded into the outer 
leaflet of the plasma membrane (Varki, 1993). However, Metz and Radin discovered a 
small, soluble lipid transfer protein in 1980, which selectively transfers GSLs between 
intracellular membranes (Lin et al., 2000; Metz&Radin, 1980). Glycolipid transfer 
protein (GLTP) senses the carbohydrate head groups of GSLs on the membrane and 
forms a soluble complex, while the hydrophobic part of the lipid is incorporated into a 
cleft-like GLTP gate. GLTP transfers both, sphingoid- and glycerol-based glycolipids, 
but requires the first sugar head group to be beta-linked to the lipid part of the molecule 
(Brown&Mattjus, 2007). When GLTP is knocked-down, GlcCer transport to the plasma 
membrane is reduced by 50%, whereas GLTP over-expression leads to a two-fold 
increase in GlcCer transport (Halter et al., 2007). Thus, GLTP transports GSLs, in 
particular GlcCer, to the plasma membrane in a vesicle-independent manner (Halter 
et al., 2007; Warnock et al., 1994). This mechanism, however, requires a yet 
unidentified flippase or a transporter to actively translocate GlcCer (or GSLs) from the 
cytoplasmic side of the plasma membrane to the outer leaflet of the membrane. 
Besides GLTP, FAPP2 is also known to transport GlcCer from the Golgi network to the 
plasma membrane (D'Angelo et al., 2007). Residues important for glycolipid transfer 
activity are conserved in FAPP2 and GLTP (Godi et al., 2004). Thus, GlcCer can either 
be transported to the plasma membrane through the vesicular pathway or by a 
cytosolic pathway involving glycolipid-transfer proteins like GLTP and FAPP2 (Sasaki, 
1990; Warnock et al., 1994).  
Once they have settled in the outer leaflet of the plasma membrane, GSLs exert a 
broad variety of functions. GSLs make up less than 5% of total membrane lipids in the 
plasma membrane of e.g. erythrocytes, but comprise more than 20% in the myelin 
sheath of neurons (Sako et al., 1987). Here, GSLs are not homogeneously distributed 
but rather cluster in so-called “lipid rafts”. The structure of lipid rafts is a topic of ongoing 
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debate, but it is widely recognised that they consist of sphingolipids like GSLs and SM, 
cholesterol, and certain proteins. GSLs can interact with each other side-by-side (cis 
interaction) to form clusters within one membrane leaflet, but they can also interact 
through their sugar head groups when facing another membrane (trans interaction) 
(Lofgren&Pascher, 1977). Cis interaction is also thought to lead to the formation of lipid 
raft-independent domains, so-called glycosphingolipid-enriched microdomains 
(GEMs), which assemble in absence of cholesterol and SM. GEMs are involved in cell 
adhesion and signal transduction (Iwabuchi et al., 1998), which is why GEMs have also 
been termed glycosynapses (Hakomori Si, 2002). Lectins, which are carbohydrate-
binding proteins, recognise and bind to certain GSL structures, a process involved in 
cell adhesion (Varki, 1994). Furthermore, GSLs have been shown to function as 
receptors for microbial toxins and bacteria (Hakomori, 1981), where Jacewicz et al. 
showed that the globoside Gb3 is a receptor for shigatoxin on HeLa cells (Jacewicz et 
al., 1986), and the ganglioside GM3 has been shown to serve as a binding site for 
choleratoxin (Kuziemko et al., 1996). Additionally, many different GSLs are known to 
serve as infection sites for numerous bacteria (Karlsson, 1989). Besides serving as 
receptors, GSLs can also modulate the function of other receptor proteins (Sorice et 
al., 2001). GSLs, and gangliosides in particular, have been shown to interact with 
growth factor receptors, which in turn modulates cell growth, although the underlying 
mechanisms are not well understood. For example, N-glycosylation of the epidermal 
growth factor receptor keeps it in a certain confirmation that is essential for its 
interaction with GM3, which, in turn, is crucial for GM3-mediated suppression of the 
receptor (Wang et al., 2001). Thus, GSLs are involved in many, and most likely yet 
unidentified, mechanisms.         
1.1.4 GSL degradation 
GSL degradation mainly takes place in the endosomes and lysosomes of the cell but, 
in one case, can also occur at the cytosolic side of the cis Golgi and the ER. Sequential 
hydrolysis by lysosomal glycosidases releases sugars, sialic acids, fatty acids, and 
sphingoid bases, which are either further degraded or re-used within the salvage 
pathway (Schwarzmann&Sandhoff, 1990). Foreign and cellular cargo reaches the 
lysosome via endocytosis, phagocytosis, or direct transport (Figure 2). During 
endocytosis, cargo is internalised via a clathrin-dependent or –indepent mechanism 
(Mayor&Pagano, 2007) (Figure 2). In a first step, parts of the plasma membrane bud 
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off into the cytosol and then enter the endocytic vesicular pathway (Figure 2). Here, 
GSLs that were previously facing the extracellular space are now present in the luminal 
part of the endocytic vesicle (Figure 2). In the following steps, vesicles fuse with early 
endosomes and become intra-endosomal vesicles with the GSLs sitting in the outer 
membrane leaflet facing the lumen of the endosome (Figure 2). GSL digestion then 
starts during acidification of the early endosomes, which favours the activity of certain 
hydrolases (Maxfield&Yamashiro, 1987), whilst early endosomes become late 
endosomes. At this point, acid sphingomyelinase (ASM) releases e.g. ceramide from 
sphingomyelin (Schulze et al., 2009). In a final step, the remaining GSLs reach the 
lysosome for degradation. Since the lysosome is full of hydrolytic enzymes, its inner 
membrane (perimeter membrane) is protected from degradation by a thick glycocalix 
made out of the carbohydrate residues of integral and membrane-associated proteins 
(Peters&von Figura, 1994) (Figure 2). Thus, enzymes sitting in the perimeter 
membrane do not have access to lipids inside the lysosome. According to the current 
view, GSLs from former plasma membrane structures reach the lysosome as intra-
lysosomal vesicles (Furst&Sandhoff, 1992), which also provide the platform for further 
degradation steps (Figure 2). With this orientation, GSLs are accessible to hydrolytic 
proteins like acid beta-glucosidase (GBA1) within the lumen of the lysosome.  
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Figure 2: GSLs reach the lysosome via endocytosis. Parts of the plasma membrane bud off into the 
cytosol and then enter the endocytic vesicular pathway. Endocytic vesicles fuse with and enter early 
endosomes, which become late endosomes due to acidification. Endocytic vesicles reach the lysosome 
as intra-lysosomal vesicles, which provide a platform for hydrolases such as GBA1 (acid beta-
glucosidase), which are involved in the step-wise break down of all kinds of GSLs.  
1.1.4.1 Beta-glucosidases 
Around 90% of mammalian GSLs are based on GlcCer (Lingwood, 2011). GlcCer is 
degraded by beta-glucosidases, which cleave the beta-glucosidic linkage of GlcCer to 
release D-glucose and ceramide (Brady et al., 1965). Degradation of GlcCer can take 
place in the lysosome by the acid beta-glucosidase GBA1, by the non-lysosomal beta-
glucosidase GBA2, or by the cytosolic beta-glucosidase GBA3. In this study, GBA1 
and GBA2 were examined in more detail.   
1.1.4.1.1 GBA1 
GBA1 is a peripheral membrane protein in the lysosome encoded by the GBA1 gene 
(NM_000157, EC 3.2.1.45) (Figure 2, Figure 4). GBA1 is synthesised at the rough ER 
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and then enters the ER lumen for N-linked glycosylation at four asparagine residues 
(Berg-Fussman et al., 1993). After protein folding, GBA1 binds to the lysosomal integral 
protein LIMP-2, which subsequently targets GBA1 to the lysosome (Reczek et al., 
2007). From here, the GBA1/LIMP-2 complex is shuttled to the Golgi, where GBA1 is 
further glycosylated. The molecular weight of GBA1 varies from 55 to 69 kDa, 
depending on the different states of glycosylation: GBA1 is synthesised as a 55 kDa 
polypeptide. By addition of high mannose-type oligosaccharide side chains in the 
Golgi, the molecular weight increases to 64 kDa and by addition of sialic acid residues, 
the protein finally reaches 69 kDa (Bergmann&Grabowski, 1989). Posttranslational 
modification and binding to LIMP-2 have both been proposed to be involved in targeting 
GBA1 to the lysosome (Van Weely et al., 1990) and keeping it stable within the 
lysosomal environment (Bergmann&Grabowski, 1989). Thus, the glycosylation state 
of GBA1 reflects its maturation, but not its potential activity (Van Weely et al., 1990). 
The activity of GBA1 depends on several factors with one of them being saposin C. 
The mechanism by which saposin C promotes GBA1 activity is not fully known yet, but 
a model proposes that the 9 kDa protein associates with both, GBA1 and the 
membrane, lifting GlcCer out of the membrane and making it accessible for GBA1 
(Alattia et al., 2006). Absence of saposin C in humans impairs the function of GBA1 
and leads to severe accumulation of the substrate, GlcCer, in the lysosome (Scriver, 
1995). The enzyme itself possesses three domains, which are involved in substrate 
binding and hydrolysis: i) a catalytic site, which senses the beta-glucoside moiety 
(Grabowski et al., 1984), ii) an aglycon-binding site with specificity for acyl moieties, 
and iii) a domain that interacts with sphingosine derivatives (Grabowski et al., 1986). 
The most prominent inhibitor for GBA1 is conduritol B epoxide (CBE) (Grabowski et 
al., 1986). It binds covalently and, thus, irreversibly to the catalytic site of GBA1 and 
has been used solve the structure of GBA1 (Premkumar et al., 2005).  
1.1.4.1.2 Gaucher disease – a lysosomal storage disorder 
Mutations in the GBA1 gene cause the most common lysosomal storage disorder in 
humans: Gaucher disease (Figure 3). The disease is named after Philippe Gaucher, 
who first described it in his doctoral thesis in 1882. The storage of non-defined 
molecules in tissues from Gaucher patients was recognised in 1907, whereas 17 years 
later, the accumulating material was characterised as cerebroside in accordance with 
the GSLs described earlier by Thudichum (Thudichum, 1901). The accumulating lipid 
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in Gaucher patients was first described as GlcCer in 1934 and, later on, located to the 
lysosome after discovery of the organelle by De Duve in 1955 (De Duve et al., 1955). 
Ten years later, Brady and co-workers described the enzyme deficiency and, thus, the 
molecular basis for the disease (Brady et al., 1965). Since then, around 200 different 
mutations in the GBA1 gene have been described, which lead to loss of function of the 
enzyme and, thereby, to the accumulation of GlcCer in the lysosome (Grace et al., 
1994; Scriver, 1995). Gaucher disease is an inherited autosomal recessive disorder 
with the most dramatic effect seen in tissue macrophages, which degrade red and 
white blood cells in the spleen (Figure 3a) (Pennelli et al., 1969). Macrophages lacking 
active GBA1 cannot break down the huge amount of membrane mass that they are 
facing and, thus, turn into “Gaucher cells”, a pathologic hallmark of Gaucher disease. 
Presence of Gaucher cells in tissues like liver and spleen results in an up to 25-fold 
increase in organ size (organomegaly), a common symptom seen in Gaucher disease 
(Figure 3b) (Cox, 2001; Scriver, 1995).  
Symptoms caused by malfunction of GBA1 can have a very early onset in life, but 
might also never manifest (Figure 3d). Due to its heterogeneous symptoms and 
phenotypes (Figure 3c), Gaucher disease has been classified into three major 
subtypes, namely type I, II, and III (Figure 3b, d). Type I Gaucher is the most common 
form of the disease, with patients being either not affected or showing symptoms like 
organomegaly of liver and spleen or defects in lung and bone marrow (Zimran et al., 
1991). Type II patients represent the acute infantile neuronopathic form characterised 
by severe neurological defects and an early onset of the disease (Scriver, 1995). 
Patients suffering from type II Gaucher usually die within the first 2-3 years of life 
(Figure 3b, d) (Brady et al., 1993). Type III, the sub-acute form of the disease, involves 
symptoms of both, type I and II Gaucher disease, and, thus, represent an intermediate 
type (Erikson et al., 1997). It has been assumed that residual GBA1 activity might help 
to predict the severity of Gaucher disease (Scriver, 1995), but the progress of the 
disease even differs between patients carrying the same mutation (Meivar-Levy et al., 
1994). Thus, no genotype-phenotype correlation has been established so far.   
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Figure 3: Gaucher disease. (a) GBA1 activity is lost in cells from Gaucher patients due to mutations in 
the human GBA1 gene. In turn, the substrate of GBA1, GlcCer, accumulates in the lysosome. This effect 
is most dramatic in tissue macrophages, which break down e.g. red and white blood cells in the spleen. 
(b) Symptoms of Gaucher disease. Patients suffer from organomegaly of e.g. liver and spleen but, for 
yet unknown reasons, can also lead to severe neurological disorders. Top picture: 14-year old girl 
suffering from type I Gaucher disease and enlargement of liver and spleen, examined by Dr. R. Brady, 
National Institute of Neurological Disorders and Stroke. Bottom picture: Stella Grace, a girl diagnosed 
with type II Gaucher disease at 5 months of age suffering from severe neurological defects. (c) In 
general, symptoms have been described in brain, lung, liver, spleen, and in bone marrow. (d) Gaucher 
disease has been classified into three major subtypes: Type I, II, and III. Type I patients mainly show 
organ enlargement (also see (b)), whereas only type II and III patients suffer from neurological 
symptoms (also see (b)). Life expectancy, however, decreases with the severity and onset of the 
neurological defects.  
It is not understood, how accumulation of GlcCer in the lysosomes causes cellular 
dysfunction. In particular, the fate of accumulating GlcCer has been a matter of debate 
during the past decades. It has been suggested that GlcCer might leave the lysosome 
and, thus, interfere with signalling pathways outside the lysosomes. Several papers 
have been published showing changes in phospholipid metabolism in neuronal 
Gaucher models (Bodennec et al., 2002) as well as in a CBE-induced macrophage 
model (Trajkovic-Bodennec et al., 2004). Furthermore, calcium homeostasis was 
altered in a neuronal Gaucher model (Korkotian et al., 1999) and in brain from type II 
Gaucher patients (Pelled et al., 2005). Both mechanisms, however, are associated with 
the ER, suggesting that GlcCer might recur at the ER. Furthermore, it remains unclear 
whether macrophage dysfunction underlies the different symptoms. Most likely, 
additional but yet unknown factors are involved in determining the fate of Gaucher 
patients (Vardi et al., 2016). 
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1.1.4.1.3 Enzyme replacement therapy (ERT) 
Since Gaucher disease is a genetically inherited disorder, it cannot be cured (yet). Still, 
two different treatment strategies were developed during the past decades to reduce 
accumulation of GlcCer and diminish the symptoms. The enzyme replacement therapy 
(ERT), involves an active, recombinant form of GBA1 (imiglucerase)  
(Grabowski&Hopkin, 2003). Brady and Pentchev initially isolated GBA1 from human 
placenta and managed to isolate 9 mg active GBA1 within one year (Pentchev et al., 
1973). Strikingly, intravenous administration of human placental GBA1 reduced the 
GlcCer accumulation in two Gaucher patients by 26% after 24 h (Brady et al., 1974). 
Today, mutated GBA1 in Gaucher patients is substituted by injection of recombinant 
GBA1 (imiglucerase) (Weinreb et al., 2002). Cerezyme (Genzyme Corporation, 
Cambridge, MA, USA) is produced and extracted from CHO cells heterologously 
expressing human GBA1 (Genzyme, Summary of Product Characteristics). Normally, 
bacteria are used for large-scale expression of proteins, but they are known to be 
incapable or at least less efficient in synthesising glycosylated proteins (Wacker et al., 
2002). In 1970, work was published claiming that most (if not all) lysosomal proteins 
are glycoproteins (Goldstone&Koenig, 1973) and today it is known that acidic 
hydrolases like GBA1 reach the lysosome via a mannose 6-phosphate receptor-
mediated pathway (Coutinho et al., 2012). In 1978, Stahl et al. found out that 
macrophages also bear a lectin moiety on their surface, which binds to terminal 
mannose residues with high affinity (Stahl et al., 1978). Thus, the mannose-type 
oligosaccharide side chains of GBA1 are used to target recombinant GBA1 to 
macrophages, from where the enzyme is then shuttled to the lysosome 
(Bergmann&Grabowski, 1989). Nevertheless, ERT requires the lifelong administration 
of Cerezyme, which costs around 200,000 $ per patient per year (Coutinho et al., 
2016). Furthermore, recombinant enzymes do not cross the blood-brain barrier, 
rendering the treatment of type II Gaucher disease impossible. Thus, Cerezyme and 
ERT are used to treat type I and III Gaucher patients, reversing some of the symptoms, 
e.g. organomegaly of liver and spleen (Genzyme Corporation, Cambridge, MA, USA). 
Cerezyme was approved for use in the United States in 1994 and, later on, also 
approved in Europe in 1997 (Starzyk et al., 2007).  
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1.1.4.1.4 Substrate reduction therapy (SRT) 
Twenty years ago, Radin proposed the substrate reduction therapy (SRT) using a drug 
that specifically inhibits GlcCerS to prevent the accumulation of GlcCer in Gaucher 
cells (Radin, 1996). At the same time, it was shown that the imino sugar N-butyl-
deoxynojirimycin (NB-DNJ) is a potent inhibitor for GlcCerS in the low micro molar 
range (Platt et al., 1994). Inhibitors based on imino sugars structurally mimic the sugar 
head group of natural substrates, with the ring oxygen atom replaced by a nitrogen 
atom. This structure makes imino sugars potent inhibitors for hydrolases that recognise 
monosaccharide head groups and glucosyltransferases like GlcCerS that transfer 
single sugars to lipid backbones (Dwek et al., 2002). NB-DNJ was first studied in a 
mouse model in 1994 (Yamanaka et al., 1994) and then tested in a clinical study in 
1998 in type I Gaucher patients (Aerts et al., 2006; Cox, 2001). Application of 100 mg 
NB-DNJ three times per day over a time period of one year significantly decreased the 
GlcCer accumulation in 28 adult type I Gaucher patients and improved liver and spleen 
size (Aerts et al., 2006). NB-DNJ was also tested in type II and III Gaucher patients, 
but did not improve neurological symptoms in these patients (Schiffmann et al., 2008). 
Today, NB-DNJ is sold by Actelion Pharmaceuticals (Basel, Switzerland) under the 
trade name Zavesca.  
1.1.4.1.5 GBA1-deficient mouse models 
Several GBA1-deficient mouse models are currently available, which are all used to 
study the underlying mechanisms in Gaucher disease. Chemical inhibition of GBA1 in 
mice has been shown to completely block GBA1 activity, resulting in accumulation of 
GlcCer in spleen, liver, and brain (Kanfer et al., 1975), accompanied by severe 
neurological defects (Stephens et al., 1978; Xu et al., 2008). The first genetic mouse 
model of Gaucher disease was generated by Tybulewicz et al., who created a null 
mutation, which resulted in a residual GBA1 activity of less than 4% (Tybulewicz et al., 
1992). Sidransky et al. showed that these mice mimicked the symptoms seen in type II 
Gaucher patients, while also showing extremely decreased longevity due to trans-
epidermal water loss caused by a skin barrier defect (Sidransky et al., 1992). To 
circumvent this problem, conditional GBA1-deficient mice have been generated. 
Enquist et al. expressed floxed GBA1 in an Mx1-Cre-loxP system, which allowed the 
Cre-mediated deletion of GBA1 upon treatment with polyinosinic-polycytidylic acid, 
which activates the Mx1 promotor (Enquist et al., 2006). The latter is administered after 
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birth so that the mice first develop normally before GBA1 is deleted. Overall, GBA1-
deficient mice resemble the phenotypes seen in Gaucher disease patients, which 
makes them an ideal model to investigate this disorder. 
1.1.4.1.6 GBA2 
Besides GBA1, non-lysosomal beta-glucosidase GBA2 also cleaves GlcCer to D-
glucose and ceramide (NM_020944.2, EC 3.2.1.45). GBA2 was first purified from 
human liver (Matern et al., 1997) and then cloned in 2001 (Matern et al., 2001). The 
enzyme is ubiquitously expressed, albeit at different levels (Matern et al., 2001; van 
Weely et al., 1993; Yildiz et al., 2006). GBA2 was first described as a beta-glucosidase 
with properties that differed from lysosomal GBA1 (Matern et al., 1992), that is 
insensitive to CBE, and is present in tissues such as brain and spleen (van Weely et 
al., 1993). GBA2 was characterised as a membrane-bound enzyme that is not located 
in the lysosomes, making it a candidate for extra-lysosomal GlcCer degradation. For a 
long time, GBA2 was thought to be a single pass transmembrane protein localised at 
the ER (Matern et al., 1992; Matern et al., 1997) or at the plasma membrane (Boot et 
al., 2007). We could recently show that GBA2 is not a transmembrane protein, but 
rather a protein tightly associated with membranes (Figure 4) (Körschen et al., 2013). 
Here, we could recover GBA2 in both, the soluble and membrane fraction of hypotonic 
protein lysates after ultracentrifugation, whereas hypotonic washes almost fully 
solubilised GBA2 that was attached to the membrane, proving that GBA2 is not a 
transmembrane protein. Furthermore, Boot et al. found that endogenous GBA2 was 
capable of cleaving the artificial substrate 4-methyl-umbelliferyl beta-D-
glucopyranoside (4-MUG) supplied in the cell culture medium, which is why they 
concluded that the catalytic side of GBA2 must be in contact with the extracellular 
space (Boot et al., 2007). In contrast to that study, we could show that both ends of the 
enzyme were directly accessible from the cytosol, arguing against the finding that the 
catalytic side of GBA2 faces the extracellular space. Immunocytochemical stainings of 
heterologously expressed GBA2 and co-staining with organelle markers revealed that 
GBA2 localises to membranes at the cytosolic side of the cis Golgi and the ER 
(Körschen et al., 2013). Thus, GBA2 is localised in close proximity to GlcCerS and the 
synthesis pathway of its substrate, GlcCer (Schweizer et al., 1994).  
In accordance with previous studies, our data showed that GBA2 is active at a less 
acidic pH compared to GBA1 and that it loses its activity in presence of detergents 
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(Körschen et al., 2013; Matern et al., 1997; van Weely et al., 1993). Furthermore, 
Matern et al. showed that GBA2 requires phospholipids to be active (Matern et al., 
1997). In a later study, Boot et al. confirmed that the lipid environment is crucial for 
GBA2 activity since the enzyme loses its activity upon membrane solubilisation (Boot 
et al., 2007). Our studies revealed a similar scenario where GBA2 lost its activity in 
absence of membranes, but re-gained its activity in the presence of pure 
phosphatidylcholine liposomes (Körschen et al., 2013).   
Besides their substrate specificity for GlcCer and artificial 4-MUG, GBA1 and GBA2 do 
not share any structural or sequence homology and clearly do not originate from the 
same ancestral gene. This is also reflected in several studies analysing the structurally 
different inhibitors for both enzymes. GBA1 shows maximal activity in presence of 
detergents, whereas GBA2 loses its activity, when its membrane surrounding is lost 
(Grabowski et al., 1986; van Weely et al., 1993). Nevertheless, GBA1 still exerts some 
remaining activity even under detergent-free conditions (Overkleeft et al., 1998; van 
Weely et al., 1993). Thus, the GBA2 activity has been determined in presence of CBE, 
the specific blocker for GBA1, in the past, to analyse the GBA2 activity independent 
from GBA1 (Grabowski et al., 1986). Since then, GBA2 has been described as the 
beta-glucosidase activity insensitive to up to 2.5 mM CBE under detergent-free 
conditions (Boot et al., 2007; Overkleeft et al., 1998). For a long time, CBE was thought 
to have no effect on the activity of GBA2, whereas Ridley et al. recently showed that 
CBE inhibits GBA2 in a concentration-dependent manner (Ridley et al., 2013). They 
determined the inhibition constant (Ki) of CBE towards both, GBA1 and GBA2, where 
the value for GBA2 was significantly higher, but still in the lower micro molar range 
(Ridley et al., 2013). Vice versa, GBA2, but not GBA1, is sensitive to the imino sugar 
NB-DNJ, the inhibitor for GlcCerS (Dwek et al., 2002; Ridley et al., 2013). We analysed 
the dose-response relationship of NB-DNJ and GBA2 in hypotonic tissue lysates from 
mouse liver, brain, and testis, demonstrating IC50 values in the low nanomolar range 
(20.9 ± 1.3 nM, 18.2 ± 0.3 nM, and 19.2 ± 0.4 nM, respectively) (Körschen et al., 2013). 
A daily dose of three times 100 mg of NB-DNJ/Zavesca during SRT to block GlcCerS, 
which results in low micromolar concentrations in blood plasma, prevents the 
accumulation of GlcCer (Aerts et al., 2006). The IC50 of NB-DNJ for GlcCerS is around 
50 µM, which should partially inhibit GlcCerS to reduce the amount of GlcCer 
produced, but should still render it active enough to synthesise some GlcCer to 
maintain necessary GSL levels (Wennekes et al., 2010). On the other hand, recalling 
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the IC50 values of NB-DNJ for GBA2, treatment with NB-DNJ should completely inhibit 
GBA2 in Gaucher patients.   
1.1.4.1.7 GBA2-associated diseases 
For GBA2, no disease has been associated to the loss of GBA2 in humans so far. 
During the past few years, mutations in the GBA2 gene have been reported in patients 
with hereditary spastic paraplegia or autosomal-recessive cerebellar ataxia with 
spasticity (Citterio et al., 2014; Hammer et al., 2013; Martin et al., 2013; Votsi et al., 
2014). Here, homozygous mutations in GBA2 were found in affected patients, whereas 
additional but heterozygous mutations were also present in unaffected family members 
(Votsi et al., 2014). The group around van der Spoel recently analysed the GBA2 
activity of the mutants found in those patients and showed that they were all inactive, 
suggesting that loss of GBA2 activity might indeed contribute to the symptoms of the 
reported diseases (Sultana et al., 2015). These findings are in line with data published 
by Martin et al., who knocked down GBA2 in zebrafish, resulting in defects of motor 
behaviour and axonal outgrowth of motor neurons, conditions that could be reversed 
with human wild-type mRNA, but not with RNA containing the mutated GBA2 sequence 
(Martin et al., 2013). Indeed, it had already been shown that the GBA2 activity 
increases during neuronal differentiation, suggesting an important role for GBA2 during 
neuron development (Aureli et al., 2012). Thus, even though GlcCer accumulates in 
both, GBA1- and GBA2-deficient models, the phenotypic outcome is completely 
different.    
During the past few years, work from different groups has suggested that GBA2 
contributes to the pathology of Gaucher disease. It has been proposed that GBA2 
protein and mRNA expression in fibroblasts obtained from GBA1-deficient mice is 
increased (Yildiz et al., 2013). Furthermore, Burke et al. showed that the GBA2 activity 
is higher in GBA1-deficient mice and leucocytes from Gaucher patients compared to 
controls, supporting the data generated by Yildiz et al. (Burke et al., 2013). In contrast 
to these findings, we have demonstrated that the GBA2 activity is significantly reduced 
in embryonal fibroblasts from GBA1-deficient mice and dermal fibroblasts obtained 
from a type II Gaucher patient (Körschen et al., 2013). One year later, Mistry et al. 
proposed that in cells from Gaucher patients, both GlcCer and GlcSph spill-over from 
the lysosomes into the cytoplasm, thereby becoming a substrate for GBA2 (Mistry et 
al., 2014). In turn, GBA2 not only hydrolyses GlcCer to glucose and ceramide, but also 
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GlcSph to glucose and sphingosine (Mistry et al., 2014). Ceramide can be further 
broken down to sphingosine and a fatty acid through the action of the neutral 
ceramidase (Mistry et al., 2014). The net result is an accumulation of sphingosine in 
the cell. It has been proposed that sphingosine is the cytotoxic metabolite that causes 
some of the defects associated with Gaucher pathophysiology (Mistry et al., 2014). In 
fact, deletion of GBA2 rescued some of the defects associated with Gaucher 
pathophysiology by reducing the accumulation of sphingosine (Mistry et al., 2014).  
1.1.4.1.8 GBA2-deficient mouse model 
In 2006, the first GBA2-deficient mouse model was published, which showed 
significant accumulation of GlcCer in tissues with high GBA2 expression like brain, 
liver, and testis (Yildiz et al., 2006). Non-lysosomal accumulation of GlcCer mainly 
resulted in impaired male fertility (Yildiz et al., 2006) and delayed liver regeneration 
after partial hepatectomy (Gonzalez-Carmona et al., 2012). Previous to the generation 
of GBA2-deficient mice by Yildiz et al., pathology arising from the loss of active GBA2 
has only been reported by studies applying pharmacology. In the past, van der Spoel 
et al. have shown that a final blood serum concentration of 57 µM NB-DNJ (Platt et al., 
1997) caused impairment of spermatogenesis in male mice after administration for at 
least three weeks, an effect that was reversible when the treatment was stopped (van 
der Spoel et al., 2002). Thus, pharmacologic block of GBA2 resulted in the same 
phenotype as in GBA2-deficient male mice (Yildiz et al., 2006).  
Interestingly, two men affected with Hereditary Spastic Paraplegia carrying mutations 
in the GBA2 gene showed a bilateral testicular hypotrophy with their sperm displaying 
severe head abnormalities (Martin et al., 2013). However, other reports identified a 
patient carrying a homozygous nonsense mutations in the GBA2 gene, who was the 
father of three children (Hammer et al., 2013). Furthermore, spermatogenesis 
remained unchanged in monkeys treated with NB-DNJ (van Weely et al., 1993) and 
healthy control patients, who orally took NB-DNJ/Zavesca for 6 weeks (Amory et al., 
2007). Of note, 6 weeks equal 42 days of Zavesca uptake, whereas one full cycle of 
spermatogenesis in humans takes around 64 days to be completed (Clermont, 1972). 
Thus, the duration of the treatment might not have been long enough to allow a valid 
conclusion. However, we could recently show that accumulation of GlcCer alters 
cytoskeletal dynamics by augmenting actin polymerisation and promoting microtubule 
persistence in dermal fibroblasts and Sertoli cells from GBA2-deficient mice, which 
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leads to severe morphological defects during sperm development resulting in male 
infertility (Raju et al., 2015).  
 
Figure 4: Beta-glucosidases. GBA1 is a soluble enzyme located inside the lysosome, whereas GBA2 
is associated with membranes at the cytosolic side of the cis Golgi and the ER. GBA3 is located in the 
cytosol. GBA1: Acid beta-glucosidase, GBA2: Non-lysosomal beta-glucosidase, GBA3: Cytosolic beta-
glucosidase. 
1.2 Aim of the thesis 
Although the non-lysosomal beta-glucosidase GBA2 has been well characterised 
during the past three decades, little is known about its interplay with GBA1 in controlling 
GlcCer homeostasis. We have shown that GBA2 activity is reduced in the absence of 
GBA1 (Körschen et al., 2013), whereas others have proposed the opposite effect 
(Burke et al., 2013; Mistry et al., 2014; Yildiz et al., 2013). Furthermore, the subcellular 
mechanisms causing the manifold phenotypes of Gaucher disease are not well 
understood. Thus, the aim of my PhD thesis is to investigate the molecular 
mechanisms underlying the regulation of GBA2 using Gaucher disease as a 
physiologically relevant model system.   
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2 Material and Methods 
2.1 Material 
Chemicals were purchased in p.A. quality from the following companies: AppliChem 
(Darmstadt), BioRad (Munich), Eppendorf (Hamburg), GE Healthcare Life Sciences 
(Munich), Invitrogen (Karlsruhe), Merck (Darmstadt), Nioline (London, UK), Pierce 
(Illinois, USA), Polysciences (Pennsylvania, USA), Qiagen (Hilden), Roth (Karlsruhe), 
Sigma (Steinheim), and Thermo Scientific (Waltham,USA). Enzymes and 
corresponding buffers were purchased from New England Biolabs (Frankfurt), 
Novagen (Darmstadt), and Roche (Mannheim). Oligonucleotides were purchased from 
Eurofins MWG Operon (Ebersberg). For the cultivation of bacterial cultures, media 
purchased from Roth (Karlsruhe) were used. Chemicals for use in mammalian cell 
culture were purchased from Invitrogen (Karlsruhe). Mammalian cell lines were 
purchased from the Coriell Institute (New Jersey, USA), the TeleThon Institutes (Italy), 
Horizon (Cambridge, UK), and ATCC (Virginia, USA). Cryo tubes were purchased from 
Greiner Bio-One (Kremsmünster, Österreich). Primary and secondary antibodies were 
purchased from Roche (Mannheim), Sigma (Steinheim), Novagen (Darmstadt), 
Millipore (Schwalbach), Abcam (Cambridge, UK), SantaCruz Biotechnology 
(Heidelberg), BD Transduction Laboratories (New Jersey, USA), LI-COR Biosciences 
(Nebraka, USA). Fluorescent alkynes were purchased from Dyomics (Jena). PVDF‐
membrane Immobilon P was purchased from Millipore (Schwalbach). Lipids were 
purchased from Avanti Polar Lipids (Alabama, USA), Sigma (Steinheim), and Matreya 
LLC (Pennsylvania, USA). Glass wool was purchased from Macherey Nagel (Düren).  
  
All solutions were prepared using double‐distilled water. If necessary, solutions were 
sterilised by autoclavation (20 min, 121 °C). 
2.2 Escherichia coli culture 
2.2.1 Bacterial strains and vectors 
The Escherichia coli (E.coli) strain XL1-Blue (Bullock 1987, Stratagene, La Jolla, USA) 
was used to amplify plasmid DNA. The E.coli strain BL21 Codon Plus (DE3) RIPL 
(Jerpseth 1998, Agilent Technologies, Santa Clara, USA) was used for expression of 
pET21-mGBA2-His or pET21-hGLTP-His.  
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2.2.2 E.coli culture medium 
For the preparation of LB-agar dishes, 15 g/l agar (Sigma) was added to LB-medium 
(Table 1). Both, medium and the medium-agar suspension, were autoclaved for 20 min 
at 121 °C and stored at RT. The medium-agar suspension was cooled down to around 
50 °C and, if needed, antibiotics were added to the medium to a final concentration of 
100 µg/ml (ampicillin) or 30 µg/ml (kanamycin), before pouring it into sterile agar 
dishes. Medium was stored at RT, agar plates at 4 °C.  
Table 1: E.coli culture medium 
LB (lysogeny broth) 
medium (Roth) 
10 g/l Tryptone 
5 g/l Yeast extract 
5 g/l NaCl 
pH 7.0 ± 0.2 
 
2.2.3 Generation of competent E.coli cells 
Competent E.coli cells were generated according to a modified protocol based on the 
CaCl2 method (Mandel&Higa, 1970). The cells were cultured in 50 ml LB medium at 
37 °C on a shaker until an optical density (OD) of 0.4 was reached, representing a cell 
number of approximately 2x108 cells/ml. The OD was measured at 600 nm (OD600). 
The culture was chilled on ice for 30 min and subsequently centrifuged for 10 min at 
5,000 x g and 4 °C. The pellet was re-suspended in 1 ml cold 0.1 M CaCl2 solution and 
brought to a final volume of 25 ml. After incubation on ice for 20 min, the cells were 
centrifuged again for 10 min at 5,000 x g and 4 °C, re-suspended in 1 ml cold 0.1 M 
CaCl2 solution containing 25% glycerin, and brought to a final volume of 5 ml. 
Subsequently, the cells were incubated on ice for 2 h 
 before aliquots were prepared and stored at -80 °C for further use.   
2.2.4 Retransformation  
100 µl of competent E.coli cells (BL21 Codon Plus (DE3) RIPL, Stratagene) was 
thawed on ice and 50 ng DNA was added together with 5 µl 10x CM (Table 2) in a total 
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volume of 50 µl followed by incubation on ice for 20 min. Bacteria were incubated for 
1 min at 42 °C, cooled down on ice for 10 min, and 200 µl LB medium was added. 
Bacteria were grown for 30 min at 37 °C in a shaking incubator. Afterwards, 100 µl of 
the suspension was streaked out on a LB plate and incubated over night at 37 °C.  
Table 2: CM solution for bacteria retransformation 
10x CM 
100 mM CaCl2 
400 mM MgCl2 
 
2.2.5 Protein expression in E.coli  
Overnight grown and transformed bacteria (2.2.4) were inoculated into 5 ml LB medium 
and incubated on a rotating shaker (New Brunswick Scientific, Edison, USA) at 37 °C 
for at least 8 h or overnight. For larger cultures, this pre-culture was used to inoculate 
500 ml LB medium 1:500 without antibiotics. The culture was grown for around 3 h until 
an OD600 of ~0.545 was reached. Expression of the protein of interest was induced by 
induction with 1 mM isopropyl beta-D-1-thiogalactopyranoside (IPTG) and the culture 
was grown at 37 °C for 3 h or more. The OD600 was determined again and the culture 
was stored at 4 °C for further use.  
2.2.6 Preparation of mGBA2-His expressed in bacteria for activity assays and 
Western blot analysis   
30 ml of mGBA2-His E.coli cultures (2.2.5) were centrifuged for 10 min at 11,000 x g 
and 4 °C and the pellet was re-suspended in 4.8 ml hypotonic buffer (represents a 1:8 
dilution of the initial volume, also see Figure 49). The cell suspension was sonicated 
by three pulses (20 s each) in ice-cold water (Branson Sonifier, also see 2.5.2) and 
20 µl of the protein lysate were used per reaction if not otherwise stated.    
2.3 Mammalian cell culture 
2.3.1 Solutions and cell culture media 
Cell culture media based on MEM, F12, and IMDM were incubated at 37 °C and 5% 
CO2, media based on DMEM were kept at 37 °C and 7.5% CO2 (Table 4). The pH of 
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PBS was set to 7.4, the buffer was autoclaved (20 min, 121 °C), and filled in sterile 
glass bottles under the hood.  
Table 3: Phosphate-buffered saline (PBS) for the cell culture 
PBS 
137 mM NaCl 
2.7 mM KCl 
6.5 mM Na2HPO4 
1.5 mM KH2PO4 
pH 7.4 
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Table 4: Cell culture media 
Coriell/TeleThon DH15 
medium 
Coriell/TeleThon M15 
medium 
HAP1 medium 
DMEM MEM/GlutaMAX IMDM 
15% FCS 15% FCS 10% FCS 
100 mM Sodium pyruvate 100 mM Sodium pyruvate 70 IU/ml Penicillin 
200 mM L-glutamine 200 mM L-glutamine 70 µg/ml Streptomycin 
 1x Non-essential amino 
acids 
 
HEK #A3 M10 medium HEK GBA1-KO DH10 
medium 
HeLa SL1P-KO/ mEFB 
DH10 medium 
MEM DMEM/GlutaMAX DMEM 
10% FCS 10% FCS 10% FCS 
1x Non-essential amino 
acids 
100 mM Sodium pyruvate 100 mM Sodium pyruvate 
1 mg/ml G418 70 IU/ml Penicillin 200 mM L-glutamine 
 70 µg/ml Streptomycin 70 IU/ml Penicillin 
  70 µg/ml Streptomycin 
Fibroblast growth medium CHO mGBA1-HA/ 
mGBA2-HA stable cell 
line medium 
Melanoma DH10 medium 
DMEM/GlutaMAX F12 DMEM 
10% FCS 10% FCS 10% FCS 
100 mM Sodium pyruvate Opt.: 0.8 mg/ml G418  
200 mM L-glutamine Opt.: 0.01 mg/ml 
Blasticidin 
 
70 IU/ml Penicillin   
70 µg/ml Streptomycin   
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2.3.2 Transient transfection using polyethylenimine (PEI) 
Cells were seeded out the day before transfection and grown to 90-95% confluency 
overnight (Table 14). DNA, OptiMEM, and polyethylenimine (PEI, Sigma) were mixed 
in a sterile tube according to Table 5 and incubated at RT for 10 min. Cell culture 
medium was removed from the dishes and replaced with starvation medium (normal 
cell culture medium containing only 2% FCS) according to Table 5. The PEI/DNA mix 
was then added to the cells and incubated overnight at 37 °C and normal CO2 
concentration for 1-3 days.     
Table 5: Pipetting scheme for transient transfection 
Dish DNA (µg) PEI (µg) OptiMEM (µl) Starvation 
medium (µl) 
4-well 0.5 1 50 200 
6-well 2.35 5 235 940 
5 cm plate 4.5 10 470 1880 
9 cm plate 8 18 846 3384 
  
Table 6: Seeding cell numbers for PEI transfection per 9 cm dish 
Cell line Seeding cell # per 9 cm dish 
HEK293 2x106 
HeLa 2x106 
HAP1 2.5x106 
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2.3.3 Plasmids used for transfection of mammalian cells 
Table 7: Plasmids used for transfection 
Plasmid Expresses Label Concentration 
(µg/µl) 
Date 
pc6-
QBImGBA1-
HA-1 
mGBA1-HA Dr. W. Bönigk, 
Molecular Sensory 
Systems, caesar, Bonn, 
Germany 
3.15 23/10/2012 
pc3-
mGBA2-HA-
1 
mGBA2-HA Dr. W. Bönigk, 
Molecular Sensory 
Systems, caesar, Bonn, 
Germany 
0.88 22/01/2015 
pc3QBIGFP-
HAmGBA2 
mGBA2-HA Dr. W. Bönigk, 
Molecular Sensory 
Systems, caesar, Bonn, 
Germany 
5.58 07/07/2011 
JAM3 JAM3 Dr. P. Haberkant, 
Proteomic Core Facility, 
EMBL Heidelberg, 
Heidelberg, Germany 
1.045 15/04/2016 
 
2.3.4 Generation of stable cell lines 
Stable cell lines produced by H. G. Körschen were generated using the vectors pc3.1-
mGBA2-HA or pc3.1-mGBA1-HA and the Neon100 µl electroporation kit by Invitrogen. 
The detailed protocol is published in (Körschen et al., 2013). 
Stable HEK293 cell clone #A3 was generated by PEI transfection (2.3.2) using the 
vector pc3-mGBA2-HA-1 (W. Bönigk, 0.88 µg/µl from 22/01/2015). As a control, a 
second plate was transfected without DNA. On the next day, cells were split 1:10, 
1:100, 1:1,000, and 1:10,000 to separate the cells and grow monoclonal colonies 
arising from one cell. On day three, G418 was added to a final concentration of 1.2 
mg/ml in 9 ml culture medium per 9 cm dish to both, the transfected and the control 
plate. On day five, the G418 concentration was lowered to 1 mg/ml and colonies were 
selected under a light microscope. The single colonies were picked using the isolated 
rim of a 10 µl pipette tip, which was placed in sterile silicon and placed on the colony 
after the cells were washed with PBS. 50 µl trypsin (0.05% in DMEM) was added per 
ring and the cells were re-suspended in the solution after brief incubation on a 37 °C 
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heating plate. Each colony was transferred to 200 µl normal culture medium containing 
1 mg/ml G418 in one well of a 96-well dish. The clones were scaled up to 5 cm dishes 
and stable expression of mGBA2 in the different clones was analysed by lysing the 
cells from one 5 cm dish in 60 µl hypotonic buffer and measuring the GBA2 activity 
compared to control samples using the fluorescence-based GBA activity assay (see 
2.5.8). Back-ups were made from 9 cm dishes with at least 4x106 cells per back-up.  
2.3.5 Cell lines 
2.3.5.1 Human dermal fibroblasts 
Human dermal fibroblasts were obtained from the Coriell Institute and from the 
TeleThon Institutes (Filocamo et al., 2014). 
Table 8: Human dermal fibroblast (hFB) cell lines 
Cell 
line 
Genotype Producer Catalogue # Disease Mutation Patient 
Sex Age 
hFB 
1 
Ctrl Coriell GM00024 C - - M 30 
y 
hFB 
2 
Mutant 
GBA1 
Coriell GM00372 A GD type I 84G ins,  
N370S 
M 29 
y 
hFB 
3 
Mutant 
GBA1 
Coriell GM00852 A GD type I 84G ins, 
N370S 
M 20 
y 
hFB 
4 
Mutant 
GBA1 
Coriell GM00877 A GD type II L444P, 
L444P, 
A456P,  
V460V 
M 1 y 
hFB 
5 
Mutant 
GBA1 
Coriell GM00878 - L444P, 
A456P,  
V460V 
F N/A 
hFB 
6 
Mutant 
GBA1 
Coriell GM01607B GD type I N370S, 
V394L 
M 30 
y 
hFB 
7 
Mutant 
GBA1 
Coriell GM04394 GD type I L444P M 1 y 
hFB 
8 
Ctrl Coriell GM05399 A - - M 1 
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hFB 
9 
Ctrl Coriell GM05757 C - - M 7 y 
hFB 
10 
Mutant 
GBA1 
Coriell GM08760 GD type II L444P M 1 y 
hFB 
11 
Mutant 
GBA1 
Coriell GM10915 A GD type I L444P M 7 y 
hFB 
12 
Mutant 
GBA1 
Coriell GM20272 B GD type III L444P M N/A 
hFB 
14 
Mutant 
GBA1 
Coriell GM01260 GD type II L444P, 
P415R 
F 11 
m 
hFB 
15 
Mutant 
GBA1 
TeleThon FFF0091977 GD type III L444P, 
L444P 
N/A N/A 
hFB 
16 
Mutant 
GBA1 
TeleThon FFF0491979 GD type III L444P, 
L444P 
N/A N/A 
hFB 
17 
Mutant 
GBA1 
TeleThon FFF1081981 GD type III L444P, 
L444P 
N/A N/A 
hFB 
18 
Mutant 
GBA1 
TeleThon FFF1161982 GD type II L444P, 
R257Q 
N/A N/A 
hFB 
19 
Mutant 
GBA1 
TeleThon FFF0181985 GD type II L444P, 
R120W 
N/A N/A 
hFB 
20 
Mutant 
GBA1 
TeleThon FFF0591990 GD type III L444P, 
F213I 
N/A N/A 
hFB 
21 
Mutant 
ASM 
TeleThon FFF040200 NP-A N/A N/A N/A 
hFB 
22 
Mutant 
ASM 
TeleThon FFF0771980 NP-A N/A N/A N/A 
hFB 
23 
Mutant 
ASM 
TeleThon FFF1142009 NP-A N/A N/A N/A 
hFB 
24 
Mutant 
ASM 
TeleThon FFF0202012 NP-B N/A N/A N/A 
hFB 
25 
Mutant 
ASM 
TeleThon FFF0681983 NP-B N/A N/A N/A 
hFB 
26 
Mutant 
ASM 
TeleThon FFF0752008 NP-B N/A N/A N/A 
hFB 
27 
Mutant 
NP-C 
TeleThon FFF0262000 NP-C N/A N/A N/A 
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hFB 
28 
Mutant 
NP-C 
TeleThon FFF0522000 NP-C N/A N/A N/A 
hFB 
29 
Mutant 
NP-C 
TeleThon FFF0782006 NP-C N/A N/A N/A 
hFB: Human dermal fibroblast, GBA1: Acid beta-glucosidase, ASM: Acid sphingomyelinase, NP-C: 
Niemann-Pick type C, GD: Gaucher disease 
2.3.5.2 Cells genetically modified using CRISPR/Cas9 
2.3.5.2.1 Human fibroblast-like cells 
Table 9: HAP1 cell lines 
Cell line Producer Catalogue # GBA1 gene 
HAP WT Horizon - - 
HAP1 GBA1-KO Horizon HZGHC002786c001 479 bp insertion in 
exon 6 
HAP1 GBA1-KO Horizon HZGHC002786c010 1 bp insertion in 
exon 6 
HAP1 GBA2-KO Horizon HZGHC004109c001 5 bp deletion in 
exon 1 
HAP1 GBA2-KO Horizon HZGHC004109c011 1 bp insertion in 
exon 1 
WT: Wild-type, GBA1: Acid beta-glucosidase, KO: Knockout 
2.3.5.2.2 Human embryonic kidney cells (HEK293) 
Table 10: HEK cell line 
Cell line Producer 
HEK GBA1-KO Gift from C. Yaacobi, Futerman lab, 
Weizmann Institute, Israel 
HEK: Human embryonic kidney cells, GBA1: Acid beta-glucosidase, KO: Knockout 
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2.3.5.2.3 Cervical cancer cells (HeLa) 
Table 11: HeLa cell line 
Cell line Producer Genotype 
Delta SGPL1 HeLa  Gift from M. Gerl, Biochemistry 
Center, Heidelberg University, 
Heidelberg, Germany 
(Gerl et al., 2016) 
SGPL1-knockout 
HeLa: Immortalised cervical cancer cells originating from Henrietta Lacks, SGPL1: Sphingosine-1-
phosphate lyase, KO: Knockout 
2.3.5.3 Murine embryonal fibroblasts 
Table 12: Embryonal mouse fibroblast cell lines 
Cell line Genotype Producer Date 
mEFB GBA1+/+ neu Ctrl Dr. Y. Yildiz, University 
Hospital Bonn, Bonn, 
Germany 
N/A (BU: 
06.06.2012) 
mEFB GBA1 -/- alt GBA1-KO Dr. Y. Yildiz, University 
Hospital Bonn, Bonn, 
Germany 
N/A 
mEFB GBA1 ko -/- GBA1-KO Dr. Y. Yildiz, University 
Hospital Bonn, Bonn, 
Germany 
N/A (BU: 
15.10.2012) 
mEFB GBA1 #E18 ko -/- GBA1-KO H. Angele, Molecular 
Sensory Systems, 
caesar, Bonn, 
Germany 
30.06.2011 
mEFB: Murine embryonal fibroblasts, Ctrl: Control, GBA1: Acid beta-glucosidase, +/+: Wild-type, -/-: 
Knockout, BU: Back-up. 
2.3.5.3.1 Isolation of murine embryonal fibroblasts 
Mouse embryos were dissected, the tail was cut off, and transferred to one well of a 6-
well dish in 3 ml fibroblast growth medium (Table 4) under the cell culture hood. Dermal 
fibroblasts from the tails were isolated using collagenase digestion. Collagenase was 
prepared as a 50 mg/ml stock in pure DMEM/GlutaMAX and sterile filtered using a 0.45 
µm mesh. 20 µl sterile collagenase solution was added per ml fibroblast growth 
medium to each well, swirled once, and the tails were cut into thin slices using a sterile 
blade. The pieces were incubated and digested for 3 h at 37 °C and 7.5% CO2. The 
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supernatants were then transferred to a Falcon and pelleted at 600 x g for 5 min at RT. 
The pellet was re-suspended in 1 ml fibroblast growth medium, transferred to 2 ml 
medium in one well of a 6-well dish, and grown overnight at 37 °C and 7.5% CO2. After 
24 h, the cells were washed once with sterile PBS followed by addition of fresh 
medium. The cells were then grown to confluency for 2-3 days and scaled up to 9 cm 
dishes.   
2.3.5.4 Melanoma cells 
Table 13: Melanoma cell lines 
Cell line Species Producer Genotype 
MEB-4 Mouse Gift from Prof. C. Thiele, 
Biochemistry and Cell 
Biology of Lipids, LIMES, 
Bonn, Germany 
Ctrl 
GM-95 Mouse Gift from Prof. C. Thiele, 
Biochemistry and Cell 
Biology of Lipids, LIMES, 
Bonn, Germany 
GlcCerS-KO 
Ctrl: Control, GlcCerS: glucosylceramide synthase, KO: Knockout 
2.3.5.5 Stable cell lines 
Table 14: Stable cell lines 
Clone # Cell type Expresses Producer Resistance 
cassette 
G4A11 CHO mGBA2-HA H. G. 
Körschen 
G418 
A8A11 CHO mGBA2-HA H. G. 
Körschen 
G418 
A8A6B5 CHO mGBA1-HA 
mGBA2-HA 
H. G. 
Körschen 
G418, 
Blasticidin 
A3 HEK293 mGBA2-HA S. Schonauer G418 
 
2.3.6 Generation of cell culture back-ups 
Cells were washed with PBS, trypsinised, and transferred to a falcon tube. Next, cells 
were pelleted for 5 min at 200 x g and RT and re-suspended in culture medium 
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containing 10% DMSO. Around 4-8x106 HAP1 cells, HEK293 cells, or CHO cells and 
at least 1x106 human dermal fibroblasts were frozen in 1 ml cryo tubes (Greiner) in a 
Mr. Frosty (Nunc) at -80 °C for 2-3 days before storage in liquid nitrogen. 
2.3.7 Culturing of cell culture back-ups 
To bring cells back into culture, 1 ml cell suspension was rapidly thawed at 37 °C (water 
bath) and transferred to 20 ml pre-warmed culture medium. The cells were pelleted for 
5 min at 200 x g and RT, re-suspended in cell culture medium, and plated in normal 
culture medium in 9 cm dishes.  
2.4 Molecular biology 
2.4.1 qPCR primers 
Table 15: Human qPCR primers 
Gene Primer 
numbers 
Sequence (5‘-3‘)  
  Forward Reverse TA (°C) 
hGBA1 C1796/97 TGCCTATGCT 
GAGCACAAGT 
GCTTCTGGGT 
CTGTCAGTAC 
60/62 
hGBA1 C1798/99 ACAGCCACAG 
CATCATCACG 
AGGTCGTTCT 
TCTGACTGGC 
62/62 
hGBA2 C1800/01 CATATAGGCA 
TGGGCTTGAG 
AGCTGCCAAC 
GACAGAACTG 
60/62 
hGBA2 C1802/03 CAGTTCTGTC 
GTTGGCAGCT 
GAAGCTGATA 
GACAGTCCAG 
62/60 
hB2m C1818/19 CGAGACATGT 
AAGCAGCATC 
GCAACCTGCT 
CAGATACATC 
60/60 
hB2m C1820/21 CGCTACTCTC 
TCTTTCTGGC 
TTCACACGGC 
AGGCATACTC 
62/62 
hAlas1 C1822/23 GGACTTCTCG 
ACTTGAGTGC 
GGGACTCGGG 
ATAAGAATGG 
62/62 
hAlas1 C1824/25 AGCTTCAGGA 
GGATGTGCAG 
AGTTCTTCAG 
CAGTCCACTG 
62/60 
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Table 16: Mouse qPCR primers 
Gene Primer 
numbers 
Sequence (5‘-3‘)  
  Forward Reverse TA (°C) 
mGBA1 C1508/09 ATGACCAACG 
CTTGCTGCTA 
GTGACTGTAC 
TGCATCCCTC 
60/62 
mGBA1 C1510/11 CCACCTACTC 
AGAAGCTGCT 
TGTCTTCTTC 
TGGGAGGCTG 
62/62 
mGBA2 C1512/13 ATCTGCTTGG 
CTCACGAGTT 
TGTCGATGAA 
AGGGGTCTTC 
60/60 
mGBA2 C1514/15 GAGAGGCCAG 
TTCTGTCGTT 
AGGTGAGGGT 
GACATTCTGG 
62/62 
mGBA2 C1573/74 ATTCAGAGGA 
CTCTGGGCAG 
TAGTGCCTCC 
TCCAATGCCA 
62/62 
mTfrc C1520/21 GGGTCTAAGT 
CTACAGTGGC 
GGCGACAGGA 
AGTGATACTC 
62/62 
mTfrc C1522/23 ATGGTTCGTA 
CAGCAGCGGA 
GCCACTGTAG 
ACTTAGACCC 
62/62 
mGusb C1532/33 CCGTACGTGG 
ATGTTATCTG 
CTCCTCACTG 
AACATGCGAG 
60/62 
mGusb C1534/35 CTAGAGGTGA 
TGGAGGAGCT 
GCTTTGGTGT 
GGGTGATCAG 
62/62 
mCHOP C2187/88 TGAAGATGAG 
CGGGTGGCAG 
GGTGGTGTAT 
GAAGATGCAC 
64/60 
mCHOP C2189/90 ACCACCACAC 
CTGAAAGCAG 
GACCTCCTGC 
AGATCCTCAT 
62/62 
mGRP78 C2195/96 CTTCGGTGCA 
GCAGGACATC 
GTAACAACTG 
CATGGGTAAC 
64/58 
mGRP78 C2197/98 CTCTGGTGAT 
CAGGATACAG 
TTTTGTTAGG 
GGTCGTTCAC 
60/58 
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2.4.2 Polymerase chain reaction (PCR), testing of qPCR primers 
To test whether primers designed for e.g. qPCR (2.4.6) amplify the sequence of 
interest, a conventional polymerase chain reaction (PCR) was performed 
(Thermocycler, SensoQuest). The PCR was done using the reaction mix shown in 
Table 17 and using the program shown in Table 18. For human and mouse primers 
(Table 15 and Table 16), cDNA obtained from a fibroblast cell line from a control patient 
(hFB 8, Table 8), or from a mouse wild-type testis was used.     
Table 17: Pipetting scheme for PCR 
Mix Stock 
0.5 µl KOD Hot Start 
polymerase (Novagen) 
1 U/µl 
3 µl KOD reaction buffer 10x 
1 µl 1:5 diluted cDNA  
or 1:10 diluted  cDNA 
 (≙ 20-50 ng) 
100 ng/µl from hFB 8  
500 ng/µl from mouse testis 
 
0.9 µl primer mix  
(≙ 0.3 µM each primer final) 
10 µM each primer 
3 µl dNTP mix 2 mM 
1.2 µl MgSO4 25 mM 
ad 30 µl with ddH2O - 
 
Table 18: PCR program 
  Step Temperature (°C) Time (s) 
I  Denaturation 95  80 
II  Denaturation 95 30 
III  Annealing 55 30 
IV  Elongation (35x to 
II) 
72 35 
V  End 8 ∞ 
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2.4.3 Agarose-gel electrophoresis 
DNA molecules were separated according to their size via agarose-gel 
electrophoresis. For the separation of DNA molecules of 75-200 base pairs (bp), gels 
containing 2% agarose (w/v) were used. Agarose was dissolved in 1x TAE buffer 
(Table 19) by boiling. Before pouring the gel, ethidium bromide (1 µg/ml) was added. 
5 µl of the 30 µl PCR approach (Table 17) was diluted in 10x loading buffer (Table 19) 
and loaded on the gel. The 1 kb DNA ladder was used as size standard (Figure 5). 
Electrophoresis was carried out in 1x TAE buffer (Table 19) at a constant voltage of 
120 V for 20 min. For gel analysis, the ethidium bromide stained DNA was visualised 
under UV light.  
Table 19: Buffers used for agarose-gel electrophoresis 
Loading buffer (10x) TAE (50x) 
10x TAE 2 M Tris/acetate, pH 7.5 
50% glycerol 50 mM EDTA 
0.25% Xylene caynol  
 
 
Figure 5: GeneRuler 1 kb Plus DNA Ladder.  
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2.4.4 SureClean protocol for DNA purification 
PCR products (2.4.2) were purified using the SureClean kit (Bioline). The SureClean 
reagent was added 1:1 to the DNA solution and mixed thoroughly. After incubating for 
10 min at RT, the DNA was centrifuged for 10 min at 14,000 x g and the DNA pellet 
was washed using 70% ethanol with a 2:1 volume of the starting sample. The mix was 
vortexed for 10 s and centrifuged for 10 min at 14,000 x g. The DNA pellet was air-
dried for 5-10 min and re-suspended in ddH2O. 
2.4.5 Sending PCR products for sequencing 
For sequencing, 7.5 µl purified DNA (2.4.4) were mixed 1:1 with ddH2O. The 
corresponding forward primers were diluted to 2 pmol/µl in ddH2O and 15 µl were sent. 
All PCR products had the predicted sequence (data not shown). 
2.4.6 Analysis of mRNA expression  
2.4.6.1 RNA isolation using the NucleoSpin RNA II kit 
Cells in culture were washed once with sterile PBS and trypsinised at 37 °C. Cells were 
collected in a Falcon tube and pelleted for 5 min at 200 x g. Pellets were either directly 
subjected to mRNA extraction of pellets were frozen in liquid nitrogen and stored at -
80 °C until further usage. Total RNA isolation was performed according to the 
manufacturer’s instructions (NucleoSpin RNA II: Macherey & Nagel, Düren, Germany). 
A minimal RNA concentration of 0.25 µg/µl was required to reversely transcribe 2 µg 
RNA using the normal reaction volume of 20 µl during cDNA synthesis (see 2.4.6.4). 
Thus, RNA was eluted from the columns using only 40 µl RNase-free ddH2O.  
2.4.6.2 RNA isolation using Trizol 
Tissues were dissected, weighted, and 1 ml Trizol (Thermo Fisher Scientific) was 
added per 50-100 mg. Tissues were homogenised using a Teflon douncer (IKA works), 
transferred to a 2 ml tube, and incubated for 5 min at RT. 200 µl chloroform were added 
per 1 ml Trizol and mixed for 15 s. After incubating for 2-3 min at RT, the sample was 
centrifuged for 15 min at 12,000 x g and 4 °C. The upper aqueous phase contained 
RNA, whereas proteins resided in the lower chloroform phase and DNA in the 
interphase. The upper phase was transferred to a new tube and 500 µl pure 
isopropanol were added per 1 ml Trizol. The solution was mixed and incubated for 
10 min at RT. RNA was precipitated by centrifuging for 10 min at 12,000 x g and 4 °C. 
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The pellet was washed with 1 ml 75% ethanol (prepared in DEPC-treated ddH2O) and 
briefly vortexed. After centrifuging for 5 min at 7,500 x g and 4 °C, the RNA pellet was 
air-dried for 5-10 min, re-suspended in 40 µl DEPC-treated ddH2O, and incubated for 
10 min at 55 °C. RNA concentration was measured using a spectrophotometer (see 
2.4.6.3). 
2.4.6.3 Quantification of nucleic acids 
To determine the DNA or RNA concentration in a solution, 1.5 µl were analysed using 
the NanoDrop instrument (NanoDrop ND-1000). The concentration was measured 
using the following values: 
dsDNA: 50 µg/ml at OD260=1 
RNA  40 µg/ml at OD260=1 
The ratio of the absorption at 260 nm and 280 nm provides information about the purity 
of the DNA/RNA and contaminations by e.g. proteins. The value should not be smaller 
than 1.8. 
2.4.6.4 Reverse transcription of mRNA using the Superscript III kit 
cDNA synthesis for qPCR analysis was performed according to the manufacturer’s 
instructions (Superscript III: Thermo Fisher Scientific). For first strand synthesis, the 
mix shown in Table 20 was prepared:  
Table 20: Pipetting scheme for reverse transcription (I) 
Mix Stock 
2 µg RNA - 
1 µl random hexamers 50 µM 
1 µl dNTP mix 10 mM each 
ad 10 µl with RNase-free 
ddH2O 
- 
 
The reaction mix was incubated at 65 °C for 5 min and chilled on ice for at least 1 min. 
Then, 9 µl of the 2x mix shown in Table 21 were added per reaction.  
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Table 21: Pipetting scheme for reverse transcription (II) 
Mix Stock 
2 µl reaction buffer 10x 
4 µl MgCl2 25 mM 
2 µl DTT 0.1 mM  
1 µl RNase Out 1 U/µl 
 
The reaction was mixed and incubated at 25 °C for 2 min before 1 U Superscript 
polymerase (1 U/µl, Invitrogen) was added. The reaction was incubated again at 25 °C 
for another 10 min, at 42 °C for 50 min, and at 70 °C for 15 min. The cDNA was stored 
at -20 °C. 
2.4.6.5 Primer efficiency test (PET) 
To reliably analyse the data obtained from qPCR, a primer efficiency test (PET) was 
performed. Here, the normal qPCR program (Table 23) was performed on a serial 
dilution (1:1, 1:5, 1:10, 1:50, 1:100, and 1:1,000) of the template (e.g. cDNA from 
human dermal fibroblasts) using the different primer pairs. In a perfect PCR cycle, the 
amount of DNA should double and the primer efficiency would be 100%. The PET was 
performed for two primer pairs per GOI (hGBA1, hGBA2) and HEK (hB2m, hAlas1) in 
duplets. The slope obtained from plotting the individual CT values against the logarithm 
of the cDNA dilutions was used to calculate the primer efficiency (E = 10-1/slope). 
Primers used for qPCR showed at least 90% and maximal 105% efficiency (Table 57 
and Table 60). For qPCR experiments, two master mixes were prepared (Table 22) 
and the PCR was performed using the program shown in Table 23. 
Table 22: Pipetting scheme for qPCR mixes I and II 
Mix I Mix II 
1 µl of a 5 µM dilution of each 
primer of one primer pair 
1 µl of diluted cDNA 
12.5 µl SYBR Green 
Supermix (Biorad) 
10.5 µl ddH2O 
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Table 23: qPCR program 
Cycle Step Step Temperature (°C) Time (s) 
1 I Denaturation 95  180 
2 I 
II 
III 
Denaturation 
Annealing 
Elongation (45x to 2) 
95 
59 
72 
10 
30 
30 
3 I Denaturation 95 60 
4 I Melt curve 
 
55 60 
5 I 55 30 
 
2.4.6.6 Quantitative real-time PCR (qPCR) 
qPCR was performed for the GOIs hGBA1 and hGBA2, and the HKGs hB2m and 
hAlas1 and human dermal fibroblast samples as templates (see Table 8, Table 55). 
Furthermore, qPCR was performed for mGBA2 and the HKGs mTfrc and mGusb on 
brain samples from control and CBE-treated mice as templates (see Figure 25a, Table 
58). The reactions were set up in triplets for each gene and each template. Additionally, 
a non-template control was set up for each primer pair. All qRT-PCR experiments were 
performed in the BioRad I-cycler with an IQ5 optical system. Data was analysed using 
the BioRad IQ5 optical system software and calculated according to the delta-delta-CT 
method (Biorad Bulletin). After running the cycles, a melt-curve analysis was 
performed to detect non-specifically amplified products. mRNA expression-levels for 
all samples were normalised to the mean of the individual HKGs. 
Table 24: cDNA dilutions for qPCR 
Sample cDNA dilution 
hFBs 1:7 
Mouse brain 1:10 
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2.5 Protein biochemistry 
2.5.1 Antibodies for immunostainings 
2.5.1.1 Primary antibodies 
The generation of monoclonal rat antibodies against different epitopes of mGBA2 is 
described in Körschen et al. 2013. Polyclonal antibodies were generated against an 
mGBA2 fusion protein carrying an N-terminal His-tag expressed and purified from 
E.coli strain BL21 Codon Plus (DE3) RIPL.  
Table 25: Monoclonal primary antibodies 
Antibody Species Producer Catalogue 
# 
Dilution Weight 
(kDa) 
WB ICC 
GBA2-3H8 rt H. G. Körschen - 1:20 - ~120 
GBA2-4A12 rt H. G. Körschen - 1:20 - ~120 
GBA2-5A8/1 rt H. G. Körschen - 1:20 - ~120 
GBA2-8G4 rt H. G. Körschen - 1:20 - ~120 
GBA2-4F8 rt H. G. Körschen - 1:20 - ~120 
GBA2-4D7 rt H. G. Körschen - 1:20 - ~120 
GBA2-12F8 rt H. G. Körschen - 1:20 - ~120 
GBA2-2H1 rt H. G. Körschen - 1:20 - ~120 
GBA2-2F8 rt H. G. Körschen - 1:20 - ~120 
GBA2-5A8/4 rt H. G. Körschen - 1:20 - ~120 
GBA2-
4A12/2F8 mix 
rt H. G. Körschen - 1:50 
each 
- ~120 
HA-Tag rt Roche 11867431
001 
1:5,000 - - 
Beta-Tubulin ms Sigma TUB 2.1 1:1,000 - 55 
His-Tag ms Novagen 70796-3 1:1,000  - 
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GFP ms Millipore MAB3580 1:5,000-
10,000 
- 30 
GM130 ms BD 
Transduction 
Laboratories 
Clone 35, 
610822 
- 1:100 130 
rt: Rat, ms: Mouse 
Table 26: Polyclonal primary antibodies 
Antibody Species Producer Catalogue 
# 
Dilution Weight 
(kDa) 
WB ICC 
Calnexin rb Sigma C4731 1:40,000 
(tissue) 
- 90 
    1:5,000-
10,000 
(cells) 
- 90 
GBA1 rb Sigma G4171 1:1,000 - 55-69 
GBA1-3kb rb H. G. Körschen - 1:5,000 - 55-69 
GFP rb Abcam ab6556 1:5,000 - - 
GBA2 rb Y. Yildiz -   ~120 
GBA2-4kb rb H. G. Körschen - 1:1,000-
5,000 
- ~120 
GBA2-5kb rb H. G. Körschen - 1:1,000-
5,000 
- ~120 
GBA2-
4kb/5kb mix 
rb H. G. Körschen - 1:5,000 
each 
- ~120 
LAMP1 rb Abcam ab24170 1:1,000 1:200 120 
GLTP gt Santa Cruz N-17 1:500 - 25 
kb: Körschen, Bonn, rb: Rabbit, gt: Goat 
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2.5.1.2 Secondary antibodies 
Table 27: Secondary antibodies 
   Dilution 
Antibody Producer Catalogue # WB ICC 
dk α gt 
IRDye680 
LI-COR 
Biosciences 
926-32224 1:20,000 - 
dk α ms 
IRDye680LT 
LI-COR 
Biosciences 
926-68022 1:20,000 - 
dk α ms 
IRDye800CW 
LI-COR 
Biosciences 
926-32212 1:20,000 - 
dk α rb 
IRDye680 
LI-COR 
Biosciences 
926-32223 1:20,000 - 
dk α rb 
IRDye800CW 
LI-COR 
Biosciences 
926-32213 1:20,000 - 
gt α rt IRDye680 LI-COR 
Biosciences 
926-32229 1:20,000 - 
gt α rt 
IRDye800CW 
LI-COR 
Biosciences 
926-32219 1:20,000 - 
d α ms Cy3 Dianova 715-165-151 - 1:500 
d α rb A647 Dianova 711-605-152 - 1:400 
ms α rt IgG2b 
HRP 
Gift from E. 
Kremmer 
- 1:1,000 - 
gt α rt HRP Dianova 112-035-068 1:5,000 - 
ms α rt kappa 
HRP 
Gift from E. 
Kremmer 
- 1:1,000 - 
dk: Donkey, gt: Goat, ms: Mouse, rb: Rabbit, rt: Rat, HRP: Horseradish peroxidase  
2.5.2 Protein preparation 
All steps were performed at 4 °C in the presence of mammalian protease inhibitor 
cocktail (mPIC, Sigma Aldrich). Tissues were homogenised in 10 ml/g wet weight of 
the organ of hypotonic buffer (Table 28) using an Ultra-thurrax (IKA) and three pulses 
(20 s each) of sonification in ice-cold water (Branson Sonifier). Tissue suspensions 
(total lysate) were subjected to low speed centrifugation for 20 min at 1,000 x g. The 
supernatant (PNS, post-nuclear supernatant) was used for activity assays (also see 
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Körschen 2013). Cultured cells were washed once with PBS and harvested using 1 ml 
of 0.5 g/l EDTA in PBS (pH 7.4) per 9 cm cell culture dish and cells were pelleted for 5 
min at 600 x g and 4 °C. Afterwards, the pellets were directly lysed in hypotonic buffer, 
sonicated (see above), and used for activity assays or Western blot analysis. If the 
lysates were left on ice for some time, they were briefly sonicated again to maintain 
the homogeneous suspension. The protein concentration was estimated using either 
the Bradford assay (2.5.2.1) or the bicinchoninic acid (BCA) test (2.5.2.2).  
Table 28: Hypotonic buffer 
Hypotonic buffer 
10 mM HEPES/NaOH, pH. 7.4 
0.5 mM EDTA 
1:500 mPIC 
in ddH2O 
 
2.5.2.1 Bradford assay 
The Bradford assay makes use of an absorbance shift of the dye Coomassie Brilliant 
Blue G-250 (Bradford reagent, Biorad) due to protein binding. Upon protein binding, 
the red form of the dye shifts to a blue form, which can be detected by measuring the 
absorbance at 595 nm. The increase of absorbance at 595 nm is proportional to the 
amount of bound dye, and, thus, represents a measure for the protein concentration. 
The Bradford reagent was diluted 1:5 in ddH2O and the shift in absorbance was 
measured in 5 µl of the (diluted) protein suspension in 1 ml diluted Bradford reagent in 
a disposable plastic cuvette at the spectrophotometer (Hitachi U-1900) and compared 
to a blank sample. The optical density (OD) at 595 nm was determined in an 
absorbance range from 0.005 to 0.15, at higher values the protein suspension was 
diluted and measured again.      
2.5.2.2 The bicinchoninic acid (BCA) test    
The bicinchoninic acid (BCA) test kit (Pierce) is based on the reduction of Cu2+ to Cu+ 
in alkaline solution and in the presence of protein, where the amount of reduced Cu+ 
ions directly correlates with the amount of protein present. The Cu+ ions react with the 
bicinchoninic acid in aqueous solution with a high absorption at 562 nm. The BCA 
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solution was prepared by mixing of solutions A and B from the kit in a ratio of 50:1. 
Dilutions of the samples to be analysed and a serial dilution of a BSA reference (10 µl) 
were prepared in a 96-well plate and mixed with 190 µl BCA solution. After incubating 
for 30 min at 37 °C, the absorption of all samples was measured at 570 nm in the 
Packrad Fusion Instrument plate reader. The protein concentration was calculated 
using the linear regression of the BSA standard.  
2.5.2.3 Deglycosylation of proteins 
Glycosylated proteins were de-glycosylated for e.g. Western blot analysis using 
PNGase F from NEB (Table 29, Table 30). 20 µg total protein were mixed with 
denaturing buffer and incubated at RT for 10 min. Then, G7 buffer, NP-40, and 
PNGase F were added and the approach was incubated at 37 °C for at least 2 h. 
Afterwards, 4x SDS sample buffer was added and the proteins were either loaded to 
polyacrylamide gel or stored at -20 °C until further usage.  
Table 29: Deglycosylation approach 
Deglycosylation approach Stock 
20 µg total protein - 
ad 22.5 µl with ddH2O - 
2.5 µl denaturing buffer 10x 
3 µl G7 buffer 10x 
3 µl NP-40 10% (w/v) 
1 µl PNGase F (NEB) 1 U/µl 
 
Table 30: Buffers used for deglycosylation 
Denaturing buffer (10x) G7 buffer (10x) 
0.5% (w/v) SDS 50 mM sodium 
phosphate buffer,  
1% (w/v) beta-mercaptoethanol pH 7.5 
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2.5.3 Studying the interaction between GBA2 and pacSphingosine  
2.5.3.1 In vitro 
Delta SGPL1 HeLa cells (Table 11) heterologously expressing mGBA1, mGBA2, and 
GFP (2.3.2 and 1.1.1), or JAM3 were harvested (2.5.2) and lysed in 200 µl of 100 mM 
HEPES/KOH (pH 7.4) + mPIC per 9 cm dish by sonication (2.5.2). The protein 
concentration was determined via Bradford assay (2.5.2.1). Samples were incubated 
directly with 6 µM pacSphingosine (pacSph) or AR451 (Table 31) for 1 h at RT. Lipids 
and binding proteins were photo cross-linked by irradiation with UV light (LED lamp, 
1.25 mA) for 7 minutes with minimal distance between the lamp and the top of the tube. 
During irradiation, the protein lysate was mixed by inversion every two minutes. 50 µg 
of total protein were filled up to 21 µl sample volume with 100 mM HEPES/KOH (pH 
7.4) and 4 µl of a 25x concentrated click-reaction mix (Table 32) were added (final 1x). 
Samples were clicked at 37 °C for 1 h before the sample volume was increased to 27 
µl with 100 mM HEPES/KOH (pH 7.4) and 9 µl 4x SDS sample buffer were added. All 
samples were loaded to a 10% polyacrylamide gel (Table 34) and subjected to SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis (2.5.4 and 
2.5.5) or stored at -20 °C until further use. Western blots were immunostained (2.5.5.2) 
using the primary antibodies against HA (Roche, Table 25) and GFP (Abcam, Table 
26) and species specific IR800-coupled secondary antibodies (Table 27).  
Table 31: Photoactivatable and clickable lipids 
Lipid Stock  Source 
pacSphingosine 
(pacSph) 
25 mM in EtOH Dr. P. Haberkant, Proteomic Core 
Facility, EMBL Heidelberg, 
Heidelberg, Germany 
AR451 24 mM in DMSO Dr. A. Rennhack, Molecular Sensory 
Systems, caesar, Bonn, Germany 
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Table 32: Click-reaction mix for pac lipids 
Click-reaction mix for pac 
lipids (1x) 
Click-reaction mix for pac 
lipids (25x) 
Stock 
1 mM CuSO4 25 mM 200 mM in ddH2O 
0.1 mM TBTA 2.5 mM 25 mM in DMSO 
25 µM Azido-DY-654 
(Dyomics) 
0.625 mM 1 mM in ddH2O 
1 mM Ascorbic acid 25 mM 100 mM in ddH2O 
 
2.5.3.2 In vivo 
Interaction of GBA2 and pacSph in vivo was performed as described in 2.5.3.1, but 
delta SGPL1 HeLa cells (Table 11) heterologously expressing mGBA1, mGBA2, and 
GFP (2.3.2 and 1.1.1), or JAM3 were incubated with normal culture medium containing 
10% de-lipidated FCS (Gift from Prof. C. Thiele) instead of the one normally used and 
6 µM pacSph or AR451 in 5 ml total volume per 9 cm dish. The cells were incubated 
at 37 °C for 1 h before harvesting, cell lysis, and UV irradiation (see 2.5.3.1).   
2.5.4 SDS-PAGE 
2.5.4.1 Self-casted polyacrylamide gels 
The separation of proteins prepared for Western blot analysis was accomplished by 
denaturing SDS-PAGE following the modified protocol by Laemmli (Laemmli, 1970). 
Electrophoresis was carried out using a minigel chamber (Biometra). The 
polyacrylamide concentration of the separating gel was varied from 7.5-15%, 
depending on the size of the protein of interest, while 5% polyacrylamide stacking gels 
were used in all experiments. The gel composition is summarised in Table 34. Protein 
samples were mixed with 4x SDS-sample buffer (final 1x, Table 33) and heated to 
98 °C for 5 min prior to loading onto polyacrylamide gel. The pre-stained maker VI 
(Applichem, Figure 6) was used as a protein standard. For electrophoretic separation, 
SDS running buffer (final 1x, Table 33) was used. For protein separation, currents of 
15 mA were applied during the stacking gel phase, whereas currents were raised to 
25 mA as soon as the samples traversed the border of the stacking to separating gel.  
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Table 33: Buffers used for SDS-PAGE 
SDS-sample buffer (4x) SDS running buffer (10x) 
200 mM Tris/HCl, pH 6.8 250 mM Tris 
0.04% Bromophenol blue 1.92 M Glycine 
4% beta-Mercaptoethanol 1% SDS 
8% SDS  
50% glycerine  
 
Table 34 Pipetting scheme for polyacrylamide gels 
 Stacking gel (5%) Separating gel (7.5-15%) 
1.5 M Tris/HCl, pH 6.8/8.8 0.5 ml (pH 6.8) 1.5 ml (pH 8.8) 
10% SDS 20 µl 60 µl 
10% APS 40 µl 40 µl 
TEMED 2.5 µl 4.5 µl 
Acrylamide 340 µl 1.5 – 3.0 ml 
ddH2O 1.12 ml 2.92 – 1.42 ml 
 
2.5.4.2 Gradient polyacrylamide gels (Invitrogen) 
The separation of proteins prepared for Western blot analysis on gradient 
polyacrylamide gels (Invitrogen) was accomplished using the XCell SureLock Mini-Gel 
System (Invitrogen). The polyacrylamide concentration of the separating gel is a 
gradient ranging from e.g. 4-12%, which provides a better separation of the proteins. 
1.0 mm tick gradient gels with 15 slots were used. As described in 2.5.4.1, protein 
samples were mixed with 4x SDS-sample buffer (final 1x, Table 33) and heated to 
98 °C for 5 min prior to loading onto polyacrylamide gel. The pre-stained maker VI 
(Applichem, Figure 6) was used as a protein standard. For electrophoretic separation, 
NuPAGE MOPS running buffer was used (final 1x, Table 35). SDS-PAGE was 
performed for 1-1.5 h at 180 V and 120 mA per gel.   
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Table 35: NuPAGE MOPS running buffer for SDS-PAGE 
NuPAGE MOPS running buffer 
(20x) 
50 mM MOPS 
50 mM Tris base 
0.1% SDS 
1 mM EDTA 
pH 7.7 
 
 
Figure 6: Protein standard used for SDS-PAGE 
2.5.5 Western blot analysis 
2.5.5.1 Immobilisation of proteins on PVDF membranes 
For immunostainings of proteins separated by SDS-PAGE (2.5.4), the proteins were 
transferred to PVDF membranes (Immobilon FL for fluorescently-labelled secondary 
antibodies and Immobilon P for HRP-conjugates secondary antibodies, Millipore, Table 
27) using the Western blot technique modified from Towbin et al. 1997. The protein 
transfer was performed in a semi-dry procedure using a blotting chamber (Roth). The 
transfer time was set to 40 min at 2.4 mA/cm2/membrane using 8x9 cm membranes. 
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After blotting, membranes were briefly re-hydrated in methanol and subjected to 
immunostaining.  
2.5.5.2 Immunostaining of immobilised proteins  
For the immunological detection of protein on PVDF membranes, sets of primary and 
secondary antibodies were used (Table 25 to Table 27). Immunostainings were carried 
out in three steps (Table 36): First, the membrane was blocked with blocking buffer 
(Table 37) to saturate non-specific binding sites for antibody binding. In a second step, 
the membrane was incubated with primary antibody, suitable for binding the protein of 
interest on the membrane. In a third step, a corresponding secondary antibody was 
added for detection of the antibody-antigen complex. The secondary antibody is 
species specific, as it is directed against a constant region of the primary antibody. 
Furthermore, the secondary antibody is conjugated with a fluorophore, IRDye680 or 
IRDye800 (Table 27), which emits light at 694 or 794 nm when exited with light of 
680 nm or 778 nm, respectively (LI-COR Biosciences). Membranes probed with 
fluorescently labelled secondary antibodies were analysed using the Odyssey Imaging 
System (LI-COR). Quantification of the Western blots was done using ImageJ (version 
1.46m). 
Immunological detection of proteins on PVDF membranes using horseradish 
peroxidase (HRP)-coupled secondary antibodies was carried out as described above, 
whereas non-specific binding sites were blocked using milk-powder. The secondary 
antibodies were conjugated with HRP, which enables the detection of the antibody-
antigen complex using the enhanced chemiluminescence (ECL) solution (Sigma).   
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Table 36: Immunostaining of immobilised proteins 
Working step Incubation time Solution 
Membrane blocking 30 min (RT) Blocking buffer 
Primary antibody 
incubation 
60 min (RT) or overnight 
(4 °C) 
Primary antibody in 
blocking buffer  
Wash 2x 10 min (RT) PBS-T 
Secondary antibody 
incubation 
60 min (RT) Secondary antibody in 
blocking buffer 
Wash 2x 10 min (RT) PBS-T 
Wash 1x 10 min PBS 
 
Table 37: Buffers used for immunostaining of immobilised proteins 
PBS washing buffer (pH 7.4) PBS-T washing buffer (pH 7.4) 
130 mM NaCl 130 mM NaCl 
7 mM Na2HPO4 7 mM Na2HPO4 
3 mM NaH2PO4 3 mM NaH2PO4 
 0.05% Tween 20 
Western blot blocking buffer for 
fluorophore-coupled secondary 
antibodies 
Western blot blocking buffer for 
HRP-coupled secondary 
antibodies 
1:1 PBS-T/Blok (Millipore) 2.5% milk powder 
 in PBS-T 
 
2.5.6 GlcCer column 
The amount of the tip of a scoop of dried GlcCer column resin was equilibrated with 1 
ml sterile-filtered PBS (pH 7.4) (= 10x column volume, CV) in a normal tube by 
centrifugation at 500 x g and 4 °C for 5 min. The resin was then incubated with 100 µl 
protein lysate or 100 µl of 0.35 µM purified GLTP (also see 
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Table 39) in PBS end-over-end at 4 °C overnight. On the next day, the sample was 
centrifuged at 500 x g and 4 °C for 5 min (supernatant = non-bound proteins) and the 
resin was washed 4x with 500 µl lysis buffer or PBS supplemented with 1% Triton X-
100. During each washing step, the resin was centrifuged at 500 x g and 4 °C for 5 
min. Bound proteins were eluted by incubation with 1 CV of lysis buffer or PBS 
containing 2% SDS end-over end at RT for 10-30 min. The resin was then centrifuged 
at 14,000 x g and RT for 5 min and the supernanant containing the eluted proteins was 
transferred to a fresh tube. The GlcCer resin was washed with PBS and air-dried with 
an open lid. Dry resin was stored at -20 °C until further use.     
2.5.7 Immunocytochemistry (ICC) 
2.5.7.1 Preparation of glass coverslips for ICC 
For immunocytochemical experiments, 4x104 cells (human dermal fibroblasts) were 
seeded on poly-L-lysine (PLL) coated 13 mm glass coverslips. The glass slides were 
distributed to a 24-well plate and covered with 500 µl of 0.1 mg/ml PLL. After incubation 
at RT for 45 min, PLL was removed and the glass slides were washed twice with PBS.  
2.5.7.2 GLTP-mediated transfer of clickGlcCer 
2.5.7.2.1 Preparation of clickGlcCer/DOPC liposomes by extrusion 
Liposomes were prepared according to the manufacturer’s protocol (Avanti Polar 
Lipids). The desired amounts of lipids (Table 38, DOPC: 1,2-Dioleoyl-sn-glycero-3-
phosphocholine) were mixed in a 2 ml glass vial and vortexed. The solvents were 
evaporated under a constant nitrogen flow while rolling the glass vial to obtain a lipid 
film. Afterwards, residual solvents were evaporated for another 30 min. The minimal 
volume to produce a lipid film is 50 µl. Dried lipids were re-suspended in the desired 
amount of buffer (e.g. PBS) and vortexed for 1.5 min. The suspension now contained 
giant multilamellar vesicles and looked milky. Unilamellar vesicles were produced by 
five consecutive freeze-thaw cycles, where the samples were frozen in liquid nitrogen 
and immediately thawed in a water bath at 37 °C. The Mini-Extruder from Avanti Polar 
Lipids was assembled according to the manufacturer’s protocol (Figure 7) and the 
membranes were pre-wetted with 500 µl PBS in 1 ml Hamilton syringes. 400 nm pore 
Whatman filters were used to produce liposomes with a diameter of 400 nm. The lipid 
suspension containing unilamellar vesicles was then sucked up by one of the two 
syringes and passed through the membrane into the second syringe 13 times. During 
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this procedure, the suspension got more transparent. Lipids were stored at 4 °C until 
further use for up to one week.     
Table 38: Lipids used for liposomes 
Lipid Stock  Company Catalogue # 
clickGlcCer 1 mg/ml in 
chloroform/methanol  
Gift from Prof. C. Thiele, 
Biochemistry and Cell 
Biology of Lipids, LIMES, 
Bonn, Germany 
- 
DOPC 20 mg/ml in 
chloroform  
Avanti Polar Lipids 850375c 
DOPC: 1,2-Dioleoyl-sn-glycero-3-phosphocholine 
 
Figure 7: Assembly scheme of the Mini-Extruder by Avanti Polar Lipids.  
 
2.5.7.2.2 Feeding of cells with clickGlcCer/DOPC liposomes 
Human dermal fibroblasts seeded on PLL-coverslips for immunocytochemical analysis 
(2.5.7.4) or seeded on the plastic surface of the culture dish (2.6.2) from control and 
type I Gaucher patients were pulsed with 200 µl DOPC liposomes containing either 0 
or 10 mol% clickGlcCer (2.5.7.2.1) for 1 h or 24 h (Table 39). Cells pulsed for 1 h were 
subsequently chased for 23 h. Afterwards, lipids were extracted, clicked to 3-azido-7-
hydroxycoumarin, and analysed by TLC (2.6.2) or fixed for immunocytochemical 
staining (2.5.7.3 following).  
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Table 39: ClickGlcCer feeding approach 
GLTP-mediated clickGlcCer transfer 
approach/well 
Stock Source 
18 µM hGLTP-His 66.6 µM Plasmid: AG Lang, Limes 
Institute, University of 
Bonn,Germany 
 published in Lauria et al. 
2013 
1:2.5 dilution of liposomes -  
ad 200 µl with PBS -  
 
2.5.7.3 Fixation of cells for ICC 
In preparation for immunocytochemical stainings, cells were fixed on PLL-coated glass 
coverslips (2.5.7.1). After removal of the cell culture medium and washing with PBS, 
cells were fixed in 300 µl of 4% paraformaldehyde (PFA) in PBS at RT for 10 min. 
Afterwards, cells were washed 3x with PBS and directly subjected to 
immunocytochemical stainings or stored in 700 µl PBS containing 0.05% sodium azide 
at 4 °C.  
2.5.7.4 Immunocytochemical staining 
Fixed cells (2.5.7.3) were washed with PBS, with 155 mM ammonium acetate, and, 
again, with PBS. Non-specific binding sites were blocked with ICC blocking buffer 
suitable for click chemistry (Table 40) at RT for 30 min. The primary antibody was 
diluted in ICC blocking buffer and added to the cells for 1 h at RT, followed by washing 
3x with PBS. The secondary antibody was also diluted in ICC blocking buffer and the 
coverslips were placed upside-down on 35 µl droplets of secondary antibody solution 
for 1 h at RT in the dark. The cells were washed once with PBS and subjected to click 
chemistry (2.5.7.5).  
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Table 40: ICC blocking buffer suitable for click chemistry 
ICC blocking buffer for click 
chemistry 
1% (w/v) Cold water fish 
gelatine 
0.01% (w/v) Saponine 
in PBS 
 
2.5.7.5 Click chemistry for ICC 
Fixed cells (2.5.7.3) were washed once with 100 mM HEPES/KOH (pH 7.4) and 0.01% 
Saponine. The click-reaction mix (Table 41) was prepared, distributed to the wells, and 
the plate was pre-warmed to 43 °C in a water bath. 10 µl of 100 mM Cu(I)TFB in 
acetonitrile were directly added to each well, the plate was swirled once, and the mix 
was incubated at 43 °C for 1 h. Afterwards, cells were washed with 100 mM 
HEPES/KOH (pH 7.4) and PBS. AP3Btn or APpic2Btn (see Figure 72a) were detected 
by placing the coverslips upside-down on 35 µl droplets of a detection mix (Table 41) 
at RT for 1 h in the dark. Afterwards, cells were washed twice with PBS and mounted 
using mounting medium (Polysciences) and incubated at RT for 1 h and stored at 4 °C 
until further use. Pictures were taken on a confocal microscope (Olympus FV1000).  
Table 41: Click-reaction mix and detection mix for cells 
Click-reaction 
mix/coverslip 
Stock Detection 
mix/coverslip 
Stock 
800 µl 100 mM 
HEPES/KOH, pH 
7.4 
- 40 µl 100 mM 
HEPES/KOH, pH 7.4 
- 
0.01% (w/v) 
Saponine 
- 1 µl Streptavidin-
Alexa488 
1 mg/ml in 
ddH2O 
12.5 µM AP3Btn  10 mM in DMSO   
12.5 µM APpic2Btn 10 mM in DMSO   
10 µM ApicSBDP 10 mM in DMSO   
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
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2.5.8 Fluorometric measurements  
2.5.8.1 Measuring principle of the Fluostar plate reader 
Fluorescence measurements of protein suspensions in multiwall plates were carried 
out using the fluorescence plate-reader Fluostar Omega (BMG Labtech). For the 
measurements, black 384-well plates with a glass bottom were used. In the Fluostar, 
the multi-well plate is moved past a detector head, which records the fluorescence of 
each well individually.  
2.5.8.2 Fluorescence-based GBA activity assay 
The assay has been performed as described previously (Körschen et al., 2013). The 
GBA activity in hypotonic protein lysates (2.5.2) was analysed by cleavage of 4-MUG 
in real-time in a Fluostar Omega reader (BMG Labtech) at 29 °C using the filter pair 
355 nm/460 nm for excitation and emission, respectively. The assay reactions were 
prepared on a 96-well plate, left) of which 4x 25 µl were transferred to a 384-well plate 
(Greiner) for analysis of quadruples. The assays were performed in the plate mode. 
Each well contained 20 - 100 μg of total protein. To discriminate between GBA1 and 
GBA2 activity, 25 μM CBE (conduritol B epoxide, Sigma Aldrich), an inhibitor for GBA1, 
or 8.2 μM NB-DNJ (N-butyldeoxynojirimycin, Sigma Aldrich), an inhibitor for GBA2, 
were included. The pH of the protein lysates and the 4-MUG solution were adjusted by 
diluting with McIlvaine buffer (Table 42). Analysis of GBA activity was initiated by 
adding 5 μl of 4-MUG (10 mM), resulting in a final concentration of 1.67 mM. The 
hydrolysis of 4-MUG was monitored and recorded as a change of relative fluorescence 
units (rfu) per minute. Per genotype, tissues or cells from at least three animals were 
analysed if not otherwise stated. 
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Table 42: Pipetting scheme for GBA activity assay 
Assay approach per well 
(96-well plate) 
Assay approach per well 
(384-well plate) 
McIllvaine buffer 
90 µl pH buffer 25 µl approach from 96-
well plate 
0.1 M citric acid 
20 µl protein sample (25 µM CBE final and  
8.3 µM NB-DNJ final) 
0.2 M Na2HPO4 
20 µl hypotonic buffer 5 µl 10 mM 4-MUG  
or: 10 µl of either/each 
390 µM CBE and/or 130 
µM NB-DNJ 
  
 
For each plate, the fluorescence was analysed for 150 cycles with the first 50 cycles 
applying 2 flashes per well and the last 100 cycles applying 10 flashes per well (Table 
43). Fluorescence was recorded from the top of each well. The gain was set to 800. 
Beta-glucosidase activity was expressed as the increase in fluorescence from cycle 50 
– 100 in rfu/min (slope).  
Table 43: Fluostar plate mode settings for beta-glucosidase activity assays 
Kinetic window 1 2 
No. of cycles 50 100 
Cycle time (s) 50 80 
No. of flashes per well 2 10 
 
2.5.9 Treatment of cells with CBE or NB-DNJ 
For treatment of cells with CBE or NB-DNJ, cells were seeded out the day before 
transfection (HEK293, 2.3.2) or the day before treatment (CHO, CHO #G4A11, hFBs) 
(Table 44). CBE or NB-DNJ were diluted to 25 µM or 2 µM in 9 ml normal culture 
medium per 9 cm plate, respectively. Cells were incubated with the blockers at 37 °C 
for 2 d before analysing the beta-glucosidase activity (2.5.8.2).    
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Table 44: Cell numbers seeded for CBE and NB-DNJ treatment 
Cell line Cell number per 9 cm dish 
HEK293 2x106 
CHO 5x105 
CHO #G4A11 5x105 
hFB 2x106 
 
2.5.10 Treatment of cells with Fumunisin B1  
For treatment of human dermal fibroblasts with Fumunisin B1 (FB1), cells were seeded 
out the day before treatment (Table 45). According to Merrill et al., the IC50 of FB1 for 
CerS is around 0.1 µM (Merrill et al., 1993b). Cells were incubated with 5 µM FB1 in 9 
ml normal culture medium per 9 cm plate. Cells were incubated at 37 °C for 2 d before 
analysing the beta-glucosidase activity (2.5.8.2).    
Table 45: Cell numbers seeded for Fumunisin B1 treatment 
Cell line Cell number per 9 cm dish 
hFB 2x106 
 
2.5.11 Lipid-BSA complexes 
2.5.11.1 Preparation of lipid-BSA complexes by sonication 
A 4 mg/ml BSA solution was prepared from a 1 M BSA stock in PBS (pH 7.4). The lipid 
stocks (Table 46) were diluted in the 4 mg/ml BSA solution to the desired 
concentration. Lipid-BSA complexes were produced by sonicating for 2 min (Branson 
Sonifier), resulting in a milky suspension. No precipitate was visible.   
Table 46: Lipids used for analysis 
Lipid Stock (mM) in 
DMSO 
Company Catalogue # 
Sphingosine 66.3 Sigma 1802 
Sphinganine 66.3 Avanti Polar Lipids 860498P 
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FTY720 29.07 Sigma SML0700 
Sphingosine-1-phosphate 20  Avanti Polar Lipids 860492P 
Ceramide 8.83 Matreya LLC 1832 
Glucosylceramide 6.16 Matreya LLC 1057 
Carnitine 31.25 Avanti Polar Lipids 870851P 
 
2.5.11.2 Treatment of cells with lipid-BSA complexes 
Cells were seeded out the day before treatment with sphingoid bases. The lipid-BSA 
complexes were diluted in 9 ml cell culture medium containing only 1% FCS in the 
desired concentration per 9 cm dish and incubated at 37 °C for 4.5 h. Afterwards, cells 
were harvested (2.5.2) und subjected to the beta-glucosidase activity assay (2.5.8.2).   
Table 47: Cell numbers seeded for lipid-BSA treatment 
Cell line Cell number per 9 cm 
dish 
CHO #A8A11 3x106 
mEF 1.2x106 
 
2.5.11.3 Treatment of protein lysates with lipid-BSA complexes 
Hypotonic lysates from CHO cells or bacterial cells expressing mGBA1-HA and 
mGBA2-HA or mGBA2-His, respectively, were prepared in tubes (Table 48) and 
incubated with a serial dilution of 10x concentrated stocks (1x final) of lipid-BSA 
complexes at RT for 1 h prior to analysis of beta-glucosidase activity (2.5.8.2).  
Table 48: Pipetting scheme for assay with lipid-BSA complexes 
Assay approach per tube Assay approach per well 
(96-well plate) 
Assay approach per well 
(384-well plate) 
72 µl hypotonic protein 
lysate 
90 µl pH buffer 25 µl approach from 96-
well plate 
8 µl 10x concentrated 
lipid-BSA stock 
20 µl protein sample 
containing lipid-BSA 
complexes 
(25 µM CBE final and 
8.3 µM NB-DNJ final) 
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 11 µl of lipid-BSA 
complex stocks 
5 µl 10 mM 4-MUG 
 9 µl 433 µM CBE (30 µM 
final) or 144 µM NB-DNJ 
(10 µM final)  
 
 ad 130 µl with hypotonic 
buffer 
 
 
2.5.11.4 Fluorometric pH measurements  
2.5.11.4.1 Cell preparation 
To study the intracellular pH, human dermal fibroblasts from control and type I Gaucher 
patients (hFB 9 and hFB 11, respectively, Table 8) were trypsinised, harvested, 
counted, and 3x104 – 7.3x104 cells/50 µl were washed twice with PBS and re-
suspended in 450 µl TYH buffer containing 5 mM HEPES/NaOH, pH 7.4 (Table 49).  
2.5.11.4.2 Buffers and solutions for BCECF measurements  
TYH buffers were prepared according to Table 49 and the osmolarity was determined 
in a 50 µl buffer sample after the pH was adjusted using a cryoscopic osmometer 
(Osmomat 030, Gonotec). The osmolarity of all buffers should be around 290 – 310 
mOsmol. From the two strongly buffered TYH buffers of pH 6.2 (50 mM MES) and 6.8 
(50 mM HEPES), five different buffers were prepared with pH values ranging from 6.18 
– 7.75 (pH 6.18 and 6.48: MES, pH 6.81, 7.56, and 7.76: HEPES) by titration with 
NaOH. To determine the final pH value (pHe) in each well, the weakly buffered TYH 
buffer (5 mM HEPES, pH 7.4) was mixed with each of the five strongly buffered TYH 
buffers in a ratio of 1:5 and the pH was determined using a pH-meter (Table 50).    
Table 49: TYH buffer 
TYH buffer 5 mM HEPES 50 mM HEPES 50 mM MES Stock 
NaCl 137.5 mM 97.5 mM 97.5 mM 5 M 
KCl 0.75 mM 0.75 mM 0.75 mM 1 M 
CaCl2 2 mM 2 mM 2 mM 1 M 
KH2PO4 1.2 mM 1.2 mM 1.2 mM 200 mM 
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MgSO4 1 mM 1 mM 1 mM 1 M 
Glucose 5.6 mM 5.6 mM 5.6 mM - 
HEPES/MES 5 mM 50 mM 50 mM - 
Sodium pyruvate 0.5 mM 0.5 mM 0.5 mM - 
L-Lactate 10 MM 10 MM 10 MM - 
 pH 7.4 /w 
NaOH 
pH 6.8 pH 6.2  
  
Table 50: pH values of pHe buffers 
pH of pHe buffer before 
mixing 
pH of pHe buffer after 
mixing 
6.18 6.24 
6.48 6.52 
6.81 6.79 
7.56 7.55 
7.76 7.75 
 
2.5.11.4.3 Loading of cells with BCECF 
Cells were loaded with BCECF-AM according to Table 51 and incubated at RT in the 
dark for 10 min. Afterwards, remaining BCECF-AM was removed by washing twice 
with TYH buffer (5 mM HEPES, pH 7.4) and centrifuging at 700 x g for 5 min.  
Table 51: Pipetting scheme for BCECF loading 
BCECF loading Stock 
Cell suspension  
(3x104 – 7.3x104 cells/50 µl) 
- 
0.05% Pluronic 10% (w/v) 
10 µM BCECF-AM 2 mM 
3 mM Probenizid 300 mM 
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2.5.11.4.4 Determining the intracellular pH in human dermal fibroblasts 
One well of a 96-well flat bottom plate (Greiner) contained 50 µl cell suspension with 
3x104 – 7.3x104 cells. To lyse the cells, Triton X-100 was prepared as a 6-fold stock 
solution (0.3% Triton X-100, 0.5% final) in five TYH (“pHe”) buffers with different pH 
values (pH 6.18 to 7.76) according to Table 50 and Table 52. First, the baseline was 
measured at 29 °C with an excitation wavelength of 440-10 nm and 485 nm for two 
cycles and the emission was detected at 520 nm. Next, 250 µl lysis/pHe buffer (Table 
52) were added and the change in BCECF fluorescence was measured over eight 
cycles (Table 53). To determine pHi in fibroblasts from control and type I Gaucher 
patients (2.5.11.4.1), the “null-point” method was applied. The method is described in 
detail in passage 3.8.   
Table 52: Buffers used for BCECF measurements 
Lysis/pHe buffer Stock 
TYH buffer  
(50 mM HEPES or MES, pH 6.32 – 7.73) 
- 
0.3% (w/v) Triton X-100 5% 
  
Table 53: Fluostar plate mode settings for BCECF measurements 
No. of cycles 10  
Cycle time (s) 55  
No. of flashes per well 100  
 
2.5.12 Ultracentrifugation of protein lysates  
To separate proteins into a membrane-bound and soluble fraction, hypotonic protein 
lysates (2.5.2) were transferred into plastic centrifugation vials suited for the TLA 100 
rotor of Optima XP Ultracentrifuge (Beckman Coulter) and ultracentrifuged for 30 min 
at 70,000 rpm and 4 °C. Supernatants were transferred to new tubes, whereas the 
pellets were solubilised in the initial amount of hypotonic buffer or a reduced volume to 
concentrate the samples. Solubilised pellets were also transferred to new tubes and 
sonicated (Branson Sonifier) until the sample appeared homogenous. The presence 
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of GBA2 was analysed either by Western blot (2.5.5) or by the fluorescence-based 
GBA activity assay (2.5.8.2).  
2.6 Lipid analysis 
2.6.1 Non-fluorescent lipid analysis using thin layer chromatography  
2.6.1.1 General glycosphingolipid extraction from cells 
Per sample, cells from 6-8 confluent 9 cm dishes were harvested as previously 
described in 2.5.2., frozen in liquid nitrogen, and stored at -80 °C until further usage. 
Then, cells were thawed on ice, re-suspended in 1 ml ddH2O and sonicated 3x for 
30 sec in ice-cold water using a Branson Sonifier. The protein concentration was 
determined by a BCA test (2.5.2.2). 2 ml methanol were added, and the mix was 
vortexed and sonicated in a water bath for 2 min. Lipids were extracted by adding 2 ml 
methanol and 3 ml “ExMi” (chloroform/methanol/ddH2O in a ratio of 10:5:1, v/v/v) and 
shaking in a 37 °C waterbath overnight. On the next day, the samples were centrifuged 
at 2,000 rpm for 10 min and the supernatant containing the lipids was filtered through 
a 230 mm long Pasteur glass pipette filled with glass fibre wool (Macherey-Nagel). The 
flow-through containing the extracted lipids was collected in a new tube. The pellet was 
re-suspended in 2 ml chloroform/methanol in a ratio of 1:1 (v/v), vortexed, sonicated 
for 5 min, and also filtered through the glass wool. Both flow-throughs containing the 
extracted lipids were pooled and transferred to a new tube.   
2.6.1.2 General glycosphingolipid extraction from mouse tissues 
To isolate lipids from spleens of control, GBA2-deficient and GBA1/GBA2-deficient 
mice, the wet weight of all tissues was determined before freezing and lyophilisation. 
All following steps were carried out in glass tubes. 1 ml ddH2O was added per tissue 
for homogenisation using a Teflon douncer. The glass vials were then covered with a 
filter paper and subjected to lyophilisation for three days. Next, the dry weight of the 
samples was determined. The dried tissue powder was then solubilised in 1 ml ddH2O, 
vortexed, and lipid extraction was carried out three times on three consecutive days: 
(i) 4 ml methanol and 3 ml “ExMi” (chloroform/methanol/ddH2O in a ratio of 10:5:1, 
v/v/v), (ii) 5 ml chloroform/methanol in a ratio of 1:1 (v/v), or (iii) 5 ml 
chloroform/methanol in a ratio of 2:1 (v/v) were added and lipids were extracted by 
shaking in a 37 °C waterbath overnight. On the next day, the samples were centrifuged 
at maximal speed for 5 min and the supernatant containing the lipids was filtered 
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through a 230 mm long Pasteur glass pipette filled with glass fibre wool (Macherey-
Nagel). The flow-through containing the extracted lipids was collected in a new tube 
and the solvents were evaporated under a constant stream of nitrogen.  
2.6.1.3 Alkaline hydrolysis of phospholipids 
Phospholipids were removed by alkaline hydrolysis with 4 M NaOH (125 µM final) in a 
shaking water bath at 37 °C for 2 h. The reaction was terminated by addition of 10 µl 
glacial acid and the liquids were evaporated using nitrogen.  
2.6.1.4 Reversed-phase chromatography 
Salts were removed using RP-18 columns (reversed phase material with 18 C atoms 
side-chains). Here, dried lipids were re-suspended in 1 ml 300 mM aqueous 
ammonium acetate by vortexing and directly loaded to the columns. Remaining lipids 
were washed off of the tube by addition of 1 ml 200 mM ammonium acetate in 
methanol/ddH2O in a ratio of 1:1 (v/v) and also applied to the column. Salts and other 
water-soluble substances were washed from the column by addition of 6 ml ddH2O, 
whereas lipids were extracted by adding 600 µl methanol and, subsequently, 8x1 ml 
chloroform/methanol in a ratio of 1:1 (v/v) to the column. The elution was collected in 
a new tube. 
2.6.1.5 Thin layer chromatography and general lipid visualisation 
For cell samples, lipids corresponding to 1-2 mg total protein and for mouse spleen 
samples, lipids corresponding to 15 mg dry weight were applied to pre-washed silica 
gel 60 plates (stationary phase, Merck, Darmstadt, Germany) and analysed by thin 
layer chromatography (TLC) using CHCl3/MeOH/ddH2O in a ratio of 70:30:5 (v/v/v) as 
liquid phase. After chromatography, lipids were visualised using a mixture of CuSO4-
pentahydrate and phosphoric acid and were baked at 180 °C (Yao 1985). To determine 
the amount of GlcCer present, the signal intensity of a serial dilution of purified 
galactosylceramide (galactose is a C-4 epimer of glucose) was analysed using a 
Densitometer and compared to the GlcCer signals.  
2.6.2 Fluorescent clickGlcCer lipid analysis using thin layer chromatography 
Besides visualisation of clickGlcCer in human dermal fibroblasts (2.5.7.5), the fate of 
clickGlcCer was also studied by TLC. As previously described in 2.5.7.1, 4x104 cells 
were seeded per well on a 24-well plate directly to the plastic surface. After pulsing 
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and chasing of clickGlcCer, cells were washed once with PBS to remove residual 
clickGlcCer. 1 ml methanol/chloroform in a ratio of 5:1 was applied to the cells and the 
culture dish was swirled once before the solvent was transferred to a 1.5 ml (safe-lock) 
Eppendorf tube (method also described in Thiele et al. (Thiele et al., 2012)). The 
solvent/lipid mix was centrifuged at full speed and RT for 2 min, resulting in 
sedimentation of a whitish protein pellet from the solution. The supernatant containing 
the lipids was transferred to a 2 ml (safe-lock) Eppendorf tube and 350 µl chloroform 
and 400 µl ddH2O were added. Everything was mixed vigorously by hand and 
centrifuged at full speed and RT for 2 min to achieve phase separation. The lower 
chloroform phase containing the lipids was transferred to a new 1.5 ml (safe-lock) 
Eppendorf tube and the solvent was evaporated using a speed-vac centrifuge. Lipids 
were re-suspended in 40 µl chloroform, vortexed for 5 min, and sonicated in a water 
bath for 5 min. After incubating at RT for 15 min, 20 µl of the lipids were transferred to 
a new 1.5 ml Eppendorf tube, while the remaining 20 µl were frozen to -20 °C. 30 µl 
click-reaction mix (Table 54) were added per sample, briefly spun down, and incubated 
for 2-3 h at 43 °C. As size standard, alkyne derivatives of ceramide, glucosylceramide, 
sphinganine, triacylglycerol, diacylglycerol, and palmitate were also clicked using the 
same click-reaction mix. The TLC chamber was pre-incubated with the first mobile 
phase (chloroform/methanol/ddH2O in a ratio of 65/25/4) for at least 30 min whilst 30 
µl of the 50 µl of each sample were applied onto a silica gel 60 plate (stationary phase, 
20x20 cm, Millipore) with a glass capillary. The click-reacted standards were diluted 
1:10 in chloroform and around 10 µl were loaded (clickable standards were 
synthesised by Prof. C. Thiele, Biochemistry and Cell Biology of Lipids, LIMES, Bonn, 
Germany) (Thiele et al., 2012). TLC was performed in the first mobile phase up to a 
height of 12 cm (~30 min). Then, the silica plate was placed to a second TLC chamber 
and run chromatography was performed in a second mobile phase (hexane/ethyl 
acetate in a ratio of 1:1) until the solvent had reached the top of the plate (~40 min). 
TLCs were shortly soaked in 4% (v/v) N,N,-diisopropylethylamine in hexane before 
fluorescent images of the TLC plates were acquired using a 420 nm LED (Roithner 
Lasertechnik, Vienna, Austria) filtered through a coloured glass filter (HEBO V01, Hebo 
Spezialglas) for excitation and an EMCCD camera (Rolera-MGi Plus Fast 1394, Q-
imaging), equipped with a 494/20 (channel for detection of the coumarin signal) and 
572/28 (channel for detection and correction of background fluorescence) bandpass 
emission filters.  
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Table 54: Click-reaction mix for extracted alkynes 
Click-reaction mix for extracted alkynes 
850 µl Ethanol 
250 µl of 10 mM [acetonitrile]4 CuBF4 in acetonitrile 
10 µl of 44.5 mM (2 mg/ml) 3-azido-7-hydroxycoumarin in ethanol 
  
2.6.3 Fluorescent alkyne lipid analysis using thin layer chromatography 
This method has been described in great detail in Thiele et al. (Thiele et al., 2012). 
Briefly, lipids were extracted by methanol/chloroform in a ratio of 4:1. Dried lipids were 
re-dissolved in chloroform and 30 µl click-reaction mix (Table 54) was added. The click 
reaction was performed at 43 °C for 3 h. The click-reacted lipids were applied to TLC 
silica plates and separated in solvent 1 (chloroform/methanol/H2O/acetic acid 
65/25/4/1, 2/3 of the plate) and subsequently in solvent 2 (hexane/ethyl acetate 1/1, 
whole plate). TLC analysis was performed as previously described in 2.6.2). 
2.6.4 Extraction and quantification of sphingolipids using mass spectrometry 
2.6.4.1 Isolation of lipids from fibroblasts for mass spectrometry 
Human dermal fibroblasts were harvested as previously described in 2.5.2, frozen in 
liquid nitrogen, and stored at -80 °C until further usage. Cell samples were thawed on 
ice, lysed in hypotonic buffer as previously described in 2.5.2, and the protein 
concentration was determined by BCA test (2.5.2.2).  
Further isolation of lipids was performed by Dr. Katharina vom Dorp, Institute of 
Molecular Physiology and Biotechnology of Plants, University of Bonn, Bonn, 
Germany. 
500 µl chloroform/methanol/formic acid in a ratio of 1:1:0.1 (v/v/v) and 50 µl of internal 
standard mix (“Sphingomix”, personal communication with Dr. K. vom Dorp) were 
added per sample and mixed thoroughly. 250 µl of 1 M KCl/0.2 M H3PO4 were added, 
samples were vortexed, and centrifuges at 5,000 rpm for 3 min to obtain phase 
separation. The lower phase containing the lipids was transferred to a fresh glass vial 
and the remaining samples were re-extracted by again adding 500 µl of 
chloroform/methanol in a ratio of 2:1 (v/v). Samples were vortexed, centrifuged at 
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5,000 rpm for 3 min and the lower phase was transferred to the glass vial and 
combined with the previous extract. Solvents were evaporated under air flow and lipids 
were re-suspended in 500 µl of pure chloroform by vortexing.  
2.6.4.2 Lipid purification using silica columns for mass spectrometry 
Lipid purification was performed by Dr. Katharina vom Dorp, Institute of Molecular 
Physiology and Biotechnology of Plants, University of Bonn, Bonn, Germany. 
Small silica columns (Strata-1-Silica, 55 µM, 70 Ǻ containing 100 mg silica) were 
equilibrated by flushing with pure chloroform for three times. Afterwards, samples 
dissolved in pure chloroform were applied and non-polar lipids were eluted with three 
column volumes (CV) of pure chloroform. Medium-polar sphingolipids (LCBs, 
ceramides, hexosylceramides) were eluted with 3 CV of acetone/isopropanol in a ratio 
of 1:1 (v/v). Very polar sphingolipids (e.g. sphingomyelin) were eluted with 3 CV of pure 
methanol. The acetone/isopropanol fraction was dried under air flow and dissolved in 
100 µl of Q-TOF solvent (chloroform/methanol/300 mM ammonium acetate in a ratio 
of 300:665:35, v/v/v) and subjected to mass spec analysis. Mass spec analysis was 
carried out as previously described in Ginkel et al. (Ginkel et al., 2012) and Raju et al. 
(Raju et al., 2015).  
2.7 Animals 
GBA1-deficient mice were generated as described in Enquist et al. (Enquist et al., 
2006). Mice deficient for GBA2 were generated as mentioned in Yildiz et al. (Yildiz et 
al., 2006). All experiments performed with animals were in accordance with the 
relevant guidelines and regulations.  
2.7.1 Injection mice with CBE 
The injection of eight days old 6OlaHsd mice with 25 – 100 mg CBE/kg/day for 10 days 
was carried out in the lab of Prof. T. Futerman (Weizman Institute, Israel) as previously 
described in Klein et al. (Klein et al., 2016). Brains were dissected, frozen, and sent to 
our lab for further analysis.  
2.7.2 Statistics 
Data presented in this study represent the mean value with standard deviation from at 
least three independent experiments. Differences between samples were analysed 
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using Student’s t-test or the analysis of variance (ANOVA) and the OriginPro software 
version 9.0. The N number represents the amount of animals or different cell lines if 
not stated otherwise. 
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3 Results 
3.1 Assay to measure GBA1 and GBA2 activity 
Studying the function of two enzymes that are ubiquitously expressed (Brady et al., 
1965; Yildiz et al., 2006) and share the same substrate requires an assay that allows 
to discriminate between the activity of lysosomal GBA1 and non-lysosomal GBA2. In 
Körschen et al., we published an activity assay that allows to individually measure the 
activity of GBA1 and GBA2 using an artificial, water-soluble and GlcCer-like substrate 
called 4-Methylumbelliferyl beta-D-glucopyranoside or, in short 4-MUG (also see 
2.5.8.2) (Körschen et al., 2013). In this assay, we made use of the differential activity 
of GBA1 and GBA2 at different pH values, which allows to distinguish between the two 
activities (Figure 8). GBA2 activity is sensitive to detergents (Körschen et al., 2013). 
Thus, pH profiles of the total beta-glucosidase activity were measured in hypotonic 
mouse tissue lysates. To further delineate the two activities, the assay was performed 
in the presence and absence of 25 µM CBE, a specific blocker for GBA1, and 8.3 µM 
NB-DNJ, a specific blocker for GBA2 (Ridley et al., 2013). Addition of NB-DNJ 
demonstrated that GBA1 represents the predominant beta-glucosidase activity at 
acidic pH values with a maximum at pH 4.25 (Figure 8, orange). Vice versa, addition 
of CBE revealed that GBA2 is active at rather neutral pH values with a maximum at pH 
5.25 (Figure 8, green). Addition of both, CBE and NB-DNJ, completely blocked any 
beta-glucosidase activity. However, although the individual activities were highest at 
the particular pH optima, the remaining activity of the other enzyme at these values 
was still evident (Figure 8). Thus, the assay was performed at the pH optimum for each 
enzyme and in the presence of the specific blockers. Based on these results, we 
defined the activity of GBA1 as the CBE-blockable activity at pH 4 and the activity of 
GBA2 as the NB-DNJ-blockable activity at pH 6 (Figure 8).  
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Figure 8: Beta-glucosidase activity in hypotonic mouse tissue lysates at different pH values. The 
beta-glucosidase activity was measured at different pH values using 1.67 mM 4-MUG. In the presence 
of 8.3 µM NB-DNJ, the GBA2-specific blocker, GBA1 activity was maximal at pH 4.25, whereas in 
presence of 25 µM CBE, the GBA1-specific blocker, GBA2 activity was maximal at pH 5.25. Thus, GBA1 
activity was measured at pH 4 and GBA2 activity was determined at pH 6 in further assays. Data 
published in Körschen et al. 2013. CBE: Conduritol B epoxide, NB-DNJ: N-butyl-deoxynojirimycin, 4-
MUG: 4-Methylumbelliferyl beta-D-glucopyranoside. Data are presented as mean ± SD. Representative 
plot of quadruples for n = 3 experiments.     
3.2 GBA2 activity is reduced in embryonal fibroblasts from GBA1-deficient 
mice 
GBA1 and GBA2 both are ubiquitously expressed and cleave the same substrate, 
GlcCer (Brady et al., 1965; Yildiz et al., 2006). The question arises why a cell 
expresses two enzymes that are spatially separated, while hydrolysing the same 
substrate? What is their specific function? Is their function mutually exclusive or do 
they interact with each other? The simplest way to address this question is to analyse 
the expression and activity of one enzyme in absence of the other.  
First, the GBA2 activity was analysed in GBA1-deficient murine embryonal fibroblasts 
(Enquist et al., 2006; Körschen et al., 2013) (Figure 9a, b). GBA1 activity was absent, 
but, surprisingly, the GBA2 activity was also reduced to around 53% of the control 
(Figure 9a, b). Next, the reverse experiment was performed by analysing the GBA1 
activity in hypotonic brain lysates from GBA2-deficient mice (Figure 9c, d). However, 
loss of GBA2 did not affect the activity of GBA1 (Figure 9c).  
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Figure 9: GBA2 activity is reduced in embryonal fibroblasts from GBA1-deficient mice. Analysis 
of the GBA1 and GBA2 activity in hypotonic lysates of wild-type (WT) and GBA1-deficient (knock-out, 
KO) embryonal fibroblasts in presence of 1.67 mM 4-MUG. (a) GBA1 activity was absent in hypotonic 
lysates of GBA1-deficient mouse embryonal fibroblasts compared to control cells. (b) GBA2 activity was 
reduced to 53% of control values in GBA1-deficient fibroblasts. (c) Vice versa, GBA1 activity remained 
unchanged in hypotonic brain lysates from GBA2-deficient mice (d), which lacked any GBA2 activity. 4-
MUG: 4-Methylumbelliferyl beta-D-glucopyranoside. Data are presented as mean + SD. N numbers are 
indicated in brackets. The p value was determined using One-way ANOVA.   
3.3 GBA2 activity is reduced in fibroblasts from Gaucher patients 
GBA1-deficient mice represent the animal model for the most common lipid storage 
disorder in humans termed Gaucher disease (Farfel-Becker et al., 2011) (also see 
1.1.4.1.2). To date, there is no genotype-phenotype relation for Gaucher disease. As 
previously mentioned, the variety of symptoms has been used to classify the disease 
into type I, II, and III Gaucher disease, where type I patients mainly show an 
enlargement of liver and spleen, type II patients are characterized by an early onset of 
the disease together with severe neurological defects, and type III patients show 
moderate neurological symptoms compared to type II patients (Grabowski, 2001). 
Thus, additional factors seem to determine the fate of a patient carrying a mutation in 
the GBA1 gene (Vardi et al., 2016).  
Since the GBA2 activity was reduced in embryonal fibroblasts from GBA1-deficient 
mice, we wondered whether GBA2 might be one of those “additional factors” that play 
a role in Gaucher disease. Thus, the GBA1 and GBA2 expression and activity were 
analysed in more detail using dermal fibroblasts from Gaucher patients with different 
mutations in the GBA1 gene and different phenotypes of the disease (Figure 12 - 
Figure 14).  
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First, a protocol to analyse the mRNA expression in dermal fibroblasts from Gaucher 
patients, with various genetic backgrounds and phenotypes, and control patients was 
established using quantitative real-time PCR (qPCR). There are several DNA-binding 
dyes available for quantitative real-time polymerase chain reaction (qPCR). Here, 
SYBR Green was used (Biorad).  
Amplicons for qPCR were designed on cDNA with a length of 75-200 base pairs (bp) 
since fragments shorter than 75 bp cannot be distinguished from primer dimers in the 
reaction and amplicons longer than 200 bp are amplified less efficiently (Real-Time 
PCR Applications Guide, Biorad) (Table 56). The template sequences did not contain 
repeats of more than four bases and the overall GC content was 50-60%. Most 
importantly, amplicons that span an intron were chosen to avoid the amplification of 
contaminating genomic DNA.  
Primers for qPCR were 20 nucleotides (nt) long, had a GC content of 50-60% (Table 
15), and have a similiar melting temperature (TM) (between 50-65 °C). Repeats of Gs 
and Cs longer than three bases and repeats of matching bases (e.g. AA and TT) were 
avoided. The specificity of the primers and the amplicon was checked using the Basic 
Local Alignment Search Tool (BLAST, http://blast.ncbi.nlm.nih.gov/) or BLAT 
(http://genome.ucsc.edu/cgi-bin/hgBlat) because some DNA sequences appear 
multiple times in the genome, especially when they are rather short. To normalise the 
expression levels of the genes of interest (GOIs, GBA1 and GBA2, Table 55), suitable 
housekeeping genes (HKGs) were selected (hB2m and hAlas1, Table 55). A 
housekeeper is a reference gene, whose expression level is constant across all tested 
samples. Normally, genes that are commonly expressed and maintain basic cellular 
functions are used. The same rules for amplicon and primer design were applied when 
choosing suitable HKGs. As a reference, one highly expressed HKG and one with 
rather low expression was chosen.  
Table 55: Human genes of interest (GOIs) and housekeeping genes (HKGs) chosen for qPCR 
analysis 
Gene Gene product Reference 
hGBA1 Acid beta-glucosidase NM_0010057 
hGBA2 Non-lysosomal beta-
glucosidase 
NM_020944 
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hB2m Beta-2-microglobulin NM_004048 
hAlas1 Aminolevulinic acid 
synthase 1 
NM_199166 
 
Table 56: Amplicon sizes of human primer pairs selected for qPCR 
Gene Primer pair Expected amplicon size 
(bp) 
hGBA1 C1796/97 249 
hGBA1 C1798/99 244 
hGBA2 C1800/01 185 
hGBA2 C1802/03 220 
hB2m C1818/19 216 
hB2m C1820/21 277 
hAlas1 C1822/23 135 
hAlas1 C1824/25 123 
bp: Base pairs 
To test whether primers designed for qPCR amplify the sequence of interest, a 
conventional polymerase chain reaction (PCR) was performed (2.4.2). For human 
primers (Table 15), cDNA obtained from a fibroblast cell line from a control patient 
(hFB 8, Table 8) was used. All amplicons (Figure 10) had the expected sizes (Table 
56), whereas primer pairs C1798/99, C1802/03, and C1824/25 showed additional PCR 
products (Figure 10).  
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Figure 10: Analysis of the amplicons of human qPCR primers and control cDNA from human 
dermal fibroblast line hFB 8. 5 µl of the PCR approach were loaded to a 2% agarose gel and the 
fragments were analysed under a UV lamp. All human amplicons had the expected sizes, whereas 
human primer pairs C1798/99, C1802/03, and C1824/25 showed additional PCR products. bp: base 
pairs.  
To reliably analyse the data obtained from qPCR, a primer efficiency test (PET) was 
performed (2.4.6.5). In a perfect PCR cycle, the amount of DNA should double and the 
primer efficiency would be 100%. The PET was performed for two primer pairs per GOI 
(hGBA1, hGBA2) and HEK (hB2m, hAlas1) in duplets. The slope obtained from plotting 
the individual CT values (the PCR cycle at which the fluorescent signal reaches the 
threshold line) against the logarithm of the cDNA dilutions was used to calculate the 
primer efficiency (E = 10-1/slope). Primers used for qPCR showed at least 90% and 
maximal 105% efficiency (Table 57 and Table 60).  
Exemplarily, the CT values of hGBA2 primer pair C1800/01 were plotted against the 
logarithm of the cDNA dilution in Figure 11. Here, the primer efficiency is 103% (Table 
57). Based on these results and those obtained from the remaining primer pairs, the 
following human primers were used for subsequent experiments: hGBA1: C1798/99, 
hGBA2: C1800/01, hB2m: C1818/19, and hAlas1: C1824/25. The PCR products 
generated by these primer pairs were send for sequencing and, thus, verified to be the 
right amplicons (data not shown).        
Results   73 
 
Figure 11: Primer efficiency test. The CT values of hGBA2 primer pair C1800/01 were plotted against 
the logarithm of the different cDNA dilutions.    
Table 57: Human qPCR primer efficiencies 
Gene Primer 
numbers 
Slope R2 value Efficiency (%) 
hGBA1 C1796/97 -3.0654 0.9993 112 
hGBA1 C1798/99 -3.1823 0.9971 106 
hGBA2 C1800/01 -3.2557 0.998 103 
hGBA2 C1802/03 -2.5901 0.9869 143 
hB2m C1818/19 -3.5344 0.9973 92 
hB2m C1820/21 -3.5809 0.9965 90 
hAlas1 C1822/23 -3.4814 0.9978 94 
hAlas1 C1824/25 -3.3301 0.9992 100 
 
qPCR was performed for the GOIs hGBA1 and hGBA2, and the HKGs hB2m and 
hAlas1 and human dermal fibroblast samples as templates (see Table 8, Table 55, 
2.4.6.6). For both, GBA1 and GBA2, there was no difference between the relative 
mRNA expression in control and Gaucher fibroblasts (Figure 12).    
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Figure 12: GBA1 and GBA2 mRNA expression in dermal fibroblasts from Gaucher patients. 
Analysis of GBA1 and GBA2 mRNA levels in control (Ctrl) and Gaucher fibroblasts using qPCR. Neither 
(a) GBA1 nor (b) GBA2 mRNA expression were changed between control and Gaucher fibroblasts. Data 
are presented as mean + SD; the different types of Gaucher disease are indicated. N numbers are 
indicated in brackets.  
Secondly, the GBA1 and GBA2 protein expression was analysed in dermal fibroblasts 
from Gaucher and control patients by Western blot analysis (Figure 13). GBA1 
expression was significantly reduced in Gaucher fibroblasts with the lowest expression 
in type II samples (Figure 13b). However, GBA2 protein expression remained 
unchanged in control and Gaucher fibroblasts (Figure 13c).  
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Figure 13: Western blot analysis of GBA1 and GBA2 protein expression in dermal fibroblasts 
from Gaucher and control patients. Hypotonic protein lysates from control (Ctrl) and Gaucher 
fibroblasts were labelled using antibodies against GBA1 (Sigma) and GBA2 (monoclonal antibody mix 
2F8/4A12). CHO cells stably over-expressing mGBA1-HA and/or mGBA2-HA were used as positive 
controls. Calnexin was used as a loading control. (a) GBA1 expression was significantly reduced in 
Gaucher fibroblasts with the lowest expression in type II samples. GBA2 protein expression remained 
unchanged in control and Gaucher fibroblasts. (b) Quantification of GBA1 protein levels normalised to 
calnexin. (c) same as (b) for GBA2. Data are presented as mean + SD. The different types of Gaucher 
disease are indicated. N numbers are shown in brackets. The p value was determined using One-way 
ANOVA.    
Finally, the GBA1 and GBA2 activity was analysed in Gaucher and control fibroblasts 
using our activity assay (Figure 14). GBA1 activity was barely detectable in all patient 
fibroblast lines, with remaining activities of 8%, 2.6%, and 5.6% for type I, II, and III, 
respectively (Figure 14a). Interestingly, GBA2 activity was also reduced to around 60% 
in all Gaucher types compared to the controls (Figure 14b). Thus, these data underline 
the finding from GBA1-deficient fibroblasts. However, since the GBA2 activity was 
evenly reduced in type I, II, and III patients, GBA2 does not play a role in genotype-
phenotype correlation of Gaucher disease.    
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Figure 14: GBA1 and GBA2 activity in Gaucher and control fibroblasts. Analysis of the GBA1 and 
GBA2 activity in hypotonic lysates of control (Ctrl) and Gaucher fibroblasts in presence of 1.67 mM 4-
MUG. (a) GBA1 activity was barely detectable in all patient fibroblast lines, with remaining activities of 
8%, 2.6%, and 5.6% for type I, II, and III, respectively. (b) The GBA2 activity was also reduced to around 
60% in all Gaucher types compared to the controls. 4-MUG: 4-Methylumbelliferyl beta-D-
glucopyranoside. Data are presented as mean + SD. The different types of Gaucher disease are 
indicated. N numbers are shown in brackets. P values were determined using One-way ANOVA.      
3.4 GBA2 activity is reduced in CRISPR/Cas9-generated GBA1-deficient cells 
3.4.1 GBA2 activity in control and GBA1-deficient HAP1 cells 
To analyse the GBA1-dependent regulation of GBA2 activity in more detail, 
independent from secondary effects that might occur in patient samples, GBA1 and 
GBA2 activity were also studied in human fibroblast-like cells, where GBA1 or GBA2 
was deleted via CRISPR/Cas9 (Figure 15). The first GBA1-deficient HAP1 cell line 
(HZGHC002786c001, abbreviated #001) contains a 479 bp insertion in exon 6 of the 
GBA1 gene and the second GBA1-deficient HAP1 cell line (HZGHC002786c010, 
abbreviated #010) contains a 1 bp insertion in exon 6, both resulting in a frame shift 
and, therefore, in gene silencing. GBA1 activity was completely absent in both GBA1-
deficient HAP1 cell lines compared to the control (Figure 15a). In fact, the GBA2 activity 
was again decreased to around 64% and 71%, respectively (Figure 15b). The 
experiment was also performed vice versa by analysing the GBA1 activity in GBA2-
deficient HAP1 cells (Figure 15c, d). In the first GBA2-deficient HAP1 cell line 
(HZGHC004109c001, abbreviated #001), 5 bp were deleted in exon 1 of the human 
GBA2 gene, whereas the second GBA2-deficient HAP1 cell line (HZGHC004109c011, 
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abbreviated #011) contains a 1 bp insertion in exon 1, both resulting in a frameshift 
and, therefore, in gene silencing. Similar to the results obtained from brain lysates from 
GBA2-deficient mice (Figure 9c), GBA1 activity remained unchanged in control and 
GBA2-deficient HAP1 cells (Figure 15c).   
 
Figure 15: GBA1 and GBA2 activity in CRISPR/Cas9-generated GBA1-deficient HAP1 cells. 
Analysis of the GBA1 and GBA2 activity in hypotonic lysates of control (Ctrl) and CRISPR/Cas9-
generated HAP1 cells deficient for GBA1 in presence of 1.67 mM 4-MUG. (a) GBA1 activity was absent 
in both GBA1-deficient HAP1 cell lines compared to the control. (b) GBA2 activity was decreased to 
around 64% and 71% compared to control cells, respectively. (c) Vice versa, GBA1 activity remained 
unchanged in control and GBA2-deficient HAP1 cells (d), showing no GBA2 activity. GBA1-deficient 
HAP1 cell lines: HZGHC002786c001 and HZGHC002786c010, GBA2-deficient cell lines: 
HZGHC004109c001 and HZGHC004109c011. 4-MUG: 4-Methylumbelliferyl beta-D-glucopyranoside. 
Data are presented as mean + SD. N numbers are indicated in brackets. P values were determined 
using One-way ANOVA.         
3.4.2 GBA2 activity in control and GBA1-deficient HEK293 cells 
Lastly, the GBA1-dependent regulation of GBA2 activity was also verified in HEK293 
cells, a widely used human-derived cell model (Graham et al., 1977). I compared the 
GBA1 and GBA2 activity in control cells and HEK293 cells deficient for GBA1, 
generated by the CRISPR/Cas9 system (obtained from C. Yaacobi, Futerman lab, 
Weizmann Institute, Israel). Again, the GBA2 activity was reduced to around 37% of 
the control (Figure 16).   
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Figure 16: GBA1 and GBA2 activity in CRISPR/Cas9-generated GBA1-deficient HEK293 cells. 
Analysis of the GBA1 and GBA2 activity in hypotonic lysates of wild-type (WT) and CRISPR/Cas9-
generated HEK293 cells deficient for GBA1 (knockout, KO) in presence of 1.67 mM 4-MUG. (a) GBA1 
activity was absent in GBA1-deficient HEK293 cells compared to the control, (b) resulting in a reduced 
GBA2 activity of only 37%. 4-MUG: 4-Methylumbelliferyl beta-D-glucopyranoside. Data are presented 
as mean + SD. N numbers are indicated in brackets. P values were determined using One-way ANOVA.      
3.5 GBA2 activity depends on GBA1 activity 
3.5.1 GBA2 activity is reduced in CBE-treated cells 
To get a more mechanistic insight, we analysed whether it is the loss of GBA1 
expression and/or activity that reduces GBA2 activity. Here, a pharmacologic approach 
was applied. CBE inhibits GBA1 with an IC50 value of 2.7 ± 0.3 µM in hypotonic testis 
lysates, while GBA2 activity is reduced at higher CBE concentrations (starting at 
around 100 µM) (Körschen et al., 2013) (Figure 17a). Vice versa, NB-DNJ inhibits 
GBA2 with an IC50 value of 19.2 ± 0.4 nM without blocking GBA1 activity (Körschen et 
al., 2013) (Figure 17b).  
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Figure 17: Dose-response relationship of CBE and NB-DNJ for GBA1 and GBA2 activity in 
hypotonic testis lysates. Analysis of the GBA1 and GBA2 activity in hypotonic testis lysates from 
control mice in the presence of 0.1-100 µM CBE or 0.01-10 µM NB-DNJ and 1.67 mM 4-MUG. (a) CBE 
inhibits GBA1 with an IC50 value of 2.7 ± 0.3 µM in hypotonic testis lysates, while GBA2 activity is 
reduced at higher CBE concentrations. (b) NB-DNJ inhibits GBA2 with an IC50 value of 19.2 ± 0.4 nM 
without blocking GBA1 activity. Data published in Körschen et al., 2013. CBE: Conduritol B epoxide, 
NB-DNJ: N-butyl-deoxynojirimycin, 4-MUG: 4-Methylumbelliferyl beta-D-glucopyranoside. Data are 
presented as mean ± SD. Representative plots of quadruples for n = 3 experiments.     
To block GBA1 activity without affecting GBA2 activity, control fibroblasts were treated 
with 25 µM CBE for 48 h (Figure 18a, b). As shown in Figure 18a, GBA1 activity was 
dramatically reduced in CBE-treated cells compared to the non-treated controls (Figure 
18a). In line with the findings from Gaucher and GBA1-deficient fibroblasts, GBA2 
activity in CBE-treated cells was reduced to about 39% of the activity in non-treated 
control cells (Figure 18b). These results demonstrate that blocking GBA1 activity is 
sufficient to reduce GBA2 activity. 
This experimental paradigm was also tested in CHO control cells (Figure 18c, d) and 
cells stably over-expressing mGBA2 (#G4A11) (Figure 18e, f). Incubation with 25 µM 
CBE for 48 h completely abolished the endogenous GBA1 activity in CHO cells (Figure 
18c, e). In line with the previous findings, the endogenous and over-expressed GBA2 
activity was decreased to around 45% and 36% compared to non-treated controls, 
respectively (Figure 18d, f).  
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Figure 18: GBA2 activity in human fibroblasts and CHO cells treated with 25 µM CBE. Human 
dermal fibroblasts and CHO cells were treated with 25 µM CBE for 48 h to block GBA1 activity. Beta-
glucosidase activities were analysed in hypotonic cell lysates in presence of 1.67 mM 4-MUG. (a) GBA1 
activity was dramatically reduced in CBE-treated fibroblasts compared to the non-treated cells. (b) GBA2 
activity in CBE-treated cells was reduced to about 39% of the activity in non-treated control cells. (c) + 
(d) and (e) + (f) same as (a) + (b) in CHO control cells and CHO cells stably over-expressing mGBA2. 
The GBA2 activity was reduced to around 45% and 36% compared to non-treated controls, respectively. 
CBE: Conduritol B epoxide, 4-MUG: 4-Methylumbelliferyl beta-D-glucopyranoside. Data are presented 
as mean + SD. N numbers are indicated in brackets. P values were determined using One-way ANOVA.      
As a control, the experiment was performed vice versa in CHO cells stably over-
expressing mGBA2 (#G4A11) and blocking its activity with 2 µM NB-DNJ for 48 h 
(Figure 19). Whereas the activity of GBA2 was completely abolished in NB-DNJ-
treated cells (Figure 19b), GBA1 activity remained unchanged (Figure 19a). 
 
Figure 19: GBA1 activity in CHO cells stably over-expressing mGBA2 treated with 2 µM NB-DNJ. 
CHO cells stably over-expressing mGBA2 were treated with 2 µM NB-DNJ for 48 h to block GBA2 
activity. The subsequent effect on the GBA1 and GBA2 activity was analysed in hypotonic cell lysates 
in presence of 1.67 mM 4-MUG. (a) GBA1 activity remained unchanged in cells treated with 2 µM NB-
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DNJ (d) in absence of GBA2 activity. NB-DNJ: N-butyl-deoxynojirimycin, 4-MUG: 4-Methylumbelliferyl 
beta-D-glucopyranoside. Data are presented as mean + SD. N numbers are indicated in brackets. The 
p value was determined using One-way ANOVA. 
To verify whether the pharmacological block of GBA1 activity does not affect GBA1 
protein expression, Western blot analysis was performed. The GBA1-specific antibody 
recognises the human, but not the hamster protein. Thus, the cell model was switched 
from CHO to HEK293 cells. HEK293 cells transiently over-expressing mGBA2 and 
endogenously expressing GBA1 were incubated with 25 µM CBE for 48 h and, again, 
CBE treatment reduced GBA2 activity to about 46% of the activity in non-treated 
control cells (Figure 20b). The experiments were also performed vice versa in HEK293 
cells over-expressing mGBA2 by blocking GBA2 activity with 2 µM NB-DNJ for 48 h 
before assessing the GBA1 and GBA2 activity (Figure 20c, d). GBA2 activity was 
absent in NB-DNJ-treated cells (Figure 20d), whereas GBA1 activity remained 
unchanged (Figure 20c). Similar to what has been observed for the other systems, 
GBA1 and GBA2 protein expression was not different between treated and non-treated 
cells (Figure 20e-h). 
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Figure 20: Analysis of the GBA1 and GBA2 activity and protein expression in HEK293 cells 
transiently over-expressing mGBA2 treated with CBE or NB-DNJ. HEK293 cells transiently over-
expressing mGBA2 were treated with either 25 µM CBE or 2 µM NB-DNJ for 48 h to block GBA1 or 
GBA2, respectively. Beta-glucosidase activities were analysed in hypotonic cell lysates in the presence 
of 1.67 mM 4-MUG and protein expression was analysed by Western blot using antibodies against 
GBA1 (Sigma) and GBA2 (anti-HA, Sigma). CHO cells stably over-expressing mGBA1-HA and mGBA2-
HA were used as positive controls. Tubulin was used as a loading control. (a) Endogenous GBA1 activity 
was blocked in with the presence of 25 µM CBE. (b) GBA2 activity in CBE-treated cells was reduced to 
around 46% of the activity in non-treated cells (Ctrl). Vice versa, (c) GBA1 activity remained unchanged 
in cells treated with 2 µM NB-DNJ (d) in absence of GBA2 activity. (e) GBA1 and GBA2 protein 
expression was not different between CBE-treated and non-treated cells. (f) Same as (e) for NB-DNJ 
treated and non-treated cells. (g) Quantification of GBA1 and GBA2 protein levels in CBE-treated and 
control cells normalised to tubulin. (h) Same as (g) for NB-DNJ-treated and control cells. CBE: 
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Conduritol B epoxide, NB-DNJ: N-butyl-deoxynojirimycin, 4-MUG: 4-Methylumbelliferyl beta-D-
glucopyranoside. Data are presented as mean + SD. N numbers are indicated in brackets. P values 
were determined using Student’s t-test.  
To rule out that CBE directly inhibits GBA2 activity, embryonic fibroblasts from GBA1-
deficient mice were incubated with 25 µM CBE for 48 h (Figure 21), which allows to 
measure CBE-dependent effects on GBA2 activity independent of GBA1. The activity 
of GBA2 remained the same in both, CBE-treated and control GBA1-deficient cells 
(Figure 21b). Thus, these results reveal that GBA1 activity regulates GBA2 activity, but 
not vice versa, and that the regulation occurs on the activity level independent of 
changes in protein expression. 
 
Figure 21: GBA2 activity in GBA1-deficient mouse embryonal fibroblasts treated with CBE. 
GBA1-deficient embryonal mouse fibroblasts were treated with 25 µM CBE for 48 h. Beta-glucosidase 
activity was analysed in hypotonic cell lysates in presence of 1.67 mM 4-MUG. (a) GBA1-deficient 
embryonal fibroblasts did not show any GBA1 activity. (b) The activity of GBA2 remained the same in 
both, CBE-treated and control GBA1-deficient cells. CBE: Conduritol B epoxide, 4-MUG: 4-
Methylumbelliferyl beta-D-glucopyranoside. Data are presented as mean + SD. N numbers are indicated 
in brackets. P values were determined using One-way ANOVA.        
To understand the underlying mechanism in more detail, the time course of the GBA1-
dependent regulation of GBA2 activity was analysed in human dermal fibroblasts and 
CHO cells stably over-expressing mGBA2 (#G4A11) (Figure 22). GBA1 activity was 
blocked with 25 µM CBE for 10 min up to 48 h before analysing GBA1 and GBA2 
activity (Figure 22). A significant reduction of GBA1 activity was observed after 3 h of 
CBE-treatment in both cell lines; GBA1 was maximally blocked after 3 h in human 
84  Results 
dermal fibroblasts (Figure 22a) and after 24 h in CHO cells expressing mGBA2 (Figure 
22b). Interestingly, GBA2 activity was only reduced when GBA1 activity was fully 
blocked (Figure 22). This result suggests that the GBA2 activity directly responds to 
GBA1-dependent changes in the cell, e.g. the accumulation of its substrate, GlcCer, in 
the lysosomes or changes of downstream metabolites in the cytoplasm.   
 
Figure 22: Time course of the GBA1-dependent regulation of GBA2 activity in human dermal 
fibroblasts and CHO cells stably over-expressing mGBA2. Fibroblasts and CHO cells stably over-
expressing mGBA2 were incubated with 25 µM CBE for 10 min up to 48 h. Beta-glucosidase activity 
was analysed in hypotonic cell lysates in presence of 1.67 mM 4-MUG. (a) GBA1 was maximally blocked 
after 3 h in human dermal fibroblasts. GBA2 activity was only reduced when GBA1 activity was fully 
blocked. (b) as in (a) for CHO cells stably over-expressing mGBA2. GBA1 was maximally blocked after 
24 h in CHO cells expressing mGBA2. Again, an effect on GBA2 was only visible when GBA1 activity 
was almost completely absent. CBE: Conduritol B epoxide, 4-MUG: 4-Methylumbelliferyl beta-D-
glucopyranoside. Data are presented as mean + SD. N numbers are indicated. P values were 
determined using Student’s t-test.    
3.6 GBA1-dependent regulation of GBA2 activity also occurs in vivo in a 
pharmacologic Gaucher mouse model 
The injection of CBE into wild-type mice represents an approved pharmacologic 
approach to evoke the Gaucher phenotype in vivo in a mouse model (Kanfer et al., 
1975; Vardi et al., 2016). This model was used to analyse whether the GBA1-
dependent regulation of GBA2 activity also occurs in vivo (Figure 23). Eight days old 
6OlaHsd mice were injected intra-peritoneally with 25 – 100 mg CBE/kg/day for 10 
days. After the treatment, mice were sacrificed and the brains dissected. First, beta-
glucosidase activity was determined in hypotonic brain lysates from CBE-treated and 
control mice. GBA1 activity was blocked at all tested CBE concentrations (Figure 23a). 
In line with our earlier findings, GBA2 activity was also reduced to around 80% at all 
CBE concentrations tested (Figure 23b). As shown above and by others, at high 
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concentrations, CBE also inhibits the activity of GBA2 (Figure 17a) (Körschen et al., 
2013; Ridley et al., 2013). The final concentration of CBE in the brain for the different 
treatments is difficult to estimate. However, the reduction of GBA2 activity was similar 
at all doses of CBE tested (Figure 23b), arguing against a direct inhibition by CBE, but 
rather favouring a GBA1-dependent effect.  
 
Figure 23: GBA1 and GBA2 activity in CBE-treated mice. Eight days old 6OlaHsd mice were injected 
intra-peritoneally with 25 – 100 mg CBE/kg/day for 10 days. Beta-glucosidase activity was analysed in 
hypotonic brain lysates in presence of 1.67 mM 4-MUG. (a) GBA1 activity was blocked at all tested CBE 
concentrations. (b) GBA2 activity was also reduced to around 80% at all CBE concentrations tested. 
CBE: Conduritol B epoxide, 4-MUG: 4-Methylumbelliferyl beta-D-glucopyranoside. Data are presented 
as mean + SD. N numbers are indicated in brackets. P values were determined using One-way ANOVA.               
To verify in this in vivo model that the regulation occurs on the activity, and not on the 
expression level, the GBA2 mRNA and protein expression was analysed (Figure 23c-
f). First, a protocol to analyse the mRNA expression in mouse brains treated with 
different amounts of CBE was established as previously described in passage 3.3 
using qPCR. Besides the GOI (mGBA2), mTfrc and mGusb were selected as suitable 
HKGs) (Table 58). 
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Table 58: Mouse genes of interest (GOIs) and housekeeping genes (HKGs) chosen for qPCR 
analysis 
Gene Gene product Reference 
mGBA2 Non-lysosomal beta-
glucosidase 
NM_172692 
mTfrc Transferrin receptor NM_011638 
mGusb Glucuronidase beta NM_010368 
 
Table 59: Amplicon sizes of mouse primer pairs selected for qPCR 
Gene Primer pair Expected amplicon size 
(bp) 
mGBA1 C1508/09 251 
mGBA1 C1510/11 169 
mGBA2 C1512/13 157 
mGBA2 C1514/15 251 
mTfrc C1520/21 159 
mTfrc C1522/23 169 
mGusb C1532/33 201 
mGusb C1534/35 137 
bp: base pairs 
To test whether primers designed for qPCR amplify the sequence of interest, a 
conventional polymerase chain reaction (PCR) was performed (2.4.2). For mouse 
primers (Table 16), cDNA obtained from a mouse wild-type testis was used. All 
amplicons (Figure 24) had the expected sizes (Table 59), but some of the primer pairs 
showed a slight DNA contamination in the H2O control and mGusb pair C1534/35 
showed an additional band.  
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Figure 24: Analysis of the amplicons of mouse qPCR primers and control cDNA from mouse 
wild-type testis. 5 µl of the PCR approach were loaded to a 2% agarose gel and the fragments were 
analysed under a UV lamp. All amplicons had the expected sizes, but some of the primer pairs showed 
a slight DNA contamination in the H2O control and mGusb pair C1534/35 showed an additional band. 
bp: base pairs.  
To reliably analyse the data obtained from qPCR, a primer efficiency test (PET) was 
performed (2.4.6.5). Based on these results, the following mouse primers were used 
for subsequent experiments: mGBA2: C1573/74, mTfrc: C1522/23, and mGusb: 
CC1532/33 (Table 60). The PCR products generated by these primer pairs were send 
for sequencing and, thus, verified to be the right amplicons (data not shown). 
Table 60: Mouse qPCR primer efficiencies 
Gene Primer 
numbers 
Slope R2 value Efficiency (%) 
mGBA2 C1512/13 -3.2545 0.9954 103 
mGBA2 C1514/15 -3.466 0.9995 94 
mTfrc C1520/21 -3.2077 0.9995 105 
mTfrc C1522/23 -3.2583 0.9999 103 
mGusb C1532/33 -3.4448 0.9987 95 
mGusb C1534/35 -3.0089 0.9948 115 
 
qPCR was performed for the GOI mGBA2 and the HKGs mTfrc and mGusb and CBE-
treated mouse brains as templates (see Table 58, 2.4.6.6). GBA2 mRNA expression 
was significantly reduced in brain treated with 25 mg CBE/kg/day and 100 mg 
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CBE/kg/day (Figure 25a). However, this did not result in a change in protein 
expression, as shown by Western blot analysis (Figure 25b, c). Here, both, GBA1 and 
GBA2, were similarly expressed in all tested samples (Figure 25d-g). Thus, the GBA1-
dependent regulation of GBA2 activity occurs not only in vitro, but also in vivo.   
 
 
Figure 25: GBA2 mRNA expression and GBA1 and GBA2 protein expression in CBE-treated mice. 
Eight days old 6OlaHsd mice were injected intra-peritoneally with 25 – 100 mg CBE/kg/day for 10 days. 
RNA was extracted from brain tissue and analysed using qPCR. Protein expression was analysed in 
hypotonic brain lysates by Western blot using antibodies against GBA1 (Sigma) and GBA2 (polyclonal 
4/5 kb mix from rabbit, non-published). CHO cells stably over-expressing mGBA1-HA and mGBA2-HA 
were used as positive controls. Calnexin was used as a loading control. (a) GBA2 mRNA expression 
was significantly reduced in brains treated with 25 mg CBE/kg/day and 100 mg CBE/kg/day. (b) 
Quantification of GBA1 protein levels in CBE-treated and control mice normalised to calnexin. (c) As in 
(b) for GBA2.  (d) – (g) Blots showing that GBA1 and GBA2 protein expression was similar in CBE-
treated and control mice treated with 25 – 100 mg CBE/kg/day. CBE: Conduritol B epoxide, 4-MUG: 4-
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Methylumbelliferyl beta-D-glucopyranoside. Data are presented as mean + SD. N numbers are indicated 
in brackets. The p value was determined using One-way ANOVA.        
3.7 Analysing the affinity of GBA2 for 4-MUG 
Loss of GBA1 activity results in a severe accumulation of GlcCer in the lysosomes 
(Brady et al., 1965). The GBA1-dependent regulation of GBA2 activity occurs only on 
the activity level (see Figure 9 and Figure 14). I wondered whether GBA2 in lysates 
from GBA1-deficient cells might be occupied cleaving the increased amount of 
endogenously accumulated GlcCer rather than the artificial substrate 4-MUG that is 
used in the assay. This would be (falsely) visible as reduced GBA2 activity in the assay. 
Matern and colleagues have previously studied the affinity of GBA2 for 4-MUG, albeit 
in a different assay system, and found a Km value of 210 µM (Matern et al., 1997). The 
affinity of GBA2 for its natural substrate, however, has not been published so far.  
3.7.1 Analysis of GlcCer levels in control and Gaucher fibroblasts by thin layer 
chromatography  
To compare the amount of endogenous GlcCer and artificial substrate (4-MUG) 
present in the assay, the amount of GlcCer in dermal fibroblasts from control and 
Gaucher patients was analysed by TLC. First, lipids were isolated from spleens of 
control, GBA2-deficient, and GBA1/GBA2-deficient mice to establish a protocol for 
GSL extraction from samples that show rather high GlcCer levels (Figure 26). To 
determine the amount of GlcCer present, the signal intensity of a serial dilution of 
purified galactosylceramide (galactose is a C-4 epimer of glucose) was analysed and 
compared to the GlcCer bands (Figure 26b). Wild-type spleen contained 0.03 µg 
GlcCer/mg wet weight, whereas the GlcCer levels was slightly elevated to 0.14 µg/mg 
wet weight in spleens from GBA2-deficient mice and strongly increased to 1.38 µg 
GlcCer/mg wet weight in GBA1/GBA2-deficient mice (Figure 26b, also published in 
Yildiz et al. (Yildiz et al., 2013).  
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Figure 26: GlcCer levels in spleen from wild-type, GBA2-deficient, and GBA1/GBA2-deficient 
mice. (a) TLC of GSLs extracted from mouse spleen with different genetic backgrounds, showing 
accumulation of GlcCer in GBA2-deficient and GBA1/GBA2-deficient tissues compared to the wild-type 
(WT) control. (b) Quantification of endogenous GlcCer levels by comparing the signal intensity to purified 
GalCer. GSL: Glycosphingolipids, FA: Fatty acid, GlcCer: Glucosylceramide, LacCer: Lactosylceramide, 
SM: Sphingomyelin, GM1/2: monosialic ganglioside 1/2, Cer: ceramide, GalCer: Galactosylceramide, 
WT: Wild-type, KO: Knockout. Data are presented as mean values. N numbers are indicated in brackets.        
Next, fibroblast samples from control and Gaucher patients were collected and lipids 
were extracted. Fibroblasts from control patients contained 1.26 µg GlcCer per mg 
protein, whereas GlcCer levels were slightly increased in type I and III fibroblasts to 
2.26 µg/mg protein and 1.7 µg/mg protein, respectively (Figure 27b). GlcCer levels in 
type II fibroblasts were comparable to the controls (1.21 µg/mg protein). Fuller et al. 
have also analysed GlcCer levels in cultured dermal fibroblasts from control and 
different Gaucher patients one week and six weeks post-confluency and found GlcCer 
levels to be increased in cells derived from both, type I and type II patients (Fuller 
2008). Control fibroblasts contained 0.5 nmol/mg total protein, whereas type I 
fibroblasts contained 1.2 nmol/mg protein and type II fibroblasts contained 3.5 nmol/mg 
protein (Fuller et al., 2008). My results showed that control fibroblasts contained 1.26 
µg GlcCer per mg protein, which, considering that GlcCer has an average molecular 
weight of 785 g/mol, resembles 1.61 nmol/mg protein, which, even though it is double 
the amount of what has been measured by Fuller and co-workers, still is in the same 
range. Thus, based on my results and those obtained by others, GlcCer also 
accumulates in dermal fibroblasts from Gaucher patients.    
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Figure 27: GlcCer levels in fibroblasts from control and Gaucher patients. (a) TLC of GSLs 
extracted from control (Ctrl) and Gaucher fibroblasts showing no pronounced accumulation of GlcCer in 
Gaucher cells. Control cells contained 1.26 µg GlcCer/mg protein, type I fibroblasts 2.26 µg/mg protein, 
type II fibroblasts 1.21 µg/mg protein, and type III fibroblasts 1.7 µg/mg protein. (b) Quantification of 
endogenous GlcCer levels by comparing the signal intensity to purified GalCer. GSL: 
Glycosphingolipids, GlcCer: Glucosylceramide, LacCer: Lactosylceramide, SM: Sphingomyelin, GM3: 
monosialic ganglioside 3, Cer: ceramide, GalCer: Galactosylceramide. The different Gaucher types are 
indicated. Data are presented as mean values. N numbers are shown in brackets. 
3.7.2 Analysis of GlcCer levels in control and Gaucher fibroblasts by mass 
spectrometry 
To validate these results, the amount of GlcCer in dermal fibroblasts from control and 
Gaucher patients was analysed by mass spectrometry (Figure 28). In total, fibroblasts 
from Gaucher patients contain 3.4 ± 0.4 pmol GlcCer/µg protein and control fibroblasts 
2.6 ± 1.1 pmol GlcCer/µg protein (Figure 28). The molecular weight of GlcCer is 
785 g/mol. Thus, 2.6 pmol GlcCer/µg protein equal 2.041 ng GlcCer/µg protein. 
Quantification of TLC control band intensities resulted in 1.26 µg GlcCer per mg protein 
(see above), which equals 1.26 ng GlcCer/µg protein. Thus, quantification of GlcCer 
levels by mass spectrometry resulted in a 1.6-fold higher value compared to TLC 
analysis. Given the fact that mass spectrometric analysis is a lot more sensitive, I used 
the latter value for further calculations. 
Generally, 75 µg of hypotonic protein lysates are used for each reaction when 
analysing the GBA2 activity. This would result in a total amount of 195-255 pmol 
endogenous GlcCer (control and Gaucher samples, respectively) present in each 
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reaction. In comparison, 50 nmol 4-MUG is used per reaction, which is around 196-
fold more than the amount of endogenous GlcCer present. Thus, it is unlikely that the 
assay underestimates the GBA2 activity. 
 
Figure 28: GlcCer levels in Gaucher and control fibroblasts. Mass spectrometric analysis of GlcCer 
levels normalised to the amount of protein per sample. GlcCer levels were slightly albeit not significantly 
increased in type II Gaucher fibroblasts and slightly lower in type III cells compared to the controls (Ctrl). 
Control cells contained 2.6 ± 1.1 pmol GlcCer/µg protein and Gaucher cells contained in total 
3.4 ± 0.4 pmol GlcCer/µg protein. The different Gaucher types are indicated. Data are presented as 
mean + SD. N numbers are shown in brackets. P values were determined using One-way ANOVA. 
3.7.3 Determining the Km value of GBA2 from control and GBA1-deficient cells 
for 4-MUG 
To experimentally verify this conclusion, GBA2 activity for 4-MUG was measured in 
GBA1-deficient HEK293 and control cells using a serial dilution of the artificial 
substrate (Figure 29). GBA2 activity reached a maximum at around 600 µM 4-MUG 
(Figure 29), using 75 µg of hypotonic protein lysates from either HEK293 control or 
GBA1-deficient cells. A further increase in substrate concentration did not cause an 
increase in the reaction rate as there was no more enzyme available to react with the 
substrate. In the assay, 4-MUG is present at a final concentration of 1.67 mM, which 
is around 2.8-fold more than the substrate concentration, at which maximal GBA2 
activity was reached. Thus, the assay is performed under saturating conditions. Control 
cells showed a maximal reaction activity (Vmax) of 1.03 ± 0.58 rfu/min, whereas the 
maximal GBA2 activity in GBA1-deficient cells was only 0.43 ± 0.17 rfu/min, 
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underlining the GBA1-dependent effect on GBA2 activity (compare Figure 14). The 
Michaelis constant Km is the substrate concentration, at which the reaction rate is half 
of Vmax (IUPAC. Compendium of Chemical Terminology). Under saturating conditions, 
Km is a measure for the affinity of an enzyme for its substrate (IUPAC. Compendium of 
Chemical Terminology). The Km determined for GBA2 in control cells was 60.25 ± 
28.64 µM, whereas the Km in GBA1-deficient cells was slightly, albeit not significantly, 
increased to 76.58 ± 23.43 µM. The Km value for GBA2 has already been determined 
by Matern and colleagues, albeit in a different assay system, with GBA2 showing a Km 
value of 210 µM towards 4-MUG, which is 3-fold higher than the value that I obtained 
(Matern et al., 1997). However, the fact that GBA2 in GBA1-deficient cells does not 
reach the same activity as in control cells, even with very high concentrations of 4-
MUG, indicates that endogenous GlcCer in GBA1-deficient cell lysates is not 
extensively occupying or competing for the active site of GBA2 and, therefore, does 
not hinder 4-MUG from entering the catalytic site. These data verify that there is indeed 
a GBA1-dependent regulation of GBA2 activity that is not imposed by design of the 
assay, but due to changes in pathways downstream of GBA1. 
 
Figure 29: Activity of GBA2 from control and GBA1-deficient HEK293 cell lysates towards 4-
MUG. Analysis of the GBA2 activity in hypotonic lysates of HEK293 control (Ctrl) or GBA1-deficient cells 
and using a serial dilution of 4-MUG. GBA2 activity reached a maximum at 600 µM 4-MUG when 75 µg 
of hypotonic protein lysates from either cell line were used. Control cells showed a Vmax of 1.03 ± 
0.58 rfu/min, whereas the maximal GBA2 activity in GBA1-deficient cells was only 0.43 ± 0.17 rfu/min. 
The Km for GBA2 in control cells was 60.25 ± 28.64 µM, whereas the Km in GBA1-deficient cells was 
slightly increased to 76.58 ± 23.43 µM. 4-MUG: 4-Methylumbelliferyl beta-D-glucopyranoside. 
Representative plot for n = 3 experiments.  
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3.7.4 A tool to search for new GlcCer-binding proteins 
GlcCer accumulates in both, GBA1-deficient and GBA2-deficient cells 
(Rosenberg&Chargaff, 1958; Yildiz et al., 2006). Besides changing the lipid 
composition of certain membranes and, thus, changing their structure and/or 
curvature, accumulation of GlcCer could also affect the function of GlcCer-binding 
proteins, which, in turn, could affect yet unknown downstream mechanisms. To date, 
only three GlcCer-binding proteins have been identified, with two of them being GLTP 
and FAPP2 (Godi et al., 2004; Metz&Radin, 1980).  
To learn more about the mechanisms involved downstream of GlcCer, we developed 
an assay to search for new GlcCer-binding proteins (collaboration with Dr. A. 
Rennhack, caesar, and Dr. G Schwarzmann, University of Bonn) (also see 2.5.6). A 
non-cleavable GlcCer-derivative was synthesised that carries an S-glycosidic linkage 
instead of an O-glycosidic linkage, which renders GlcCer in its normal steric 
conformation, but cannot be cleaved by glucocerebrosidases (Figure 30a). The GlcCer 
derivative was coupled to a NHS-Tentagel and the GlcCer-coupled beads were 
incubated with protein lysates to allow batch purification of possible binding proteins. 
Finally, the elute will be analysed by mass spectrometry to identify the purified proteins 
(Figure 30b). I tested the specificity of the GlcCer beads by incubating them with 
purified and hGLTP (Figure 30c, d, see 3.15.1). The empty NHS-Tentagel matrix as 
well as the one coupled to GlcCer were incubated with 100 µl 0.35 µM hGLTP before 
washing with PBS to remove non-bound protein (Figure 30c, d). Bound protein was 
eluted from the column using 2% SDS in PBS and analysed by Western blot using a 
specific anti-GLTP antibody (Figure 30c, d). As visible in Figure 30c, hGLTP did not 
bind to the empty column material and was fully recovered in the flow-through. In 
contrast, fewer hGLTP was found in the flow-through of the GlcCer-column and hGLTP 
was recovered in the elution fraction (E, Figure 30d). Thus, this systems serves as a 
valid tool to search for yet unknown GlcCer-binding partners. Due to time limitations, 
the experiment was followed up during my PhD.       
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Figure 30: A tool to search for new GlcCer-binding proteins. (a) A non-cleavable GlcCer-derivative 
was synthesised to allow purification of GlcCer-binding proteins. The GlcCer derivative carries an S-
glycosidic linkage instead of an O-glycosidic linkage, which renders GlcCer in its normal steric 
conformation, but cannot be cleaved by beta-glucosidases. (b) The GlcCer derivative was coupled to a 
NHS-Tentagel and the GlcCer-coupled beads can be incubated with a protein lysate to allow batch 
purification of possible binding proteins. (c) The normal NHS-Tentagel matrix as well as (d) the GlcCer-
coupled one were incubated with 100 µl 0.35 µM GLTP before washing with PBS to remove non-bound 
protein. Bound protein was eluted from the column using 2% SDS in PBS and analysed by Western blot 
GLTP-specific antibody (Santa Cruz). GLTP did not bind to the pure column material but was recovered 
in the elution fraction of the GlcCer-column. In: Input, FT: Flow-through, E: Elution, GlcCer: 
Glucosylceramide, GLTP: Glycolipid transfer protein.  
3.8 Analysing the intracellular pH in GBA1-deficient and control cells 
GBA2 activity is sensitive to the environmental pH. Thus, I determined the intracellular 
pH (pHi) in both, control and Gaucher fibroblasts, using BCECF to study whether a 
change in the cytoplasmic pH in GBA1-deficient cells might be responsible for the 
reduction in GBA2 activity. BCECF (2',7'-Bis-(2-Carboxyethyl)-5-(and-6)-
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Carboxyfluorescein, Invitrogen) is a molecule commonly used to measure changes in 
the cytosolic pH in cells. BCECF is a fluorescein derivative that emits (em) light at 590 
nm when excited (ex) at 490 nm in a pH-dependent manner: the fluorescence intensity 
increases with increasing pH. Furthermore, BCECF allows to do ratiometric 
measurements because the emission at 590 nm is independent of the surrounding pH 
when excited at 440 nm (isosbestic point) (Figure 31). In fact, the ratio 
[(440ex520em)/(485ex520em)] is independent from both, the amount of BCECF taken up 
by a cell and the total number of cells and with a pKa value of 6.98, it can be used to 
calibrate the intracellular pH. Fibroblasts were loaded with BCECF-AM, the 
acetoxymethyl ester form of BCECF, which is non-fluorescent, but membrane 
permeable. When BCECF-AM enters the cytosol of cells, cytosolic esterases convert 
it to its membrane impermeable, but fluorescent form (Gallo, 2001).  
 
Figure 31: The pH indicator BCECF. (a) Chemical structure of BCECF. Fibroblasts were loaded with 
non-fluorescent but membrane permeable BCECF-AM. When BCECF-AM enters the cytosol of cells, 
cytosolic esterases convert it to its membrane impermeable, but fluorescent form. (b) Excitation‐ (blue) 
and emission‐ (red) spectra of BCECF. (c) Relative fluorescence intensity of BCECF in dependence of 
the pH (4.5 – 9.0). Excitation at 490 nm, emission at 520 nm. The isosbestic point is at 439 nm. BCECF: 
2',7'-Bis-(2-Carboxyethyl)-5-(and-6)-Carboxyfluorescein. AM: Acetoxymethyl. Modified according to 
www.lifetechnologies.com. 
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The BCECF fluorescence was calibrated by releasing BCECF from the cells into 
strongly buffered TYH buffers of different pH values (“null-point” method). BCECF will 
change its fluorescence according to the difference of pHi and the pH of the 
extracellular solution (pHe). Only if pHi = pHe, no change is observed. This calibration 
is performed using several extracellular solutions of different pH values to generate a 
calibration curve, which can be used to calculate the apparent pHi. 
Lysing the cells and releasing BCECF from the cytosol into the extracellular buffer 
requires addition of a detergent (Rink et al., 1982). To lyse the cells, Triton X-100 was 
first diluted in TYH buffer of pH 8.0, with a final concentration of 0.01-0.5%. The ratio 
(440ex520em)/(485ex520em) was plotted over time (Figure 32). Addition of all tested 
Triton X-100 concentrations immediately lysed the cells, resulting in the release of 
BCECF and an increase in fluorescence, showing that pHe was higher than pHi (Figure 
32). Control experiments verified that the addition of Triton X-100 itself does not evoke 
a change in pH and, thus, a change in fluorescence (Dr. D. Fusshöller, Molecular 
Sensory Systems, caesar, Bonn, non-published data). Thus, a final concentration of 
0.05% Triton X-100 was used to lyse cells in further experiments. 
 
Figure 32: Changes in BCECF fluorescence upon Triton X100‐induced lysis of control 
fibroblasts. Changes in BCECF fluorescence in control fibroblasts plotted as the ratio R 
(440ex520em)/(485ex520em) over time, recorded in the Fluostar before and after injection of Triton X-
100. Addition of all tested Triton X-100 concentrations immediately lysed the cells, resulting in the 
release of BCECF and in a change in fluorescence. A final concentration of 0.05% Triton X-100 was 
used to lyse cells in further experiments. The N number is indicated.  
To determine pHi in fibroblasts from control and type I Gaucher patients, the “null-point” 
method was applied. Cells were loaded with BCECF-AM and kept in TYH buffer 
containing 5 mM HEPES at pH 7.4 in a 96-well plate. TYH buffers containing either 
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50 mM HEPES or 50 mM MES were prepared and checked to have a final pH of 6.24, 
6.52, 6.79, 7.55, and 7.75 when mixed with 5 mM HEPES TYH buffer of pH 7.4 in a 
ratio of 5:1. After measuring the BCECF baseline, TYH buffers containing Triton X-100 
were added to the cells and a change in fluorescence was observed over time (Figure 
33). The ratio [(440ex520em)/(485ex520em)] was normalised to the baseline fluorescence 
and plotted over time (Figure 33a, c). Here, ratios below 0 indicate that pHi is more 
acidic than pHe and traces above 0 that pHi is more basic than pHe (Figure 33a, c). 
The “pH-null point” is the pHe, at which no change in ΔR/R occurs because pHi and 
pHe are equal. Applying a liner fit to the ΔR values for each pHe results in a “pH-null 
point” of 7.04 ± 0.32 (crossing point x axis) in control fibroblasts and 7.08 ± 0.32 in 
Gaucher fibroblasts (Figure 33b, d), which is similar to the pHi of 7.2 in HEK293 cells 
(Sell 2014). Thus, there is no difference in pHi between fibroblasts from control and 
Gaucher patients.     
 
Figure 33: Null-point calibration of pHi in control and Gaucher fibroblasts. pHi was determined by 
a “null‐point” calibration using BCECF fluorescence, as explained in the text. Representative 
fluorescence changes of ΔR/R (%) of BCECF recorded in (a) control and (c) Gaucher fibroblast 
suspensions in the Fluostar. 50 µl of pH‐buffered TYH (50 mM HEPES or MES) supplemented with 
0.05% Triton X-100 was injected in 250 μl pH‐buffered (5 mM HEPES, pH 7.4) fibroblast suspension, 
resulting in a defined pHe. The mean ΔR/R after 294, 336, and 378 s (3 data points) was determined for 
(b) control and (d) Gaucher fibroblasts and plotted against the pH values. A linear fit yielded a ΔR/R = 
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0 at pHe = 7.04 ± 0.32 in (b) control fibroblasts and (d) 7.08 ± 0.32 in Gaucher fibroblasts. R: Ratio, s: 
Seconds. Representative plots for n = 3 experiments.  
3.9 Determining the pH optimum of GBA2 in GBA1-deficient and control cells 
To test whether a change in the pH optimum for GBA2 activity underlies the reduction 
of GBA2 activity in GBA1-deficient cells, a pH profile of GBA2 activity was measured 
from pH 3.5 to pH 7.0 in embryonal fibroblasts from GBA1-deficient and control mice 
(Figure 34). The highest GBA2 activity in embryonal fibroblasts from control mice was 
measured at pH 5.5, which is slightly more basic than the optimal pH value determined 
in liver lysates of control mice (pH 5.25, see Figure 8). However, the highest GBA2 
activity in lysates of GBA1-deficient embryonal fibroblasts was measured at pH 5.25, 
which is slightly more acidic than pH 5.5 (control cells), but not dramatically different 
(Figure 34). This in in line with findings from other groups, who have determined a pH 
optimum for GBA2 in human fibroblasts of 5.8 (Aureli et al., 2009; Aureli et al., 2016).   
 
Figure 34: pH optimum of GBA2 activity in embryonal fibroblasts from control and GBA1-
deficient mice. Analysis of the GBA2 activity in hypotonic lysates of control and GBA1-deficient mouse 
embryonal fibroblasts at a pH ranging from 3.5 – 7.0 in presence of 1.67 mM 4-MUG. The highest GBA2 
activity in embryonal fibroblasts from control mice was measured at pH 5.5, whereas the highest GBA2 
activity in lysates of GBA1-deficient embryonal fibroblasts was measured at pH 5.25. 4-MUG: 4-
Methylumbelliferyl beta-D-glucopyranoside. Data are presented as mean + SD. The N number is 
indicated.     
3.10 Rescuing GBA2 activity in GBA1-deficient cells 
Since the activity of GBA2 seems to be directly correlated to the activity of GBA1, I 
tested whether GBA2 activity could be restored by over-expressing mGBA1 in GBA1-
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deficient cells. HAP1 GBA1-deficient cells were transfected with mGBA1 and analysed 
two days after transfection. Transfection resulted in over-expression of GBA1 (Figure 
35a), and GBA1 activity of 0.45 rfu/min (Figure 35b). However, the slight increase in 
GBA1 activity did not increase the activity of GBA2 (Figure 35c).  
 
Figure 35: GBA1 and GBA2 protein expression and activity in HAP1 cells deficient for GBA1 
transiently transfected with mGBA1. Analysis of total (endogenous and heterologous) GBA1 protein 
expression in HAP1 GBA1-deficient cell lysates after deglycosylation using PNGaseF by Western blot 
using a GBA1-specific antibody (Sigma). CHO cells stably over-expressing mGBA1-HA were used as a 
positive control. GBA1 and GBA2 activity were analysed in hypotonic cell lysates in presence of 1.67 mM 
4-MUG. (a) GBA1-HA protein expression was visible in GBA1-deficient HAP1 cells after transfection. 
(b) Transfection with mGBA1 resulted in GBA1 activity of 0.45 rfu/min. (c) The GBA2 activity remained 
unchanged in GBA1-deficient HAP1 cells transfected with mGBA1 compared to the controls. PNGaseF: 
Peptide-N-Glycosidase F (NEB), KO: Knock-out, 4-MUG: 4-Methylumbelliferyl beta-D-glucopyranoside. 
Data are presented as mean + SD. N numbers are shown in brackets. P values were determined using 
One-way ANOVA.   
3.11 GBA1 and GBA2 activity in dermal fibroblasts from Niemann-Pick patients 
Niemann-Pick disease also belongs to the group of lysosomal storage disorders 
(Vanier&Millat, 2003). The disease is classified into three major categories (Crocker, 
1961), although there is no clear genotype-phenotype correlation, similar to what has 
been shown for Gaucher disease. Niemann-Pick type A and B (NP-A and –B) result 
from a deficiency in acid sphingomyelinase, an enzyme that is encoded by the SMPD1 
gene in humans (Schuchman, 2010). Acid sphingomyelinase resides in the lysosomes 
and breaks down sphingomyelin to ceramide and phosphocholine (Schuchman, 2010). 
Thus, in case of NP-A and –B, sphingomyelin accumulates to harmful quantities in the 
lysosomes, causing enlargement of liver and spleen (mainly type B) or severe 
neurological defects (mainly type A) (Crocker, 1961). Mutations in NPC1 or NPC2 
cause the third form of Niemann-Pick disease, namely type C (NP-C) (Pentchev et al., 
1994). The proteins encoded by these genes are essential for the export of cholesterol 
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from the lysosomes (Sleat et al., 2004). Therefore, NP-C is now considered a cellular 
lipid trafficking disorder that mainly, but not only, involves cholesterol (Pentchev et al., 
1994). As for NP-A and –B, the age of onset of the disease is extremely heterogeneous 
and so is the variety of symptoms: patients suffering from the disease show visceral 
involvement of liver and spleen, and also neurologic manifestations (Vanier, 2010).   
A recent study by Marques and co-workers proposed that the activity of GBA2 is 
increased in the brain of NP-C mice (Marques et al., 2015). To reduce the GBA2 
activity back to normal control levels, they either bred NP-C mice to GBA2-deficient 
mice to create double knockout mice or treated NP-C mice with a brain-permeable 
inhibitor for GBA2 to block its activity. Interestingly, reduction of GBA2 activity 
significantly improved the motor coordination and lifespan of these NP-C mice, while 
cholesterol mis-trafficking was still observed (Marques et al., 2015). Based on their 
data, Marques and co-workers concluded that GBA2 might be a therapeutic target in 
Niemann-Pick disease type C.       
To learn more about the regulation of GBA2 in Niemann-Pick disease, the GBA1 and 
GBA2 activity was analysed in dermal fibroblasts obtained from NP-A, -B, and –C 
patients and compared to control fibroblasts (Figure 36). The GBA1 activity in NP-A 
and –B fibroblasts was variable, with GBA1 being slightly more active in some of the 
tested cell lines (Figure 36a). GBA2, however, remained constant in all tested NP-A 
and –B samples (Figure 36b). Interestingly, the GBA1 activity was significantly reduced 
to around 10% and 12% in two of the three tested NP-C samples (Figure 36a). Vanier 
et al. already published work in 1983 showing that a reduction in GBA1 activity is a 
secondary effect in NP-C cells, resulting in accumulation of GlcCer up to levels seen 
in Gaucher samples (Vanier, 1983). Interestingly, the GBA2 activity in these cell lines 
was also reduced to 48% (Figure 36b). As seen above (Figure 22), GBA2 activity was 
only significantly reduced when GBA1 activity was almost fully absent (Figure 36b). 
However, my results do not confirm the data obtained by Marques and co-workers. 
Their data were generated using different methods and different samples (mouse brain 
versus dermal fibroblasts from Niemann-Pick patients). To be able to fully compare the 
two data sets, I would have to analyse the GBA1 and GBA2 activity in brains from NP-
C and control mice with our assay.      
102  Results 
 
Figure 36: GBA1 and GBA2 activity in dermal fibroblasts from control and Niemann-Pick disease 
patients. Analysis of beta-glucosidase activity in hypotonic lysates of control fibroblasts and cells 
carrying mutations in either the SMPD1 gene or the NPC1/2 gene, resulting in Niemann-Pick disease 
type A, B, or C, in presence of 1.67 mM 4-MUG (a) The GBA1 activity was very heterogeneous in NP-
A and –B cells and significantly reduced in NP-C cells. (b) The GBA2 activity was comparable to control 
values in NP-A and –B cells but reduced to 48% and 77% in NP-C cells. 4-MUG: 4-Methylumbelliferyl 
beta-D-glucopyranoside. Data are presented as mean + SD. N numbers are indicated in brackets. P 
values were determined using One-way ANOVA.     
3.12 GBA2 activity is not dependent on the availability of GlcCer 
In GBA1-deficient cells, GlcCer accumulates and the GBA2 activity is reduced. In turn, 
I wondered if a reduction in GlcCer levels would also affect the beta-glucosidase 
activity. In this scenario, GBA1 and GBA2 could work as “sensors” for GlcCer in the 
cell. The easiest way to study this hypothesis is to analyse the GBA1 and GBA2 activity 
in cells that lack GlcCer. As previously mentioned, ceramides are synthesised at the 
cytosolic side of the ER and have various acyl chain lengths, which are specific to one 
of the six CerS, which catalyse their transfer to sphinganine/sphingosine 
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(Levy&Futerman, 2010). Therefore, the presence of certain ceramide species depends 
on the activity of a certain CerS. In general, lack of ceramide also leads to lack of 
GlcCer. GlcCer, however, is synthesised by GlcCerS at the cytoplasmic side of the cis 
and medial part of the Golgi (Basu et al., 1968; Schweizer et al., 1994). 
3.12.1 GBA1 and GBA2 activity in tissues from CerS2-deficient mice 
To study this hypothesis, GBA1 and GBA2 activity was analysed in brain, testis, and 
liver from ceramide synthase 2 (CerS2)-deficient mice (Imgrund et al., 2009). CerS2 
tissue expression is quite broad with major expression in liver, kidney, and bone 
marrow and moderate expression in brain and testis (Levy&Futerman, 2010). Whilst 
GBA1 is ubiquitously expressed amongst all tissues (Brady et al., 1965), GBA2 shows 
highest expression in brain, liver, and testis (Yildiz et al., 2006). Thus, the latter three 
organs were chosen for activity and expression analysis (Figure 37). GBA1 activity was 
similar in brain, testis, and liver from CerS2-deficient and control mice (Figure 37a). In 
CerS2-deficient liver, GBA2 was slightly less active compared to control livers (Figure 
37b). Furthermore, GBA2 activity was similar in brain and testis from CerS2-deficient 
mice and control brain (Figure 37b). As a control experiment, GBA2 protein expression 
was verified in CerS2-deficient tissues by Western blot analysis and, as expected from 
the assay results, GBA2 was similarly expressed in all tissues from both genotypes 
(Figure 37c-i). Thus, lack of a certain ceramide species does not affect the activity of 
GBA1 or GBA2. 
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Figure 37: GBA1 and GBA2 activity and protein expression in tissues from CerS2-deficient mice. 
Analysis of GBA1 and GBA2 activity in hypotonic lysates of control and CerS2-deficient mice in presence 
of 1.67 mM 4-MUG. GBA2 protein expression was analysed in hypotonic lysates by Western blot using 
a GBA2-specific antibody (clone 2F8, rat, Körschen et al. 2013). Tubulin was used as loading control. 
(a) GBA1 activity was similar in brain, testis, and liver from CerS2-deficient and control mice. (b) GBA2 
was slightly but not significantly less active in CerS2-deficient liver and remained unchanged in brain 
and testis. (c) GBA2 protein expression was similar in hypotonic brain lysates from control and CerS2-
deficient mice. (d) Quantification of GBA2 protein expression in brain from control and CerS2-deficient 
mice normalised to Tubulin. (e) + (f) and (g) - (i) as (c) + (d) for testis and liver lysates. CerS2: Ceramide 
synthase 2, 4-MUG: 4-Methylumbelliferyl beta-D-glucopyranoside. Data are presented as mean + SD. 
N numbers are indicated in brackets. P values were determined using One-way ANOVA.       
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3.12.2 GBA1 and GBA2 activity in cells treated with Fumonisin B1 
As previously mentioned, there are six CerS known, with each isoform showing a 
specificity for a particular acyl chain-length. To block ceramide synthesis, a 
pharmacologic approach was applied that blocks all six CerS at once by using 
Fumonisin B1 (FB1) (Figure 38). FB1 is produced by several species of Fusarium 
molds (Marasas, 2001) and inhibits N-acylation of both, sphingosine and sphinganine, 
during ceramide synthesis (Merrill et al., 1993a; Merrill et al., 1993b; Merrill&Wang, 
1992). Merrill and co-workers demonstrated that around 50% of CerS activity is 
blocked by 75 nM FB1 in mouse brain microsomes (Merrill et al., 1993a). Thus, dermal 
fibroblasts from control patients were incubated with 5 µM FB1 for 48 h to fully block 
CerS activity (Figure 38). Cells were harvested and hypotonic protein lysates were split 
in two fractions, with one sample maintaining the initial concentration of 5 µM FB1 in 
the lysate (Figure 38). However, GBA1 and GBA2 activity in FB1-treated cells was 
similar to control cells (Figure 38). Thus, these data confirm my previous results (see 
Figure 37), underlining that the absence of ceramide does not affect GBA1 and GBA2 
activity.   
 
Figure 38: GBA1 and GBA2 activity in human dermal fibroblasts treated with Fumonisin B1. 
Analysis of GBA1 and GBA2 activity in hypotonic lysates of human dermal fibroblasts treated with 5 µM 
Fumonisin B1 to block CerS activity compared to control cells in presence of 1.67 mM 4-MUG. (a) GBA1 
and (b) GBA2 activity remained unchanged in cells treated with 5 µM Fumonisin B1. 4-MUG: 4-
Methylumbelliferyl beta-D-glucopyranoside. Data are presented as mean + SD. N numbers are indicated 
in brackets.   
3.12.3 GBA1 and GBA2 activity in cells deficient for GlcCerS 
Furthermore, I analysed the activity of GBA1 and GBA2 in cells that do not express 
GlcCerS, termed GM-95 cells, and thereby, lack any glycosphingolipids (Ichikawa et 
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al., 1994). GM-95 cells, formerly known as MEB-4 cells (Nozue et al., 1988), were 
generated from a mouse B16 melanoma cell line (termed MEB-4 cells) by N-methyl-
N'-nitro-N-nitrosoguanidine (MNG) mutagenesis (Nozue et al., 1988). MNG adds alkyl 
groups to O6 of guanine and O4 of thymine, causing mutations between GC and AT 
(Merck Index, 11th Edition, 6017). These changes are not detected by the DNA 
mismatch repair–system, resulting in mutations that may cause gene silencing (Merck 
Index, 11th Edition, 6017). According to Ichikawa and co-workers, GM-95 cells do not 
express an active form of ceramide glucosyltransferase (Ichikawa et al., 1994), 
meaning these cells do not synthesise any glycosphingolipids, whereas ceramide 
levels are normal. Compared to the parental cell line (MEB-4), GM-95 cells show an 
elongated and fibroblast-like morphology, while exhibiting longer proliferation times 
(Ichikawa et al., 1994). According to my previous hypothesis, GBA1 activity might be 
reduced in these cells due to the lack of total GlcCer and could then also evoke the 
same effect on GBA2 activity that I had previously seen in Gaucher fibroblasts. But, 
again, GBA2 could also work as an independent “sensor” for GlcCer at the Golgi, 
meaning that lack of GlcCer in GM-95 cells could also have a GBA1-independent effect 
on GBA2.     
The GBA1 and GBA2 activity was studied in GlcCer-deficient (GM-95) and control 
(MEB-4) cells to analyse whether the absence of GlcCer affects the activity of either 
beta-glucosidase (Figure 39). Surprisingly, neither GBA1 nor GBA2 activity were 
significantly changed between both cell lines (Figure 39). Thus, the absence of GlcCer 
has no effect on the regulation of GBA1 and GBA2. Of note, this result does not rule 
out that increased levels of GlcCer affect GBA1 or GBA2 activity. 
 
Figure 39: GBA1 and GBA2 activity in GlcCerS-deficient cells. Analysis of GBA1 and GBA2 activity 
in hypotonic lysates of control (MEB-4) and GlcCerS-deficient (GM-95) mouse melanoma cells in 
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presence of 1.67 mM 4-MUG. Both, GBA1 (a) and GBA2 (b) activity, remained unchanged in the 
absence of GlcCer. GlcCerS: glucosylceramide synthase, 4-MUG: 4-Methylumbelliferyl beta-D-
glucopyranoside. Data are presented as mean + SD. N numbers are indicated in brackets.    
3.13 The effect of sphingoid bases on GBA2 activity 
3.13.1 Sphingosine inhibits GBA2 activity 
Deficiency of GBA1 in Gaucher patients causes the accumulation of not only GlcCer, 
but also glucosylsphingosine (GlcSph) (Ferraz et al., 2016). As previously mentioned, 
it has been proposed that in cells from Gaucher patients, both, GlcCer and GlcSph, 
spill-over from the lysosomes into the cytoplasm, thereby becoming a substrate for 
GBA2 (Mistry et al., 2014). This increase of a GBA2-dependent break down of GlcCer 
would lead to an accumulation of cytotoxic sphingosine in the cell, which has been 
proposed to cause some of the defects associated with Gaucher pathophysiology 
(Mistry et al., 2014). In favour of this hypothesis, deletion of GBA2 rescued some of 
the defects associated with Gaucher pathophysiology (Mistry et al., 2014). 
I hypothesised that cells, accumulating GlcCer and GlcSph in the lysosomes due to a 
loss of GBA1 activity, have developed a mechanism, whereby GBA2 activity is 
diminished to avoid accumulation of the cytotoxic metabolite sphingosine. The simplest 
scenario that could be envisioned would be a regulation of GBA2 activity by 
sphingosine. To test this hypothesis, I analysed if the GBA2 activity is sensitive to 
sphingosine. 
CHO cells stably over-expressing mGBA2 were incubated with 20 µM sphingosine for 
4.5 h and the GBA1 and GBA2 activity was measured (Figure 40a). Surprisingly, both, 
GBA1 and GBA2 activity, were significantly reduced to around 26% and 42% of the 
non-treated samples, respectively (Figure 40b, c). In Gaucher disease patients, this 
effect only applies to GBA2 as GBA1 is not active (see Figure 14). However, the 
experimental set up in CHO cells does not allow to conclude whether both, GBA1 and 
GBA2, are sensitive to sphingosine because a down-regulation of GBA1 activity by 
sphingosine would be sufficient to reduce GBA2 activity, without sphingosine having a 
direct effect on GBA2. Arguing against this is the short incubation time with sphingosine 
(4.5 h). In previous experiments using CBE, GBA1 activity was significantly reduced 
after 3 h and GBA2 activity was only reduced when GBA1 was almost completely 
blocked for several hours (see Figure 22). Thus, an incubation time of only 4.5 h might 
not be sufficient to reduce GBA2 activity via GBA1. However, one has to keep in mind 
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that CBE and sphingosine might possess different properties when entering a cell (e.g. 
trafficking time to the lysosomes) and their mechanism of action on GBA1 are, most 
likely, also completely different.    
 
Figure 40: GBA1 and GBA2 activity in CHO cells stably over-expressing mGBA2 treated with 
20 µM sphingosine. Analysis of GBA1 and GBA2 activity in hypotonic lysates of CHO cells stably over-
expressing mGBA2 treated with 20 µM sphingosine compared to control cells in presence of 1.67 mM 
4-MUG. (a) Structure of sphingosine. (b) GBA1 and (c) GBA2 activity were significantly reduced to 
around 26% and 42% of the non-treated samples, respectively. 4-MUG: 4-Methylumbelliferyl beta-D-
glucopyranoside. Data are presented as mean + SD. N numbers are indicated in brackets. P values 
were determined using One-way ANOVA.       
To tackle this problem, embryonal fibroblasts from GBA1-deficient mice were 
incubated with 20 µM sphingosine for 4.5 h to study the effect of sphingosine on GBA2 
in a GBA1-independent manner (Figure 41). As seen in Figure 41, incubation with 20 
µM sphingosine reduced the GBA2 activity in control cells to around 62% compared to 
the non-treated samples. Interestingly, sphingosine further reduced the GBA2 activity 
in GBA1-deficient cells to only 6% compared to 14% in the non-treated GBA1-deficient 
samples (Figure 41). Thus, GBA1 and GBA2 are both sensitive to sphingosine.     
Results   109 
 
Figure 41: GBA2 activity in control and GBA1-deficient mouse embryonal fibroblasts treated with 
20 µM sphingosine. Analysis of the GBA2 activity in hypotonic lysates of GBA1-deficient mouse 
embryonal fibroblasts treated with 20 µM sphingosine compared to control (Ctrl) cells in presence of 
1.67 mM 4-MUG. Incubation with 20 µM sphingosine reduced the GBA2 activity in control cells to around 
62% and to only 6% compared to 14% in GBA1-deficient samples. 4-MUG: 4-Methylumbelliferyl beta-
D-glucopyranoside. Data are presented as mean + SD. N numbers are indicated in brackets. P values 
were determined using One-way ANOVA.       
3.13.2 GBA2 is also sensitive to sphinganine 
Sphinganine differs from sphingosine by one double bond in the alkyl chain (Figure 
42a). To test whether sphinganine, the saturated form of this sphingoid base, also 
exhibits an inhibitory effect, experiments were repeated in CHO cells stably over-
expressing mGBA2 using 20 µM sphinganine (Figure 42). Again, both enzymes were 
less active after incubation with sphinganine, albeit the effect was stronger for GBA1 
(Figure 42b). In summary, GBA1 and GBA2 are both sensitive to sphingosine and 
sphinganine, suggesting that the steric dimension of the sphingoid alkyl chain is 
irrelevant for the inhibitory effect. 
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Figure 42: GBA1 and GBA2 activity in CHO cells stably over-expressing mGBA2 treated with 20 
µM sphinganine. Analysis of GBA1 and GBA2 activity in hypotonic lysates of CHO cells stably over-
expressing mGBA2 treated with 20 µM sphinganine compared to control cells in presence of 1.67 mM 
4-MUG. (a) Structure of sphinganine. (b) GBA1 and (c) GBA2 activity were significantly reduced to 
around 26% and 63% of the non-treated samples, respectively. 4-MUG: 4-Methylumbelliferyl beta-D-
glucopyranoside. Data are presented as mean + SD. N numbers are indicated in brackets. P values 
were determined using One-way ANOVA.       
3.13.3 Sphingosine reduces the GBA2 activity in protein lysates from       
different mouse tissues 
Next, I tested whether the inhibitory effect of sphingosine on GBA2 is direct or involves 
a signalling cascade that requires an intact cell. I analysed GBA1 and GBA2 activity in 
hypotonic protein lysates from murine brain after incubation with 20 µM sphingosine 
for 1.5 h and compared the results to non-treated control lysates (Figure 43). GBA1 
activity remained unchanged after incubation with sphingosine, whereas the GBA2 
activity was slightly, but significantly, reduced to 81% (Figure 43). These data again 
support the idea that sphingosine blocks GBA2 directly and independent from GBA1. 
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Figure 43: GBA1 and GBA2 activity in control brain lysates incubated with 20 µM sphingosine. 
Analysis of GBA1 and GBA2 activity in hypotonic brain lysates from control mice incubated with 20 µM 
sphingosine compared to control lysates in presence of 1.67 mM 4-MUG. (a) The GBA1 activity 
remained unchanged after incubation with sphingosine, whereas the (b) GBA2 activity was slightly, but 
significantly, reduced to 81% compared to the controls. 4-MUG: 4-Methylumbelliferyl beta-D-
glucopyranoside. Data are presented as mean + SD. N numbers are indicated in brackets. P values 
were determined using One-way ANOVA. 
To validate these results, I made use of the different localisations of GBA1 and GBA2. 
Microsomes originate from ER membranes and contain GBA2, but not GBA1 
(Körschen et al., 2013). Microsomes can be separated from other cellular organelles 
by differential centrifugation: Nuclei and cellular debris are sedimented at rather low g-
forces (low speed centrifugation, e.g. 1,000 x g), while soluble enzymes and organelles 
like mitochondria and the ER (microsomes) remain in the supernatant. After high speed 
centrifugation (e.g. 15,000 x g), organelles are separated from the soluble lysate 
fraction. Finally, microsomes are sedimented at around 80,000 x g (ultracentrifugation) 
(Claude, 1946). Microsomes were prepared from brain and liver of GBA2-deficient and 
control mice (Figure 44) (Optima MAX-XP Ultracentrifuge, Beckman Coulter). 
The different steps of the microsomal preparation from liver were verified by Western 
blot analysis using an anti-GBA2 antibody and an organelle marker for the ER, calnexin 
(Figure 44b). Both, GBA2-deficient and control microsomal samples, were strongly 
positive for calnexin, demonstrating that the enrichment worked. The anti-GBA2 
antibody also labelled a band in the microsomal fraction of the control but not in the 
GBA2-deficient sample, demonstrating that GBA2 was enriched in this fraction (Figure 
44b). GBA2 was also present in the supernatant after ultracentrifugation, although this 
fraction was negative for calnexin, underlining the finding that GBA2 is only membrane-
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associated (Figure 44b) (Körschen et al., 2013). To verify the absence of lysosomes 
and, thereby, GBA1 in the microsomal fraction, I also stained with an anti-GBA1 
antibody (Figure 44b). GBA1 is highly glycosylated (Bergmann&Grabowski, 1989), 
making it difficult to detect defined protein bands on the Western blot without de-
glycosylation of the protein. Thus, bands labelled by the anti-GBA1 antibody were not 
very defined and rather cloudy (Figure 44b).    
 
Figure 44: Preparation of microsomes from mouse liver. Purification of microsomes from a 
hypotonic lysate of a mouse liver by differential centrifugation. (a) Flow-chart of microsome preparation. 
(b) The single fractions were analysed for the presence of GBA1 and GBA2 by Western blot using 
specific antibodies against GBA1 (Sigma) or GBA2 (mix of monoclonal antibody clones 4A12 and 2F8 
from rat, Körschen et al. 2013). The ER-resident protein calnexin was used to verify the presence of ER 
membranes. GBA2 was enriched in the microsomal fraction/P3 of the control mouse together with 
calnexin. P: Pellet, S: Supernatant, WT: Wild-type, KO: Knockout.  
To further verify the preparation, I also analysed the beta-glucosidase activity in the 
input and pellet fractions (Figure 45). The main activity for both, GBA1 and GBA2, was 
detected in the first pellet fraction, indicating that most of the protein was lost during 
the first step. Accordingly, the GBA2 activity recovered in the last pellet fractions was 
rather low compared to the input (Figure 45b). Unfortunately, there was activity 
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detectable at both pH values in the microsomal fraction, indicating that GBA1 was still 
present in the pellet fraction after ultracentrifugation (Figure 45a). 
 
Figure 45: GBA1 and GBA2 activity in different fractions from hypotonic mouse liver lysates after 
differential centrifugation. Analysis of GBA1 and GBA2 activity in hypotonic liver lysates from control 
mice in presence of 1.67 mM 4-MUG. (a) Most of GBA1 and (b) GBA2 remained in the first pellet fraction, 
indicating that most of the protein was lost during the first step. The GBA2 activity recovered in the last 
pellet fractions was rather low compared to the input. The separation of GBA2 from GBA1 did not work. 
4-MUG: 4-Methylumbelliferyl beta-D-glucopyranoside. N numbers are indicated in brackets.  
Thus, I tested the same approach using hypotonic lysates of a mouse brain (Figure 
46). In brain lysates, the absolute GBA2 activity is much higher than the activity of 
GBA1 (Figure 46). However, also here, most of GBA1 and GBA2 seem to be lost after 
the first centrifugation, which resulted in very little beta-glucosidase activity in the last 
pellet fraction (Figure 46). As seen for liver (Figure 45), GBA1 activity was detectable 
in the microsomal fraction (Figure 46a), albeit the activity of GBA2 in the microsomal 
fraction was significantly higher than the GBA1 activity (38 rfu/min versus 6.5 rfu/min) 
(Figure 46).   
 
Figure 46: GBA1 and GBA2 activity in different fractions from hypotonic mouse brain lysates 
after differential centrifugation. Analysis of GBA1 and GBA2 activity in hypotonic liver lysates from 
control mice in presence of 1.67 mM 4-MUG. (a) Most of GBA1 and (b) GBA2 seems to remain in the 
first supernatant, resulting in very little GBA2 activity in the microsomal/P3 pellet fraction. The separation 
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of GBA2 from GBA1 did not work. 4-MUG: 4-Methylumbelliferyl beta-D-glucopyranoside. N numbers are 
indicated in brackets. 
3.14 Sphingosine directly inhibits GBA2 
3.14.1 Expression of mGBA2-His in bacteria 
To finally reveal whether sphingosine exerts a direct effect on GBA2, I switched to a 
prokaryotic system and expressed mGBA2 in E.coli BL21 CodonPlus DE3 RIPL, which 
contain the DE3 bacteriophage lambda lysogen and, thus, carry the lacI gene together 
with its promotor (binding site for RNA polymerase), the lac operon, and the gene for 
T7 RNA polymerase under control of lacUV5 promoter (Figure 47) (Agilent 
Technologies). The lacI gene encodes the lac repressor. Under normal conditions, the 
lac repressor is constantly expressed and binds to the operator between the lacUV5 
promoter and the gene for T7 RNA polymerase. Thus, T7 RNA polymerase is not 
expressed. The lac operon itself consists of its promoter, the operator, and the coding 
sequence of the lacZ gene, encoding the beta-galactosidase that cleaves lactose. 
Bacteria were transformed with a pET21 vector containing the coding sequence of 
mGBA2-His under control of the T7 promotor (EMD Biosciences). Thus, it is only 
expressed after addition of isopropyl beta-D-1-thiogalactopyranoside (IPTG), a 
molecular mimic of allolactose that binds to the lac repressor. Binding of the lac 
repressor to IPTG prevents it from further occupying the operator and, thus, activates 
expression of the T7 RNA polymerase, which can then bind to its promoter (T7 
promoter) and initiate the transcription of mGBA2-His. 
 
Figure 47: The lac operon. Schematic drawing of the lac operon containing the lacI gene and its 
promoter and the lac operon and its promoter and operator. The single functions are described in the 
text.  
I followed mGBA2 expression in the bacterial lysates by analysing the GBA2 protein 
expression and activity in hypotonic lysates before and after addition of 1 mM IPTG 
(Figure 48). mGBA2-His expression was only observed after IPTG induction (Figure 
48a, c). Furthermore, NB-DNJ-blockable beta-glucosidase activity at pH 6 was only 
measured in the IPTG-induced sample, demonstrating that these bacteria contain no 
endogenous GBA2 activity (Figure 48c). Of note, the bacteria also lack beta-
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glucosidase activity at pH 4, demonstrating that they also lack endogenous GBA1 
activity (Figure 48b). 
 
Figure 48: Expression of mGBA2 in E. coli. Bacteria of the E.coli strain BL21 CodonPlus DE3 RIPL 
were transformed with a pET21 vector containing mGBA2-His under the control of the T7 promotor. 
Induction of mGBA2 expression by addition of 1 mM IPTG was followed by Western blot using an anti-
His antibody (Novagen). Beta-glucosidase activity was analysed at pH 4 and pH 6 before and after 
addition of IPTG in presence of 1.67 mM 4-MUG. (a) mGBA2-His was only detectable after IPTG 
induction. (b) There was no beta-glucosidase activity detectable at pH 4 in the bacteria culture before 
and after induction with IPTG. (c) NB-DNJ-blockable beta-glucosidase activity was only measurable at 
pH 6 in the IPTG-induced bacteria culture. IPTG: Isopropyl beta-D-1-thiogalactopyranoside, 4-MUG: 4-
Methylumbelliferyl beta-D-glucopyranoside. N numbers are indicated. 
The bacterial lysate was very viscous and difficult to pipet, which is why I made a serial 
dilution of the lysate to identify a dilution that was easy to pipet and showed a prominent 
GBA2 activity (Figure 49). Here, the 1:8 diluted sample had the smallest variation when 
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assayed as quadruples with an activity of 2.9 rfu/min (Figure 49). Thus, all experiments 
with bacterial lysates expressing mGBA2 were carried out in 1:8 diluted samples.  
 
Figure 49: GBA2 activity in a serial dilution of hypotonic bacterial lysates over-expressing 
mGBA2. The GBA2 activity in a serial dilution of bacterial lysates was analysed in presence of 1.67 mM 
4-MUG. The 1:8 diluted sample had the smallest variation with an activity of 2.9 rfu/min and was used 
for further experiments. 4-MUG: 4-Methylumbelliferyl beta-D-glucopyranoside. Data are presented as 
mean of quadruples + SD. N numbers are indicated in brackets. 
To determine the amount of active GBA2 in the bacterial lysates, the total GBA2 activity 
in the lysates was correlated with the amount of GBA2 protein present. The latter was 
determined by Western blot analysis using an anti-GFP antibody and, as a reference, 
a purified GFP-fusion protein with a known protein concentration (Figure 50a). GFP-
tagged mGBA2 was expressed in CHO cells and the activity of over-expressed GBA2 
was analysed in these lysates. Here, 40 µg total lysate showed an endogenous activity 
of 0.5 ± 0.1 rfu/min and a total activity of 2.45 ± 0.14 rfu/min, resulting in an activity of 
1.94 rfu/min for the over-expressed GBA2 protein (Figure 50c). I analysed the signal 
intensity of GFP-mGBA2 by Western blot using an anti-GFP antibody and compared 
the signal to the reference protein (Figure 50a, b). Here, e.g. 5 µg total protein from the 
CHO cell lysate corresponded to 7563 arbitrary units according to the anti-GFP 
antibody staining. By plotting a standard curve of the reference protein, I correlated the 
total amount of GFP/mGBA2 with the total amount of the reference protein (Figure 
50b). Thus, 5 µg total protein from the CHO cell lysate contained 30.51 ng 
heterologously expressed mGBA2, which represents 244.08 ng GBA2 in 40 µg total 
protein and a GBA2 activity of 1.94 rfu/min (Figure 50c). I used 20 µl of a 1:8 diluted 
bacterial lysate over-expressing mGBA2-His to generate each data point in the 
following experiments (see Figure 51 following). Since 20 µl of this sample showed a 
GBA2 activity of 2.9 rfu/min (see Figure 49), it contained 359.31 ng GBA2.    
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Figure 50: Determining the absolute amount of active GBA2 in bacterial lysates. GFP-tagged 
mGBA2 was expressed in CHO cells and analysed by Western blot using a GFP-specific antibody 
(Abcam). The activity of GBA2 was determined in GFP-mGBA2-transfected CHO cells in presence of 
8.3 µM NB-DNJ and compared to the non-transfected control in presence of 1.67 mM 4-MUG. (a) 5 µg 
total protein from the CHO cell lysate had a GFP signal intensity of 7563 arbitrary units. (b) Plotting a 
standard curve of the reference protein revealed that 5 µg total protein from the CHO cell lysate 
contained 30.51 ng heterologously expressed mGBA2. (c) 40 µg total CHO lysate possessed a 
heterologous GBA2 activity of 1.94 rfu/min, which represented 244.08 ng GBA2. R2 value: coefficient of 
determination, 4-MUG: 4-Methylumbelliferyl beta-D-glucopyranoside, au: Arbitrary units. Data are 
presented as mean of quadruples + SD. N numbers are indicated in brackets. 
I first analysed the dose-response relationship of the beta-glucosidase activity to NB-
DNJ (Figure 51). The IC50 for NB-DNJ in bacterial lysates over-expressing mGBA2 
was 14.51 ± 2.7 nM, which is similar to the IC50 values previously determined in 
hypotonic lysates of mouse brain, liver, and testis (18.2 ± 0.3 nM, 20.9 ± 1.3 nM, and 
19.2 ± 0.4 nM, respectively) (Körschen et al., 2013). Furthermore, the IC50 did not 
significantly change in the presence of 25 µM CBE (13.64 ± 3.4 nM, Figure 51b), 
demonstrating that the beta-glucosidase activity in the bacterial lysates was solely due 
to GBA2 (also compare Figure 48).  
 
Figure 51: Dose-response relationship of GBA2 to NB-DNJ. Analysis of the GBA2 activity in bacterial 
lysates over-expressing mGBA2 in presence of a serial NB-DNJ dilution and 1.67 mM 4-MUG. Data 
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were normalised to a non-treated control. (a) The IC50 for NB-DNJ in bacterial lysates over-expressing 
mGBA2 was 14.51 ± 2.7 nM. (b) The IC50 for NB-DNJ in presence of 25 µM CBE was 13.64 ± 3.4 nM. 
NB-DNJ: N-butyl-deoxynojirimycin, CBE: Conduritol B epoxide, 4-MUG: 4-Methylumbelliferyl beta-D-
glucopyranoside. Data are presented as mean of quadruples ± SD. Representative plot for n = 3 
experiments. 
3.14.2 Sphingoid bases directly inhibit GBA2 activity 
I then assayed the dose-response relationship of GBA2 for sphingosine in bacterial 
lysates. Sphingosine reduced the GBA2 activity with an IC50 of 25.04 ± 0.2 µM (Figure 
52). In summary, these results demonstrate that sphingosine directly inhibits GBA2 
(Figure 52). 
 
Figure 52: Dose-response relationship of GBA2 to sphingosine. Analysis of the GBA2 activity in 
bacterial lysates over-expressing mGBA2 in presence of sphingosine and 1.67 mM 4-MUG. Data were 
normalised to a non-treated control. The IC50 for sphingosine in bacterial lysates over-expressing 
mGBA2 was 25.04 ± 0.2 µM. 4-MUG: 4-Methylumbelliferyl beta-D-glucopyranoside. Data are presented 
as mean of quadruples ± SD. Representative plot for n = 3 experiments. 
I could already show that sphinganine, the saturated derivative of sphingosine, affects 
the GBA2 activity when incubated with CHO cells stably over-expressing mGBA2 (see 
Figure 42). Thus, I also wanted to test whether sphinganine has the same effect on 
GBA2 in bacterial lysates and analysed the dose-response relationship of sphinganine 
for GBA2 over-expressed in bacteria (Figure 53). In accordance with my previous 
results, sphinganine inhibited GBA2 with an IC50 of 30.56 ± 4.47 µM, suggesting that 
the steric dimension of the sphingoid alkyl chain is irrelevant for the inhibitory effect.   
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Figure 53: Dose-response relationship of GBA2 to sphinganine. Analysis of the GBA2 activity in 
bacterial lysates over-expressing mGBA2 in presence of a serial dilution of sphinganine and 1.67 mM 
4-MUG at pH 6. Data were normalised to a non-treated control. The IC50 for sphinganine in bacterial 
lysates over-expressing mGBA2 was 30.56 ± 4.47 µM. Representative plot for n = 3 experiments, data 
are presented as mean of quadruples ± SD. 
In the cell, sphingosine can be phosphorylated by sphingosine kinases to sphingosine-
1-phosphate (S1P), a sphingoid messenger that controls multiple signalling pathways 
(Spiegel&Milstien, 2003). S1P is structurally similar to sphingosine, but additionally 
bears a phosphate head group (Figure 54a). I analysed whether GBA2 is also sensitive 
to S1P by determining the dose-response relationship of S1P for GBA2 over-
expressed in bacteria. Sphingosine-1-phosphate did not inhibit GBA2 activity, 
suggesting that the presence of a phosphate group disturbs the inhibition of GBA2 
(Figure 54b).  
 
Figure 54: Dose-response relationship of GBA2 to sphingosine-1-phosphate. Analysis of GBA2 
activity in bacterial lysates over-expressing mGBA2 in the presence of sphingosine-1-phosphate and 
1.67 mM 4-MUG. Data were normalised to a non-treated control. (a) Structure of sphingosine-1-
phosphate. (b) Sphingosine-1-phosphate had no effect on GBA2 activity. 4-MUG: 4-Methylumbelliferyl 
beta-D-glucopyranoside. Data are presented as mean of quadruples ± SD. Representative plot for n = 3 
experiments. 
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Fingolimod, or FTY720, is derived from myriocin (ISP-1), a metabolite of the fungus 
Isaria sinclairii, and is a manufactured analogue of sphingosine, approved for the 
treatment of Multiple Sclerosis (Figure 55a) (Kappos et al., 2010). Just like sphingosine 
(2-amino-1.3-dihydroxy-4-trans-octadecen), FTY720 (2-amino-2-[2-(4-octylphenyl)-
ethyl]) propane-1,3-diol) is also substituted with an amine at C2 and carries two 
hydroxyl groups in the head region. Other than sphingosine, FTY720 carries an 
octylphenyl group in its carbon tail, while sphingosine itself only bears a double bond 
at C4 (compare Figure 40a and Figure 55a). In vivo, FTY720 is phosphorylated to form 
FTY720-phosphate, which resembles naturally occurring S1P and also binds to S1P-
surface receptors of cells (Brinkmann et al., 2002; Chun&Hartung, 2010), 
demonstrating that FTY720 behaves like natural sphingosine. To test whether FTY720 
blocks GBA2 activity, I analysed the dose-response relationship of FTY720 for GBA2 
over-expressed in bacteria (Figure 55b). GBA2 activity was also inhibited by FTY720 
with a slightly lower IC50 value of 18.6 ± 0.44 µM. Thus, GBA2 activity is sensitive to 
sphingoid bases, but without any head group attached to C1 (like e.g. S1P).  
 
Figure 55: Dose-response relationship of GBA2 to FTY720. Analysis of the GBA2 activity in bacterial 
lysates over-expressing mGBA2 in presence of FTY720 and 1.67 mM 4-MUG. Data were normalised to 
a non-treated control. (a) Structure of FTY720. (b) The IC50 for FTY720 in bacterial lysates over-
expressing mGBA2 was 18.6 ± 0.44 µM. 4-MUG: 4-Methylumbelliferyl beta-D-glucopyranoside. Data 
are presented as mean of quadruples ± SD. Representative plot for n = 3 experiments. 
In a cellular system, change in ceramide levels did not affect GBA2 activity (see Figure 
37 - Figure 39). Nevertheless, ceramide is composed of sphingosine coupled to a fatty 
acid via an amide bond without any head group (Figure 56a). I revisited the effect of 
ceramide on GBA2 activity by using GBA2 over-expressed in bacteria. Cell lysates 
were incubated with C18 ceramide and the activity of GBA2 was analysed. However, 
ceramide did not block GBA2 activity (Figure 56b). Thus, GBA2 seems to be only 
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sensitive to sphingoid bases (sphingosine, sphinganine, FTY720) and not to higher 
order derivatives (ceramide).  
 
Figure 56: Dose-response relationship of GBA2 to C18 ceramide. Analysis of the GBA2 activity in 
bacterial lysates over-expressing mGBA2 in presence of C18 ceramide and 1.67 mM 4-MUG. Data were 
normalised to a non-treated control. (a) Structure of C18 ceramide. (b) C18 ceramide had no effect on 
GBA2 activity. 4-MUG: 4-Methylumbelliferyl beta-D-glucopyranoside. Data are presented as mean of 
quadruples ± SD. Representative plot for n = 3 experiments. 
3.14.3 Sphingosine does not quench the fluorescence of 4-
Methylumbelliferone  
In our beta-glucosidase activity assay, I determine the beta-glucosidase activity 
according to the increase in fluorescence over time (see Figure 8) (Körschen et al., 
2013), when 4-MUG is cleaved to beta-D-glucose and 4-Methylumbelliferone (4-MU) 
(Figure 57a). 4-MU is highly fluorescent at 365 nm excitation and emits light at 445 nm 
(The Merck Index, 12th ed., Entry# 4903). To test whether the addition of sphingosine 
(or other sphingoid bases) quenches the fluorescence of 4-MU, I tested the 4-MU 
fluorescence in the presence of 0-400 µM sphingosine (Figure 57b). The fluorescence 
increased in a dose-dependent manner and there was no difference in the presence 
or absence of sphingosine (Figure 57b). Thus, sphingosine did not quench the 
fluorescence of the cleavage-product of 4-MUG.    
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Figure 57: 4-MU fluorescence in presence of sphingosine. Analysis of the fluorescence of 4-MU in 
presence of sphingosine. (a) GBA1 and GBA2 cleave 4-MUG to β-D-glucose and 4-MU. (b) The 
fluorescence of 4-MU increased in a dose-dependent manner and there was no difference in the 
presence or absence of sphingosine. 4-MUG: 4-Methylumbelliferyl beta-D-glucopyranoside, 4-MU: 4-
Methylumbelliferone. Data are presented as mean of quadruples ± SD. The N number is indicated.  
3.14.4 The sphingosine-dependent inhibition of GBA2 is reversible and 
rather non-competitive 
To further characterise the sphingosine-dependent block of GBA2 activity, I tested 
whether the block is reversible (Figure 58). Three samples of hypotonic lysates of 
bacteria expressing mGBA2 were pre-incubated with either 25 µM sphingosine to 
evoke a half-maximal block of GBA2 activity (two samples) or with DMSO as a control 
(one sample) (see Figure 58a). Then, all samples were diluted 1:6.5, resulting in a final 
sphingosine concentration of 3.85 µM. In a control sample, the initial sphingosine 
concentration of 25 µM was maintained by re-addition of sphingosine (Figure 58a). 
25 µM sphingosine reduced the GBA2 activity to 50% of the control (DMSO) sample, 
whereas almost full GBA2 activity was recovered when sphingosine was diluted to 
3.85 µM (Figure 58b). These results indicate that sphingosine reversibly blocks GBA2 
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activity. In parallel, hypotonic lysates of bacteria expressing mGBA2 were also pre-
incubated with either 14 nM NB-DNJ or PBS to follow the reversible inhibition of GBA2 
by NB-DNJ (Ridley et al., 2013) (Figure 58c). In the presence of 14 nM NB-DNJ, the 
GBA2 activity was reduced to 33%, whereas dilution to 2.15 nM NB-DNJ recovered 
the GBA2 activity to 56% of the control (Figure 58c).  
 
Figure 58: Sphingosine reversibly inhibits GBA2. Analysis of the GBA2 activity in bacterial lysates 
over-expressing mGBA2 in presence of 25 µM sphingosine or 14 nM NB-DNJ diluted 1:6.5 in hypotonic 
buffer with or without maintaining the concentration of sphingosine or NB-DNJ in presence of 1.67 mM 
4-MUG. Data were normalised to the non-treated control (Ctrl). (a) Flow-chart of the experiment. (b) The 
GBA2 activity was recovered in lysates after diluting 25 µM sphingosine down to 3.85 µM, demonstrating 
that the block is reversible. (c) Dilution of NB-DNJ, the reversible blocker for GBA2, also results in 
recovery of GBA2 activity. NB-DNJ: N-butyl-deoxynojirimycin, 4-MUG: 4-Methylumbelliferyl beta-D-
glucopyranoside. Data are presented as mean + SD. N numbers are indicated in brackets. P values 
were determined using One-way ANOVA. 
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To characterise the type of reversible inhibition, I incubated bacterial lysates over-
expressing mGBA2 with 25 µM sphingosine and competed the inhibitory effect by 
adding increasing amounts of 4-MUG (Figure 59). Data were analysed according to 
Michaelis-Menten. In the presence of sphingosine, the GBA2 activity (Vmax) was 
reduced to about 50% of the control activity (3.53 ± 0.13 rfu/min versus 1.93 ± 0.13 
rfu/min), indicating a non-competitive inhibition of sphingosine for GBA2. However, the 
Km value was shifted towards higher concentrations (171.03 ± 13.83 µM versus 303.97 
± 44.30 µM), which does not resemble the classic non-competitive inhibition model. 
Thus, my data suggest that the inhibition of GBA2 by sphingosine follows the rules of 
mixed inhibition, where the inhibitor can bind to an allosteric site of the enzyme if it has 
not bound its substrate yet, as well as to the enzyme-substrate complex. In this case, 
the Km value is increased, which resembles a lower affinity of the enzyme for its 
substrate, and Vmax is decreased.  
 
Figure 59: GBA2 activity in presence of 25 µM sphingosine and a serial dilution of 4-MUG. 
Analysis of the GBA2 activity in bacterial lysates over-expressing mGBA2 in presence of 25 µM 
sphingosine and an increasing amount of 4-MUG. Data were normalised to the non-treated control and 
compared to DMSO-treated samples. Vmax of GBA2 was reduced to about 50% in presence of 25 µM 
sphingosine of the control activity (3.53 ± 0.13 rfu/min versus 1.93 ± 0.13 rfu/min). The Km value was 
shifted from 171.03 ± 13.83 µM to 303.97 ± 44.30 µM in the presence of sphingosine. 4-MUG: 4-
Methylumbelliferyl beta-D-glucopyranoside. Data are presented as mean of quadruples ± SD. 
Representative plot for n = 3 experiments,  
Since 4-MUG is not the natural substrate for GBA2, I also tested whether GlcCer and 
sphingosine compete for the same binding site. Again, bacterial lysates over-
expressing GBA2 were incubated with 25 µM sphingosine and then assayed in the 
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presence of increasing amounts of GlcCer (Figure 60) with a final 4-MUG concentration 
of 1.67 mM. As seen in the previous experiment, increasing amounts of GlcCer, just 
as 4-MUG, did not reverse the inhibitory effect of sphingosine (Figure 60). Of note, the 
GBA2 activity in both samples decreased when high concentrations of GlcCer were 
reached (Figure 60). Since there was no precipitate visible in both samples, the 
remaining pool of active GBA2 most likely started to rather cleave the natural substrate 
instead of 4-MUG, which in this assay appears as a reduction in fluorescence and, 
thereby, looks like a decrease in overall activity (Figure 60). In conclusion, these data 
strengthen the result that sphingosine binds an allosteric site evoking a mixed inhibition 
of GBA2.  
            
Figure 60: GBA2 activity in presence of 25 µM sphingosine and a serial dilution of GlcCer. 
Analysis of the GBA2 activity in bacterial lysates over-expressing mGBA2 in presence of 25 µM 
sphingosine and C18 GlcCer in presence of 1.67 mM 4-MUG. GlcCer did not reverse the sphingosine-
dependent effect. At high GlcCer concentrations, GBA2 seemed to rather cleave natural GlcCer 
compared to 4-MUG, resulting in a decrease in fluorescence. 4-MUG: 4-Methylumbelliferyl beta-D-
glucopyranoside. Data are presented as mean of quadruples ± SD. The N number is indicated.  
3.14.5 GBA1 is sensitive to sphingosine and sphinganine 
Since both, sphingosine and sphinganine, had an inhibitory effect on GBA1 when 
incubated with cells (Figure 40 and Figure 42), I also tested whether both sphingoid 
bases would exhibit a direct effect on the activity of GBA1. Thus, I analysed the dose-
response relationship of both lipids on the GBA1 activity using hypotonic cell lysates 
from CHO cells stably over-expressing mGBA1 (#A8A6B5) (Figure 61). Sphingosine 
inhibited GBA1 with an IC50 value of 15.81 ± 1.3 µM and sphinganine inhibited showed 
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the same effect with an IC50 value of 37.63 ± 4.4 µM (Figure 61). Of note, neither 
sphingosine nor sphinganine evoked a full block of GBA1 activity even at high 
concentrations (Figure 61). Thus, GBA1 was probably not fully accessible for the 
sphingoid bases in the lysate even though the enzyme seemed to still be accessible 
for the substrate 4-MUG resulting in remaining activity/fluorescence (Figure 61).  
 
Figure 61: Dose-response relationship of GBA1 to sphingosine and sphinganine. Analysis of the 
GBA1 activity in lysates from CHO cells stably over-expressing mGBA1 in presence of a serial dilution 
of sphingosine or sphinganine and 1.67 mM 4-MUG at pH 4. Data were normalised to a non-treated 
control. The IC50 for (a) sphingosine and (b) sphinganine in CHO cell lysates over-expressing mGBA2 
was 15.81 ± 1.3 µM and 37.63 ± 4.4 µM, respectively. 4-MUG: 4-Methylumbelliferyl beta-D-
glucopyranoside. Data are presented as mean ± SD. N numbers are indicated. 
3.14.6 Intracellular sphingosine levels are not increased in Gaucher 
fibroblasts 
To analyse whether intracellular sphingosine levels are indeed altered in GBA1-
deficient cells, dermal fibroblasts from control and Gaucher patients were analysed by 
mass spectrometry (Figure 62). Sphingosine levels were not significantly increased in 
Gaucher fibroblasts with 1.32 ± 0.81 pmol/µg protein in type I samples, 2.23 ± 2.28 
pmol/µg protein in type II samples, and 1.2 ± 0.51 pmol/µg protein in type III samples 
compared to 1.41 ± 0.61 pmol/µg protein in control cells (Figure 62a). Sphinganine 
levels showed a similar distribution with 5.72 ± 2.1 pmol/µg protein in control cells and 
5.05 ± 3.12 in type I, 7.72 ± 6.1 in type II, and 4.53 ± 2.62 pmol/µg protein in type III 
Gaucher fibroblasts (Figure 62b). Thus, neither sphingosine nor sphinganine levels 
were significantly changed in fibroblasts from Gaucher patients.  
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Figure 62: Sphingosine and sphinganine levels in Gaucher and control fibroblasts. Mass 
spectrometric analysis of sphinganine and sphingosine levels normalised to the amount of protein per 
sample. (a) Sphingosine levels were not significantly increased in all three Gaucher types with type II 
cells showing the highest sphingosine amount. Control (Ctrl) cells contained 1.41 ± 0.61 pmol 
sphingosine/µg protein and Gaucher cells contained in total 1.2 – 2.23 pmol sphingosine/µg protein. (b) 
As for (a) with sphinganine control values of 5.72 ± 2.1 pmol per µg protein and Gaucher cells containing 
4.53 – 7.72 pmol sphinganine/µg protein. The different Gaucher types are indicated. Data are presented 
as mean + SD. N numbers are shown in brackets. P values were determined using One-way ANOVA.   
3.15 Analysing ER stress in dermal fibroblasts from GBA2-deficient mice 
In Gaucher disease, the human GBA1 gene is prone to mutations, which comprise 
missense mutations and, thereby, premature termination of the gene, splice site 
mutations, and deletions (Hruska et al., 2008). GBA1 is synthesised on polyribosomes 
at the ER (Erickson et al., 1985). The pre-mature GBA1 undergoes N-linked 
glycosylation at four specific glycosylation sites, after which the enzyme is then 
subjected to ER quality control. In case the protein is correctly folded, GBA1 is 
transported to the Golgi, where its N-glycan moieties are further modified. In a last 
step, GBA1 is shuttled to the lysosomes. This process does not take place in Gaucher 
cells, because mutant GBA1 is not properly folded. In 2008, work was published 
showing that mRNA expression levels of GRP78 are slightly increased in fibroblasts 
from Gaucher disease type I and II patients as well as in Niemann-Pick type C patients 
(Wei et al., 2008). Furthermore, GRP78 and CHOP mRNA levels were increased in 
dermal fibroblasts derived from Gaucher disease patients, carrying different mutations 
in the GBA1 gene (Maor et al., 2013). In contrast to these findings, Farfel-Becker et al. 
did not see any change in GRP78 and CHOP mRNA expression in both, cell culture 
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models and animal-derived cells of neuronopathic Gaucher disease (Farfel-Becker et 
al., 2009). However, both, GRP78 and CHOP, are so-called ER stress marker genes 
for a mechanism called unfolded protein response (UPR), which is activated by 
accumulation of misfolded protein in the ER (Cao&Kaufman, 2012). Thus, UPR 
prevents the accumulation of unfolded proteins by activating e.g. chaperones to 
increase the protein-folding capacity or the degradation of proteins through ER-
associated protein degradation (ERAD) (Kaufman, 2002). Activation of UPR can be 
monitored by analysing the expression of e.g. GRP78 and CHOP (Walter&Ron, 2011). 
The 78 kDa glucose-regulated protein GRP78 is an ER chaperone and key regulator 
of ER stress transducers. Under normal conditions, the kinases IRE1 and PERK as 
well as the transcription factor ATF6 are bound to GRP78, which keeps them in an 
inactive state (Rutkowski&Kaufman, 2004). During ER stress, all three proteins are 
released from GRP78 and activated, which in turn stimulates UPR (Bertolotti et al., 
2000; Ye et al., 2000). ATF6 subsequently gets processed, enters the nucleus, and 
activates UPR target genes like GRP78 (Ye et al., 2000). Thus, GRP78 is an ER 
chaperone with anti-apoptotic properties that controls and regulates UPR (Lee, 2005). 
Thus, mRNA expression of the GRP78 gene is commonly used as a biological marker 
for UPR and, thus, ER stress. 
On the other hand, expression of the transcription factor CHOP (CCAAT-enhancer-
binding protein homologous protein) is associated with ER stress-induced apoptosis 
(Oyadomari&Mori, 2004). CHOP is expressed at very low levels, but activation of IRE1, 
PERK, and ATF6 stimulate CHOP mRNA expression, promoting its translocation from 
the cytosol to the nucleus (Ron&Habener, 1992). Over-expression of CHOP leads to 
apoptosis in several cell lines and CHOP-deficient mice are less prone to ER stress 
(Oyadomari&Mori, 2004). Thus, CHOP is a key player for the induction of apoptosis. 
My previous studies have shown that the GBA1 and GBA2 mRNA expression remains 
unchanged in dermal fibroblasts derived from Gaucher patients with different 
phenotypes (Figure 12). Still, the GBA2 activity is reduced in these and other cells in a 
GBA1-dependent manner (Figure 14). We have shown that GBA2 localises to both, 
the cytoplasmic side of the cis Golgi and the ER (Körschen et al., 2013). Thus, a 
change in GBA2 activity might directly affect ER membrane properties, leading to ER 
stress. Thus, I wondered whether a change in GBA2 activity might generate ER stress. 
Because the severity of the GBA1-dependent effect on GBA2 activity varied between 
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samples, I analysed the mRNA levels of GRP78 and CHOP in mouse dermal 
fibroblasts from control and GBA2-deficient mice using qPCR (Yildiz et al., 2006). First, 
a protocol to analyse the mRNA expression in mouse fibroblasts was established as 
previously described in passage 3.3 using qPCR. Besides the GOIs (mCHOP and 
mGRP78, Table 61 and Table 62), the previously established HKGs were used (3.6). 
Table 61: Mouse genes of interest (GOIs) chosen for ER stress qPCR analysis 
Gene Gene product Reference 
mCHOP CCAAT-enhancer-binding 
protein homologous 
protein 
NM_007837 
mGRP78 78 kDa glucose-regulated 
protein 
NM_0011634 
 
Table 62: Amplicon sizes of mouse primer pairs selected for ER stress qPCR 
Gene Primer pair Expected amplicon size 
(bp) 
mCHOP C2187/88 93 
mCHOP C2189/90 124 
mGRP78 C2195/96 196 
mGRP78 C2197/98 208 
bp: Base pairs 
To test whether primers designed for qPCR amplify the sequence of interest, a 
conventional polymerase chain reaction (PCR) was performed (2.4.2). For mouse 
primers (Table 16), cDNA obtained from mouse wild-type fibroblasts was used. All 
amplicons (Figure 63) had the expected sizes (Table 62). 
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Figure 63: Analysis of the amplicons of mouse ER stress qPCR primers and control cDNA from 
mouse wild-type fibroblasts. 5 µl of the PCR approach were loaded to a 2% agarose gel and the 
fragments were analysed under a UV lamp. All amplicons had the expected sizes. bp: base pairs. 
To reliably analyse the data obtained from qPCR, a primer efficiency test (PET) was 
performed (2.4.6.5). Based on these results, the following mouse primers were used 
for subsequent experiments: mCHOP: C2189/90 and mGRP78: C2197/98 (Table 63). 
The PCR products generated by these primer pairs were send for sequencing and, 
thus, verified to be the right amplicons (data not shown). 
Table 63: Mouse ER stress qPCR primer efficiencies 
Gene Primer 
numbers 
Slope R2 value Efficiency (%) 
mCHOP C2187/88 -3.245 0.9988 103.3 
mCHOP C2189/90 -3.2648 0.9986 102.4 
mGRP78 C2195/96 -3.5847 0.998 90.1 
mGRP78 C2197/98 -3.4489 0.9986 95.0 
 
However, mRNA expression levels of GRP78 and CHOP were similar between control 
and GBA2-deficient fibroblasts (Figure 64). Thus, there is no evidence for ER stress in 
absence of GBA2.    
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Figure 64: Analysis of ER stress markers in GBA2-deficient mouse dermal fibroblasts. mRNA 
expression of the ER stress markers GRP78 and CHOP was analysed in control and GBA2-deficient 
dermal fibroblasts by qPCR. Neither GRP78 nor CHOP were altered in GBA2-deficient samples. ER: 
Endoplasmic reticulum, GRP78: 78 kDa glucose-regulated protein, CHOP: CCAAT-enhancer-binding 
protein homologous protein. Data are presented as mean + SD. N numbers are indicated in brackets.     
3.15.1 Studying the subcellular distribution of GlcCer  
Even though the mass spectrometric analysis of sphingosine levels in dermal 
fibroblasts from Gaucher and control patients did not reveal any difference (Figure 
62a), I wondered whether a local increase in cytoplasmic sphingosine levels could 
occur in GBA1-deficient cells. To date and to my knowledge, there is no fluorescent 
probe available that allows to visualise the subcellular localisation of sphingosine. 
Thus, I tackled this problem via a different approach: As previously mentioned, loss of 
GBA1 in Gaucher patients leads to the accumulation of GlcCer and GlcSph (Ferraz et 
al., 2016). Both lipids have been proposed to spill-over from the lysosome into the 
cytoplasm, where they become a substrate for GBA2 and Sph is released from both, 
GlcCer (via Cer and a neutral ceramidase) and GlcSph (Mistry et al., 2014). This 
scenario requires GlcCer (and GlcSph) to co-localise with GBA2. Thus, I established 
a protocol to visualise GlcCer in the cell. Here, immunocytochemistry is a common 
technique that uses a specific primary antibody, which is visualised by binding of a 
fluorescently conjugated secondary antibody. The (sub-) cellular localisation of the 
labelled protein can then be studied by using a fluorescence microscope. Antibodies 
have not only been generated against proteins, but also against certain lipids. An 
polyclonal anti-GlcCer antibody from rabbit is commercially available (RAS_0010, 
Glycobiotech) and its specificity for GlcCer has been tested in vitro by TLC 
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immunostainings and in vivo by immunohistochemical stainings of human epidermis 
(Brade et al., 2000). The antibody did neither react with other glycosphingolipids nor 
with ceramide, suggesting that the beta-glycosidic linkage between ceramide and 
glucose (head group) represents the epitope (Brade et al., 2000). Furthermore, the 
antibody has been used to demonstrate that GlcCer is localised within lamellar bodies 
and at the trans Golgi network in the stratum granulosum of human forearm skin 
biopsies (Vielhaber et al., 2001). In absence of FAPP2, GlcCer localises to the cis 
Golgi (D'Angelo et al., 2007). 
To study the localisation of GlcCer in the cell, I established an immunogold labelling 
protocol for ultrathin sections for transmission electron microscopy (TEM) in 
collaboration with the Electron Microscopy and Analysis (EMA) facility at research 
center caesar (Bonn). The immunostaining protocol was established using control and 
GlcCerS-deficient cells, which do not synthesise GlcCer. In fact, immunogold labelling 
of GlcCer was present in control but not in GlcCerS-deficient cells (D'Angelo et al., 
2007). Thus, I tried to reproduce the visualisation of GlcCer in control and GlcCerS-
deficient cells using our experimental set up. First, the detection of 1.4 nm Nanogold 
particles was verified using a transmission electron microscope (Figure 65). Individual 
gold particles were visible (arrows, Figure 65a), but were too small to be properly 
identified at a lower magnification mode. Therefore, the size of the gold particles was 
enhanced for 3 min using a gold-enhancement kit (Nanoprobes) (Figure 65b). After 3 
min, the particle size was around 18 nm, which, however, was too large for proper 
labelling. In further experiments, the enhancement time was reduced to 1 min.  
   
 
Figure 65: Detection of Nanogold particles. (a) Detection limit of pure 1.4 nm Nanogold. Micrograph 
of 1.4 nm gold particles (Nanoprobes, USA) on a continuous carbon film. Individual gold nanoparticles 
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are visible (arrows) but too small for proper identification at lower magnifications. Magnification: 100,000, 
scale bar: 20 nm. (b) Detection limit of 1.4 nm Nanogold after enhancement. 1.4 nm gold particles were 
enhanced with a gold-enhancement kit (both Nanoprobes). The particle size was large enough for easy 
detection but slightly too large for proper labelling. Enhancement time: 3 min. For further experiments, 
enhancement time was reduced to 1 min. Magnification: 20,000, scale bar: 100 nm.  (c) Particle size 
distribution after enhancement of (b). Mean particle size is 18 (±6) nm.  
Sections of GlcCerS-deficient and control cells were immuno-labelled using the anti-
GlcCer antibody according to the protocol presented in Vielhaber et al. (Vielhaber et 
al., 2001). Signals in control cells were mainly present in the nucleus (Figure 66a). In 
GlcCerS-deficient cells, the gold labels were evenly distributed over the section, 
representing the background signal (Figure 66c).  
 
Figure 66: Immuno-labelling of GlcCerS-deficient and control cells using the anti-GlcCer 
antiserum. The cells were labelled according to Vielhaber et al. 2001. (a) Micrograph of section of 
control cells. Labelling accumulated mainly in the nucleus. (b) High-pass filtered version of (a) to visually 
enhance the gold particles. Scale bar: 200 nm. (c) Micrograph of a section of GlcCerS-deficient cells. 
The particles were evenly distributed representing the background. Scale bar: 200 nm. (b) High-pass 
filtered version of (a) to visually enhance the gold particles. 
In further experiments, the protocol was modified to block non-specific nuclear 
epitopes and suppress the background (Figure 67) by blocking with EDTA. 
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Figure 67: Immunogold labelling of sections of control cells using the anti-GlcCer antiserum 
after histone blocking. (a) Multi image map of two control cells. Image processing using IMOD. 
Histones in nucleus were blocked using EDTA. (b) Magnified view (red frame in navigator image) of the 
nucleus region. Binding of gold particles to the histones was successfully reduced by blocking with 
EDTA. Magnification: 10,000, scale bar: 500 nm. (c) High-pass filtered version of (b) to visually enhance 
the gold particles. 
To further improve the immunogold staining, the protocol presented by Vielhaber and 
co-workers was slightly modified. Instead of 3% normal goat serum in PBS, a blocking 
solution containing BSA was used (Aurion). To reduce non-specific binding, the 
primary antibody was diluted to 1:400 and was incubated at 4 °C overnight. Washing 
steps were carried out using 0.1% BSA in PBS containing 20 mM NaCl (pH 7.4). 
Finally, the samples were pre-fixed using 2.5% glutaraldehyde in PBS containing 20 
mM NaCl (pH 7.4) before enhancement of the gold particles using the gold-
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enhancement kit (Nanoprobes). The result of immunostaining improvements are 
shown in Figure 68: Unfortunately, there was no specific labelling of the anti-GlcCer 
antibody in the Golgi or ER region.  
 
Figure 68: Immunogold labelling of sections of control cells using the anti-GlcCer antiserum 
after protocol modification. (a) Multi image map of a control cell. Image processing using IMOD. (b) 
Magnified view (red frame in navigator image) of the nucleus region. There was no specific GlcCer-
labelling in the Golgi or ER region of the cell. Magnification: 10,000, scale bar: 500 nm.  
To finally reveal whether the anti-GlcCer antiserum detects GlcCer at all, DOPC 
liposomes of 100 nm and 800 nm diameter containing GlcCer were prepared and 
handled as described above. There was no specific labelling of liposome membranes 
containing GlcCer, showing that the anti-GlcCer antibody does not recognise GlcCer 
in membranes.  
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Figure 69: GlcCer/DOPC-liposomes after labelling with the anti-GlcCer antiserum. Size-enhanced 
gold particles are distributed over the grid. There was no specific labelling of liposome membranes 
containing GlcCer. Magnification: 8,000, scale bar: 500 nm. 
Thus, a different strategy was developed (Figure 70). Recently, it has been shown that 
GLTP was sufficient to transfer GM1 from artificial donor liposomes to increase 
glycolipid levels at native membranes (Lauria et al., 2013). I adapted this approach and 
established a protocol to feed dermal fibroblasts with a clickable GlcCer derivative 
(clickGlcCer), carrying a terminal alkyne group at the fatty acid residue (Prof. C. Thiele, 
non-published) (Figure 70b, c), and compared the subcellular distribution of (click) 
GlcCer between control and Gaucher fibroblasts (Figure 71 and following). Cells 
constantly internalise material such as ligands, plasma membrane proteins, and lipids 
via endocytosis (Grant&Donaldson, 2009). In fact, it has been estimated that cells 
internalise material equivalent to their cell surface about one to five times per hour 
(Steinman et al., 1983). Upon endocytosis, cargo is usually transported to the early 
endosomes, where material is sorted. From here, the material is either forwarded to 
the trans Golgi network, recycled and brought back to the plasma membrane, or 
shuttled to late endosomes and, finally, to the lysosomes for degradation 
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(Grant&Donaldson, 2009). Thus, after being transferred from extracellular liposomal 
membranes to the outer leaflet of the plasma membrane via GLTP, clickGlcCer should 
enter the endosomal pathway and would, eventually, end up in the liposomes of control 
and Gaucher fibroblasts (Deduve, 1964). As GBA1 is almost inactive in the latter, 
clickGlcCer, similar to endogenous GlcCer, should not be degraded and, thus, 
accumulate in the lysosomes. If accumulating GlcCer indeed spills over from the 
lysosomes in GBA1-deficient cells, it should then be possible to visualise this process 
via clickGlcCer.  
To establish the protocol using dermal fibroblasts, I first tested whether cells take up 
clickGlcCer via the aforementioned approach and metabolise it to glucose and 
ceramide, which would be further broken down by an acid ceramidase to release 
sphingosine and the fatty acid carrying the alkyne group (compare Figure 70) (Gatt, 
1963). In immunocytochemical stainings, a labelled fatty acid would not be 
distinguishable from labelled GlcCer, producing a misleading result. In GBA1-deficient 
cells, acid ceramidase could also release the fatty acid from GlcCer to produce GlcSph. 
Thus, pulse and chase times had to be carefully examined to ensure the presence of 
clickGlcCer.    
Control human dermal fibroblasts were seeded on glass coverslips coated with poly-
L-lysine. His-tagged human GLTP (hGLTP-His) was expressed in bacteria and purified 
using the ÄKTA chromatography system from GE Healthcare (Lauria et al., 2013). The 
cells were incubated with 10 µM hGLTP and DOPC (1,2-Dioleoyl-sn-glycero-3-
phosphocholine) liposomes containing 0 mol%, 1 mol%, 5 mol%, or 10 mol% 
clickGlcCer diluted 1:2.5 in sterile PBS (Figure 70a). Cells were pulsed for 10 min and 
the lipids were chased for either 30 minutes or overnight at 37 °C. Then, the total lipids 
were either extracted for TLC analysis or the cells were fixed using 4% PFA in PBS for 
immunocytochemistry (Labelling for immunocytochemistry: Figure 70b, labelling for 
TLC: Figure 70c). As a control, cells were also fed with 5 µM clickSphinganine. 
Extracted lipids were clicked to 3-azido-7-hydroxycoumarin in presence of Cu(I)TFB at 
43 °C for 2 h (Figure 70c). 3-azido-7-hydroxycoumarin is a fluorescent organic 
chemical compound that can be clicked to an alkyne group and is then excited by light 
of 404 nm and emits light at 480 nm (Sivakumar et al., 2004). Thus, clickable lipids can 
be visualised after TLC simply at 404 nm. ClickGlcCer in fixed and permeabilised cells 
was clicked to azido biotin (AP3Btn or APpic2Btn, Figure 72a) at 37 °C for 1 h and 
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biotin was then detected via a fluorophore-labelled streptavidin to visualise ectopic 
GlcCer in the cells (Figure 70b).  
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Figure 70: Visualisation of GlcCer in the cell. Schematic drawing of the experiment described in the 
text. (a) GLTP-mediated transfer of clickGlcCer from DOPC liposomes to the outer leaflet of the plasma 
membrane of cells. (b) Visualisation of clickGlcCer in cells fixed with PFA via azido biotin (AP3Btn or 
APpic2Btn, Figure 72a) and detection via a fluorophore-labelled streptavidin. (c) Visualisation of 
clickGlcCer via 3-azido-7-hydroxycoumarin and excitation at 404 nm after thin layer chromatography 
(TLC). GLTP: glycolipid transfer protein, DOPC: 1,2-Dioleoyl-sn-glycero-3-phosphocholine, ER: 
Endoplasmic reticulum, Cu: Copper.  
Incubation with different amounts of clickGlcCer showed a clear dose-dependent 
signal on the TLC plate with no signal in the control lanes and stronger signals in the 
10 mol% sample (Figure 71a). Overall, chasing for 30 minutes resulted in better signals 
than incubation overnight, even though no additional coumarin-labelled bands became 
visible, suggesting that clickGlcCer did not get metabolised (Figure 71a). I also 
compared the signal intensity between cells that were incubated with liposomes 
containing 5 mol% clickGlcCer produced by an extruder (E, Figure 71a, upper pictures, 
Figure 71b) or by sonication (S, Figure 71a, bottom pictures, Figure 71b). An extruder 
produces rather large, unilamellar vesicles by repetitive extrusion through a membrane 
of a defined size (Avanti Polar Lipids). Here, liposomes with a diameter of 400 nm were 
produced. In comparison, sonication of lipid suspensions generates small unilamellar 
vesicles with diameters from 15 to 50 nm (Avanti Polar Lipids). As displayed in Figure 
71a, the amount of clickGlcCer present in control fibroblasts after a 30 minutes chase 
was significantly higher when cells were pulsed with 5 mol% liposomes produced by 
sonication compared to extrusion. It has already been shown that the fusion rate 
constant of liposomes depends on liposome size, with smaller liposomes fusing more 
easily with other membranes (Bentz&Duzgunes, 1985). Thus, these findings are 
reflected in Figure 71a, where smaller liposomes (sonication) resulted in a stronger 
signal than larger liposomes (extrusion). Nevertheless, when clickGlcCer/DOPC 
liposomes fuse with the plasma membrane, clickGlcCer gets incorporated into both, 
the intracellular and extracellular membrane leaflet. ClickGlcCer sitting in the inner 
leaflet of the plasma membrane becomes accessible to e.g. glycolipid transfer proteins 
like GLTP and FAPP2, because it faces the cytoplasm when present in the “outer” 
leaflet of emerging endosomes. With this orientation, clickGlcCer would not reach the 
lumen of the lysosome, since GSLs show very slow spontaneous trans-bilayer 
movement due to their large polar head group (Buton et al., 2002). Thus, I decided to 
prepare rather large (400 nm) liposomes that are less likely to fuse with the plasma 
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membrane of cells and favour the transfer of clickGlcCer to the outer leaflet of the 
plasma membrane via GLTP (Lauria et al., 2013). 
Even though the experiment and the presence of clickGlcCer per se was verified by 
TLC analysis (Figure 71a), there was no difference in fluorescence intensity of 
streptavidin-Alexa488 between cells pulsed with clickGlcCer and the negative control 
(Figure 71b). The click reaction between clickGlcCer and biotin-azide as well as the 
detection of the latter by streptavidin-Alexa488, however, seemed to work, since there 
was a clear fluorescent signal visible in cells pulsed with 5 µM clickSphinganine (Figure 
71b). This result suggests that the feeding and clicking of clickGlcCer itself works, but 
that there was a subsequent problem during detection of the biotinylated (AP3Btn) 
clickGlcCer, probably due to a still rather low abundance of the lipid in the cells after 
feeding.    
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Figure 71: Analysis of clickGlcCer feeding by TLC and microscopy. Control fibroblasts were 
incubated with 10 µM hGLTP and DOPC liposomes containing no, 1, 5, or 10 mol% clickGlcCer to 
facilitate GLTP-mediated transfer of click-GlcCer to the plasma membrane. Cells were pulsed with 
clickGlcCer for 10 minutes and the lipid was then chased for either 30 minutes or 24 h. Lipids extracted 
from the cells were clicked to 3-azido-7-hydroxycoumarin and analysed by thin layer chromatography 
(TLC) at 404 nm. Cells for microscopy were fixed using 4% PFA in PBS, clicked to azido biotin (AP3Btn), 
and detected via a streptavidin coupled to Alexa488 to visualise ectopic GlcCer (green) in the cells. (a) 
TLC analysis of clickGlcCer fed to control fibroblasts. Chasing for 30 minutes resulted in better signals 
than incubation for 24 h and in dose-dependent band pattern for clickGlcCer. Comparison of liposomes 
containing 5 mol% produced by extrusion or sonication resulted in a stronger signal coming from 
sonicated liposomes. (b) There was no difference in fluorescence intensity of streptavidin-Alexa488 
between cells pulsed with clickGlcCer and the negative control. Incubation with 5 µM clickSphinganine 
resulted in a clear fluorescent signal. Blue channel: DAPI. GlcCer: Glucosylceramide, TAG: 
Triacylglycerol, SM: Sphingomyelin, PC: Phosphatidylcholine, DOPC: 1,2-Dioleoyl-sn-glycero-3-
phosphocholine, GLTP: Glycolipid transfer protein. Scale bars are indicated.    
To solve this problem, I first tested a more sensitive azido-biotin (APpic2Btn, Figure 
72a) (Gaebler et al., 2016), carrying a picolyl moiety, which chelates copper, the 
catalyst for the click reaction, and, thereby increases the detection sensitivity (Gaebler 
et al., 2016). Additionally, I also tested two different catalysts for the click reaction, 
(Cu(I)TFB and CuSO4/TBTA) (Figure 72b). Control dermal fibroblasts were pulsed with 
either 10 mol% clickGlcCer/DOPC liposomes diluted 1:2.5 in PBS together with 18 µM 
hGLTP for 15 min and chased for 1 h or with 5 µM clickSphinganine for 1 h (Figure 
72b). After fixation, cells were clicked to either AP3Btn or APpic2Btn in the presence 
of Cu(I)TFB or CuSO4/TBTA and visualised using streptavidin-Alexa488 (Figure 72b). 
AP3Btn showed strong signals in cells pulsed with 10 mol% clickGlcCer and clicked in 
presence of CuSO4/TBTA, but the signal was even more pronounced using APpic2Btn 
(Figure 72b). The overall fluorescence in both, cells pulsed with clickGlcCer or 
clickSphinganine, was very strong, but samples clicked in presence of CuSO4/TBTA 
generally showed more background than cells clicked in presence of Cu(I)TFB (Figure 
72b). Since samples clicked to APpic2Btn in presence of Cu(I)TFB displayed nice 
results, I chose this combination for further experiments (Figure 72b).    
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Figure 72: Analysis of different Cu-based click catalysts and azido-biotin derivatives. Control 
fibroblasts were pulsed with 18 µM hGLTP and DOPC liposomes, containing 10 mol% clickGlcCer 
(green) or 5 µM clickSphinganine (green), for 15 minutes and chased for 1 h. ClickSphinganine was 
pulsed for 1 h without further chase. The lipids were clicked in the presence of either Cu(I)TFB or 
CuSO4/TBTA to AP3Btn or APpic2Btn. ClickGlcCer was detected via a streptavidin coupled to Alexa488. 
(a) Structures of AP3Btn, APpic2Btn, and ApicSBDP. Published in (Gaebler et al., 2016). (b) Detection 
with APpic2Btn was more sensitive than AP3Btn and Cu(I)TFB showed less dirt than CuSO4/TBTA. 
Scale bar is indicated. A: Azido, PX: Polyethylenglycol spacer with length of x ethylene glycol units, pic: 
linker contains picolyl moiety, Btn: Biotin, BDP: BODIPY/ boron-dipyrromethene, CuSO4: Copper (II) 
sulfate, TBTA: Tris(benzyltriazolylmethyl)amine, GlcCer: Glucosylceramide, DOPC: 1,2-Dioleoyl-sn-
glycero-3-phosphocholine, GLTP: Glycolipid transfer protein. Scale bar is indicated.   
Besides testing different azido-biotins and click catalysts, I also tested a protocol to 
deliver clickGlcCer to the plasma membrane of cells in a complex with bovine serum 
albumin (BSA). Albumin is the most abundant protein found in blood plasma where it 
e.g. binds hydrophobic molecules to carry them through the body (He&Carter, 1992). 
Since lipids are mainly hydrophobic and, thus, cannot simply be fed to cells in aqueous 
solutions, they have been complexed to BSA for this purpose since many years 
(Lambeth et al., 1988). I prepared clickGlcCer/BSA complexes by lyophilisation 
(personal communication with Dr. Ü. Coskun, DZD-Paul Langerhans Institute, 
Technische Universität Dresden, Dresden) and pulsed control dermal fibroblasts with 
or without 2, 20, or 200 µM of the complex re-suspended in sterile PBS for 15 minutes 
and chased the lipids for 1 h (Figure 73). As a control, I also prepared DOPC liposomes 
containing no or 10 mol% clickGlcCer and followed the same feeding protocol using 
GLTP-mediated transfer as previously described (Figure 70). As previously shown 
(Figure 72b), cells pulsed with 10 mol% clickGlcCer diluted 1:2.5 in PBS in presence 
of 18 µM GLTP and clicked to streptavidin-Alexa488 catalysed by Cu(I)TFB displayed 
a strong signal compared to cells pulsed without clickGlcCer (lower panel, Figure 73). 
In comparison, there was barely any fluorescence detectable in cells pulsed with 
different amounts of clickGlcCer complexed to BSA (upper panel, Figure 73). Thus, I 
continued with the protocol using GLTP-mediated transfer of clickGlcCer for further 
experiments.  
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Figure 73: Transfer of clickGlcCer to cells in complex with BSA. ClickGlcCer/BSA complexes were 
prepared via lyophilisation and control fibroblasts were incubated with 0, 2, 20, or 200 µM clickGlcCer 
for 15 minutes. Lipids were chased for 1 h and clicked to APpic2Btn in the presence of Cu(I)TFB. 
APpic2Btn was visualised using streptavidin-Alexa488 (upper panel). As controls, cells were incubated 
with DOPC liposomes containing no or 10 mol% clickGlcCer (lower panel). There was almost no 
fluorescence detectable in cells pulsed with different amounts of clickGlcCer/BSA (upper panel). GLTP-
mediated transfer of clickGlcCer worked nicely with liposomes containing 10 mol% clickGlcCer 
compared to the controls (lower panel). Blue channel: DAPI. GlcCer: Glucosylceramide, BSA: Bovine 
serum albumin, GLTP: Glycolipid transfer protein, DOPC: 1,2-Dioleoyl-sn-glycero-3-phosphocholine. 
Scale bar is indicated.      
To increase the subcellular resolution of clickGlcCer, I switched from biotin-conjugated 
azides to ApicSBDP (azido-picolyl-sulfo-tetramethyl-BODIPY), an azide that carries a 
BODIPY moiety (Figure 72a and Figure 74) (Gaebler et al., 2016). BODIPY (boron-
dipyrromethene) is a fluorescent dye that has been extensively used to study the 
structure of membranes (Kaiser&London, 1998). BODIPY possesses sharp excitation 
and emission peaks in the visible light range and is highly soluble in organic solvents 
(Karolin et al., 1994). Most importantly, directly using a dye-conjugated azide to detect 
clickGlcCer simplifies the staining protocol and should also provide a better resolution 
since the dye is much closer to the lipid. 
As previously described, fibroblasts from control and type I Gaucher patients were 
pulsed with either 0 or 10 mol% clickGlcCer/DOPC liposomes for 1 h or 24 h (Figure 
74 - Figure 76). Cells pulsed for 1 h were subsequently chased for 23 h (Figure 74 and 
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Figure 75). Afterwards, lipids were extracted, clicked to 3-azido-7-hydroxycoumarin, 
and either analysed by TLC (Figure 74) or fixed using 4% PFA in PBS and blocked 
using a buffer containing cold-water fish gelatine, saponine, and PBS (Figure 75 and 
Figure 76). To reveal the subcellular localisation of clickGlcCer at certain organelles, 
cells were immunocytochemically labelled using antibodies against the lysosomal 
marker protein LAMP1 (Lysosomal-associated membrane protein 1) (Chen et al., 
1985) or the Golgi marker giantin (Linstedt&Hauri, 1993). Primary antibodies were 
detected using Cy3- and Alexa647-conjugated secondary antibodies before the cells 
were clicked to ApicSBDP in presence of Cu(I)TFB and imaged using a fluorescence 
microscope (Figure 75 and Figure 76). 
TLC analysis showed that both, control and Gaucher fibroblasts, took up clickGlcCer 
equally well (Figure 74). Here, pulsing for 24 h resulted in a much stronger clickGlcCer 
signal than pulsing for only 1 h (Figure 74). On the other hand, since additional bands 
appeared in the samples pulsed for 24 h, clickGlcCer was partially metabolised to 
sphingomyelin and phosphatidylcholine (Figure 74). These bands were not visible in 
cells pulsed for only 1 h (Figure 74).  
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Figure 74: Analysis of clickGlcCer in control and Gaucher fibroblasts by TLC. Fibroblasts from 
control and Gaucher patients were incubated with 18 µM hGLTP and DOPC liposomes containing no 
or 10 mol% clickGlcCer to facilitate GLTP-mediated transfer of click-GlcCer to the plasma membrane. 
Cells were pulsed with clickGlcCer for 1 h and chased for 23 h or only pulsed for 24 h. Lipids extracted 
from the cells were clicked to 3-azido-7-hydroxycoumarin and analysed by TLC at 404 nm. Pulsing for 
24 h resulted in a stronger signal than the shorter pulsing time. ClickGlcCer was partially metabolised 
to sphingomyelin and phosphatidylcholine during longer pulsing times. TAG: triacylglyerol, GlcCer/GC: 
Glucosylceramide, SM: sphingomyelin, Cer: Ceramide, Pal: Palmitic acid, PC:  phosphatidylcholine, 
GLTP: Glycolipid transfer protein, DOPC: 1,2-Dioleoyl-sn-glycero-3-phosphocholine.   
The ratio of clickGlcCer uptake between pulsing times of 1 h versus 24 h was also 
reflected in the fluorescence intensity of immunocytochemically stained samples: 
There was barely any difference visible between cells incubated with no or 10 mol% 
clickGlcCer (Figure 75). As also displayed on the TLC, there were no obvious 
differences between control and Gaucher fibroblasts (Figure 74).   
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Figure 75: Microscopic analysis of control and Gaucher fibroblasts pulsed with clickGlcCer. 
Fibroblasts from control and Gaucher patients were incubated with 18 µM hGLTP and DOPC liposomes 
containing 0 or 10 mol% clickGlcCer (green) to facilitate GLTP-mediated transfer of clickGlcCer to the 
plasma membrane. Cells were pulsed with clickGlcCer for 1 h and chased for 23 h. Cells were fixed with 
4% PFA in PBS and immunostained using the lysosomal marker protein LAMP1 (magenta, red) and the 
Golgi marker protein giantin (red). ClickGlcCer was clicked to ApicSBDP and visualised at 488 nm. The 
signal intensity of clickGlcCer was very weak in (a) control and (b) Gaucher fibroblasts. The antibody 
staining clearly showed lysosomal and Golgi structures. Lower pictures were zoomed-in. GlcCer: 
Glucosylceramide, GLTP: Glycolipid transfer protein, DOPC: 1,2-Dioleoyl-sn-glycero-3-phosphocholine. 
Scale bars are indicated.       
In comparison, signal intensity was much stronger in cells incubated with 10 mol% 
clickGlcCer for 24 h (Figure 76). Here, a clear difference between cells incubated with 
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0 or 10 mol% clickGlcCer was visible (Figure 76). BODIPY-labelled clickGlcCer 
staining was detected throughout the whole cell with a prominent staining that co-
localised with the Golgi marker, resulting in a yellow signal in both, control and Gaucher 
fibroblasts (Figure 76). ClickGlcCer also seemed to localise to lysosomal structures, 
but did not co-localise with LAMP1 (Figure 76).  
In summary, clickGlcCer was found to localise predominantly to the Golgi in both, 
control and Gaucher fibroblasts, when pulsed for 24 h (Figure 76). Even though a minor 
portion of clickGlcCer was metabolised during this time, the majority of the signals still 
originated from clickGlcCer (Figure 74). Thus, there were no obvious difference 
between the localisation of clickGlcCer in fibroblasts from control and Gaucher 
patients. Due to time limitations, the experiment was not further optimised.            
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Figure 76: Microscopic analysis of control and Gaucher fibroblasts pulsed with clickGlcCer. 
Fibroblasts from control and Gaucher patients were incubated with 18 µM hGLTP and DOPC liposomes 
containing 0 or 10 mol% clickGlcCer (green) to facilitate GLTP-mediated transfer of clickGlcCer to the 
plasma membrane. Cells were pulsed with clickGlcCer for 24 h. Cells were fixed with 4% PFA in PBS 
and immunostained using the lysosomal marker protein LAMP1 (magenta, red) and the Golgi marker 
protein giantin (red). ClickGlcCer was clicked to ApicSBDP and visualised with light at 488 nm. There 
was a clear difference in signal intensity visible between cells pulsed with or without clickGlcCer. (a) 
Control and (b) Gaucher fibroblasts took up clickGlcCer equally well. The antibody staining clearly 
showed lysosomal and Golgi structures. ClickGlcCer localised predominantly to the Golgi in both, control 
and Gaucher fibroblasts. Lower pictures were zoomed-in. GlcCer: Glucosylceramide, GLTP: Glycolipid 
transfer protein, DOPC: 1,2-Dioleoyl-sn-glycero-3-phosphocholine. Scale bars are indicated.       
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3.15.2 Studying the interaction of sphingosine and GBA2 
3.15.2.1 Photoactivatable and clickable sphingosine (pacSph) 
To further investigate the binding of sphingosine to GBA2, I designed an assay using 
a bifunctional sphingosine derivative. Photoactivatable and clickable sphingosine 
(pacSph) features a photoactivatable diazarine ring that covalently binds to proteins in 
close proximity upon activation with UV-light (Haberkant et al., 2016). Furthermore, 
pacSph is equipped with a terminal alkyne group that can be subsequently labelled by 
click chemistry to visualise protein-lipid complexes (Haberkant et al., 2016).  
3.15.2.2 Assay to pull-down sphingosine-binding proteins 
By using pacSph, Dr. P. Haberkant could already show that pacSph directly binds to 
GBA1 (non-published data). This finding is supported by my results showing that GBA1 
activity is sensitive to sphingosine (see Figure 61a). Thus, I aimed to study the 
interaction between both, GBA1 and GBA2, using pacSph, while GBA1 served as a 
positive control. During the respective assay, either intact cells or protein lysates were 
incubated with pacSph and, subsequently, with azido-biotin. The protocol contains 
several protein precipitation steps to separate pacSph that was neither cross-linked 
nor clicked. Thus, I first tested two different protein precipitation protocols to verify that 
GBA1 and GBA2 are not lost during precipitation. First, I prepared hypotonic protein 
lysates from CHO cells stably over-expressing mGBA1-HA and mGBA2-HA and 
precipitated the proteins three times using chloroform/methanol (Figure 77a). 
Unfortunately, a lot of both, GBA1 and GBA2, was already lost after the first 
precipitation step and there was barely any protein visible after the third precipitation 
(Figure 77a). Thus, I switched to a different precipitation protocol using ethanol. Here, 
almost all protein from the input was successfully recovered after the third precipitation 
(Figure 77b). Therefore, I chose the latter protocol for the assay.  
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Figure 77: Comparison of protein precipitation using CHCl3/MeOH or EtOH. Analysis of presence 
GBA1 and GBA2 in hypotonic lysates of CHO cells stably over-expressing mGBA1 and mGBA2 after 
three rounds of protein precipitation by Western blot using a specific anti-HA antibody (Kremmer). (a) 
GBA1 and GBA2 were already almost completely lost during the first precipitation when precipitated 
with CHCl3/MeOH. (b) EtOH precipitation of GBA1 and GBA2 almost full recovered both proteins after 
three precipitations. kDa: Kilo Dalton.  
In a first attempt, CHO cells stably over-expressing mGBA1-HA and mGBA2-HA were 
incubated with 6 µM pacSph for 4 h. Then, cells were washed and incubated in PBS 
for UV-radiation using a LED lamp (1.25 mA) for 5 min (UV+). In parallel, a control 
plate was incubated without UV-radiation (UV-, Figure 78b). The cells were harvested 
and lysed using hypotonic buffer (L, Figure 78b, c) and proteins were precipitated using 
ethanol to separate the remaining, non-cross-linked pacSph from the protein-lipid 
complexes (Precipitation 1, Figure 78b, c). The protein pellets were re-suspended in 
HEPES buffer and the suspension was clicked to azido-biotin (AP3Btn, see Figure 
72a) at 37 °C for 3 h. Afterwards, proteins were precipitated again to remove residual, 
non-clicked azido-biotin from the sample (Precipitation 2, Figure 78b, c). The protein 
pellets were re-suspended in PBS and loaded to a neutravidin column. Neutravidin is 
a derivative of streptavidin, a protein purified from Streptomyces avidinii, which has a 
very high affinity for biotin (Gyorgy et al., 1940). The neutravidin beads in the column 
bind biotinylated proteins and, thus, every protein that has bound to pacSph. In a final 
step, proteins were eluted (E, Figure 78b, c) and the samples, including the beads, 
were analysed by Western blot using an anti-HA antibody (Figure 78b, c). Although 
protein precipitation using ethanol was successfully tested before (compare Figure 
77b), the majority of GBA2 was lost during the precipitation and only a small amount 
of GBA2 was loaded to the neutravidin column (Figure 78c). Some GBA2 protein was 
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detected in the flow-through fraction (FT, Figure 78c), but there was also GBA2 present 
in the elution and the bead fraction after elution in the UV+ samples (Figure 78c), 
indicating that GBA2 had directly bound to sphingosine. Similar results were obtained 
for GBA1, which was generally more expressed than GBA2 and showed a clear band 
in the input and elution fraction of the UV+ sample, supporting the results from Dr. P. 
Haberkant (Figure 78c). The samples without UV irradiation (UV-, Figure 78b) served 
as a negative control because without cross-linking, no proteins should have covalently 
bound to pacSph and, thus, have bound to the column material. However, there were 
faint GBA1 bands visible in the elution fraction of the UV- samples, suggesting that the 
binding of GBA1 and pacSph was either extremely strong or that there was some non-
specific binding of GBA1 to the column material (Figure 78b).   
 
Figure 78: Photo-crosslinking and clicking of pacSph in CHO cells stably over-expressing 
mGBA1 and mGBA2. CHO cells stably over-expressing mGBA1 and mGBA2 were fed with 6 µM 
pacSph before irradiation with UV light to photo-crosslink binding proteins. Western blot analysis and 
immunostaining of GBA1 and GBA2 by a specific anti-HA antibody (Kremmer) after clicking pacSph to 
biotin-azide and precipitating biotinylated proteins via neutravidin beads. (a) Flow-chart of the 
experiment. The protocol is described in the text. (b) There were faint GBA1 bands visible in the elution 
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fraction of samples without UV irradiation. (c) Faint bands of both, GBA1 and GBA2, were visible in the 
elution fraction when samples were UV irradiated. L: Lysate, FT: Flow-through, E: Elution, B: Beads 
boiled in SDS sample buffer, kDa: Kilo Dalton.  
As previously mentioned, sphingosine is not only a precursor for higher-order GSLs, 
but also for glycerolipids (Figure 1, Figure 79). Sphingosine is released from GSLs in 
the lysosome and then transported back to the ER, where it can be re-used to produce 
ceramide via the salvage pathway (Schwarzmann&Sandhoff, 1990). Here, 
sphingosine can be phosphorylated by S1P kinases to produce S1P (Spiegel&Milstien, 
2003), which can be irreversibly cleaved by S1P lyase (SGPL1) to produce 
hexadecenal and phosphoethanolamine (Serra&Saba, 2010), which enters the 
biosynthesis pathway for glycerolipids (Nakahara et al., 2012).   
 
Figure 79: Sphingosine is a precursor for both, glycosphingolipids and glycerolipids. The 
different synthesis pathways are described in the text. S1P: Sphingosine-1-phosphate, SGPL1:  
Sphingosine-1-phosphate lyase, GlcCer: Glucosylceramide.  
During the aforementioned assay, pacSph is incubated with cells for 4 h. Here, 
Haberkant et al. showed that pacSph was already metabolised and incorporated into 
the glycerolipid phosphatidylcholine after incubation for only 1 h (Haberkant et al., 
2016). This effect had also been recognised by others, where radioactive or 
fluorescently labelled sphingosine was found to be rapidly degraded and subjected to 
the glycerolipid pathway when incubated with cells (Kim et al., 2013; Riboni et al., 
1999). In this case, binding of glycerolipids such as phosphatidylcholine and GBA1 or 
GBA2, but not the interaction between pacSph and the beta-glucosidases would be 
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observed. To prevent that, I switched to delta SGPL1 HeLa cells that were generated 
using the CRISPR/Cas9 system (Figure 80) (Gerl et al., 2016; Haberkant et al., 2016). 
First, I tested the heterologous expression of mGBA1 and mGBA2 in this cell type. 
Delta SGPL1 HeLa cells were transfected using PEI and harvested 24 h later to 
perform hypotonic cell lysis. The ectopic expression of both proteins was analysed by 
Western blot using an anti-HA antibody (Figure 80). As shown in Figure 80, both, GBA1 
and GBA2, are expressed in delta SGPL1 HeLa cells.      
 
Figure 80: Expression of mGBA1 and mGBA2 in delta SGPL1 HeLa cells. Delta SGPL1 HeLa cells 
were transfected with mGBA1 and mGBA2 using polyethylenimine (PEI) and expression was compared 
to non-transfected controls by Western blot using a specific anti-HA antibody (Kremmer). Calnexin was 
used as a loading control. HeLa cells showed detectable levels of ectopically expressed GBA1 and 
GBA2 after transfection. SGPL1: Sphingosine-1-phosphate lyase, KO: knock-out, kDa: Kilo Dalton.   
As a negative control for the assay, I co-expressed GFP - a protein that would most 
likely not bind to pacSph and could, therefore, serve as a quality control for the assay 
itself. I first tested whether the ethanol precipitation protocol also works for GFP (Figure 
81). GFP was successfully recovered in the protein pellet even after three precipitation 
steps, albeit not as efficiently as GBA1 and GBA2 (Figure 81, compare Figure 77b).  
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Figure 81: Precipitation of GFP from hypotonic cell lysates using EtOH. GFP was co-expressed 
with mGBA1 and mGBA2 in delta SGPL1 HeLa cells and the recovery of GFP after EtOH precipitation 
was analysed by Western blot using a specific anti-GFP antibody (Abcam). Calnexin was used as a 
control. GFP was recovered in the protein pellet even after three precipitation steps, albeit some protein 
was lost. In: Input, kDa: Kilo Dalton.  
The pacSph assay was performed with delta SGPL1 HeLa cells heterologously 
expressing GFP, mGBA1, and mGBA2 (Figure 82). Here, both, GBA1 and GBA2, 
could be recovered in the elution fraction of the UV+ sample (Figure 82b). GFP, which 
served as a putative negative control, showed a faint band in the elution fraction, 
representing the background of non-specific protein binding to the column material 
(Figure 82b). I quantified the amount of GBA1 and GBA2 present in the elution fraction 
relative to the input. GBA1 was 2-fold and GBA2 was 1.6-fold more abundant in the 
elution fraction than GFP (background) (Figure 82b). Thus, pacSph directly binds to 
both, GBA1 and GBA2. A fact that was quite puzzling was that the results for the UV- 
samples looked very similar (Figure 82a). Even if GBA1 and GBA2 had a very high 
affinity for pacSph, I would expect that, without a covalent linkage, most of the proteins 
bound to pacSph would be washed off during the experiment, resulting in much fewer 
signal and an overall different result compared to the UV+ sample. To verify my results, 
I tackled the question with a different approach.  
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Figure 82: Purification of GBA1 and GBA2 via pacSph. Delta SGPL1 HeLa cells transiently 
expressing mGBA1, mGBA2, and GFP were fed with 6 µM pacSph for 4 h before irradiation with UV 
light to photo-crosslink pacSph-binding proteins. After clicking pacSph to biotin-azide and purifying 
bound proteins via neutravidin beads, protein lysates were subjected to Western blot analysis using an 
anti-HA specific antibody to detect GBA1 and GBA2 (Kremmer). (a) GBA1 and GBA2 were partially 
recovered in the elution fraction in samples without UV irradiation. (b) GBA1, GBA2, and GFP were 
recovered in the elution fraction in samples photo-crosslinked by UV light. GBA1 was 2-fold more 
abundant and GBA2 was 1.6-fold more abundant than GFP. L: Lysate, FT: Flow-through, E: Elution, B: 
Beads boiled in SDS sample buffer, kDa: Kilo Dalton.   
I repeated the experiment by incubating lysates from delta SGPL1 HeLa cells 
heterologously expressing GFP, mGBA1, or mGBA2 with 6 µM pacSph in vitro using 
protein lysates rather than intact cells (Haberkant et al., 2016). Furthermore, I 
introduced another negative control, AR451 (Dr. A. Rennhack, caesar, non-published, 
see Table 31). AR451 is a marker and potent modulator for gamma-secretase. It was 
synthesised to label gamma-secretase via UV-crosslinking of its diazarine group and 
can subsequently be detected by clicking a marker carrying an azido moiety to its 
terminal alkyne group (Dr. A. Rennhack, non-published). Lastly, pacSph was also 
incubated with lysates from delta SGPL1 cells heterologously expressing JAM3, a 
protein that has been shown to specifically bind to pacSph (Haberkant et al., 2016) 
(Figure 83). Protein lysates were UV-irradiated before clicking to azido-DY-654 
(Dyomics) and separation by size via SDS-PAGE (Figure 83). According to Dr. P. 
Haberkant, pacSph-protein complexes should turn up as strong DY-654-positive bands 
already visible in in-gel fluorescence in the UV+ sample compared to the UV- lane 
when excited with light of 680 nm wavelength (Figure 83). JAM3 is supposed to run at 
a height of 35-55 kDa (personal communication with Dr. P. Haberkant). However, 
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Figure 83 only shows a distinct change in fluorescence intensity between the UV- and 
UV+ sample at around 65 kDa. Thus, I could not reproduce the results obtained by Dr. 
P. Haberkant. As there were also no clear differences visible between non-transfected 
and transfected GFP/mGBA1/mGBA2 samples and the UV+ sample and UV- controls, 
I decided to transfer the proteins to a nitrocellulose membrane by Western blotting and 
specifically detect the proteins using an anti-HA antibody.  
 
Figure 83: In-gel fluorescence of pacSph and AR451 clicked to azido-DY-654. Lysates from delta 
SGPL1 cells transiently expressing mGBA1, mGBA2, and GFP, or JAM3 were incubated with 6 µM 
pacSph before irradiation with UV light to photo-crosslink binding proteins. In-gel fluorescence of 
pacSph- or AR451-binding proteins after labelling with azido-DY-654 (Dyomics). No distinct bands at 
the height of GBA1 (55-69 kDa) or GBA2 (~120 kDa) were visible in samples incubated with pacSph or 
AR451. There was also no band visible in JAM3-expressing samples at around 35-55 kDa. AR451: 
marker and potent modulator for gamma-secretase, kDa: Kilo Dalton. Representative blot for n = 3 
experiments.     
After transfer, pacSph-DY-654-labelled proteins were still fluorescent when excited at 
680 nm (Figure 84, displayed in red channel). According to the signal pattern, many 
different proteins of different sizes were bound to pacSph, whereas there were fewer 
signals visible in the UV+ lane of the sample incubated with AR451 (Figure 84). Here, 
only one protein band was highlighted at around 30 kDa (Figure 84). In cell lysates 
expressing mGBA1 and mGBA2, two thin but distinct bands appeared at around 120 
kDa, the height of mGBA2 (Figure 84, left). GBA1 and GBA2 were detected using an 
anti-HA antibody and a fluorescently labelled secondary anti-rat antibody. GBA1 bands 
were visible at around 60 kDa and GBA2 bands were present at around 120 kDa 
(Figure 84, displayed in green channel). When both channels were merged, the bands 
arising from the pacSph-labelled protein co-localised with the GBA2 band resulting in 
a yellow signal (Figure 84, merged channels), demonstrating that pacSph binds to 
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GBA2. The pacSph-DY-654 band was also visible in the non-transfected control, most 
likely due to binding to endogenous GBA2 (Figure 84). In contrast, pacSph did not bind 
to GBA1, indicating that I could not reproduce the findings from Dr. P. Haberkant 
(personal communication with Dr. P. Haberkant) (Figure 84). The negative control 
AR451 neither bound to GBA1 nor to GBA2 (Figure 84). The anti-HA antibody 
displayed a lot of background labelling with proteins of low molecular weight, making 
it difficult to clearly see GFP with an anti-GFP staining (Figure 84). However, there are 
distinct bands visible in the transfected samples that do not co-localise with pacSph or 
AR451 (Figure 84). Thus, GBA2 but not GBA1 or GFP specifically bound to pacSph.  
 
Figure 84: Labelling of GBA2 with pacSph in vitro. Lysates from delta SGPL1 cells transiently 
expressing mGBA1, mGBA2, and GFP also displayed in Figure 83 were analysed by Western blot using 
a specific anti-HA (Kremmer) and anti-GFP (Abcam) antibody and a fluorescently labelled secondary 
antibody (IR 800). (a) Flow-chart of the experiment. The protocol is described in the text. (b) A thin but 
distinct band was visible at the height of GBA2 (~120 kDa) in samples endogenously and heterologously 
expressing GBA1 and GBA2 incubated with pacSph and visualised by clicking to azido-DY-654 
(Dyomics, red channel). Bands at 120 kDa co-localised with GBA2 (green channel), resulting in a yellow 
signal (merge channel). Neither GBA1 nor GFP co-localised with pacSph. SDS-PAGE: sodium dodecyl 
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sulfate polyacrylamide gel electrophoresis, WB: Western blot, IR-680: Infrared wavelength 680 nm, IR-
800: Infrared wavelength 800 nm, AR451: marker and potent modulator for gamma-secretase, kDa: Kilo 
Dalton. Representative blots for n = 3 experiments.        
In a final experiment, I wanted to test whether the experimental set up described above 
would also work when incubating intact delta SGPL1 HeLa cells expressing mGBA1 
and mGBA2 with 6 µM pacSph for 4 h before cell lysis (Figure 85). Thus, I repeated 
the experiment in vivo, harvested the cells, and induced the UV-mediated cross linking 
of pacSph in vitro (Figure 85a). Again, the samples were clicked to azido-DY-654 
before separating the proteins by SDS-PAGE (Figure 85). In Western blot analysis, 
GBA1 and GBA2 were detected by an anti-HA antibody and an IRDye800-labelled 
secondary antibody (IR-800, Figure 85b). As seen in the previous experiment, many 
different proteins had bound to pacSph, which resulted in several prominent bands at 
different heights (IR-680, Figure 85b). Nevertheless, the red channel again displayed 
a band at 120 kDa that co-localised with mGBA2 in the green channel (Figure 85b). 
GBA1, however, did not bind to pacSph. In summary, these data show that GBA2 
specifically binds to pacSph when incubated in a cell lysate or in intact cells.    
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Figure 85: Labelling of GBA2 with pacSph in vivo. Delta SGPL1 cells transiently expressing mGBA1, 
mGBA2, and GFP were fed with 6 µM pacSph before harvesting and irradiation with UV light to photo-
crosslink binding proteins. PacSph-bound proteins were visualised by clicking pacSph to azido-DY-654 
(Dyomics); GBA1 and GBA2 were detected with an anti-HA specific antibody and a fluorescently labelled 
secondary antibody (IR-800). (a) Flow-chart of the experiment. The protocol is described in the text. (b) 
A thin but distinct band was visible at the height of GBA2 in samples endogenously and heterologously 
expressing GBA1 and GBA2 incubated with pacSph and visualised by clicking to azido-DY-654 (red 
channel). Bands at 120 kDa co-localised with GBA2 (green channel), resulting in a yellow signal (merge 
channel). SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis, WB: Western blot, 
IR-680: Infrared wavelength 680 nm, IR-800: Infrared wavelength 800 nm, kDa: Kilo Dalton. 
Representative blots for n = 1 experiment.   
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To validate that pacSph is not metabolised when incubated with protein lysates from 
delta SGPL1 HeLa cells transiently expressing mGBA1-HA and mGBA2-HA, the in 
vitro protocol was repeated and lipids were extracted using methanol/chloroform after 
incubating the samples with 6 µM pacSph for 1 h. The lipids were clicked to 3-azido-7-
hydroxycoumarin and analysed by TLC (Figure 86b). Quantification of the bands 
revealed that pacSph is partially, albeit not predominantly, metabolised to pacCer (14% 
of the total signal intensity versus 1.5% without incubation (Figure 86c). Thus, the 
amount of pacSph in the samples was decreased to 85% of the total signal intensity 
(Figure 86c). A minor part of pacSph was also metabolised to pacPC (increase in signal 
intensity from 0.02% to 1.6%) (Figure 86c). Thus, the bands visible in Figure 84 and 
Figure 85 arouse from pacSph.   
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Figure 86: Analysis of pacSph in protein lysates from delta SGPL1 HeLa cells transiently 
expressing mGBA1-HA and mGBA2-HA. Delta SGPL1 HeLa cells transiently expressing mGBA1-HA 
and mGBA2-HA were lysed and incubated with 6 µM pacSph for 1 h. (a) Western blot analysis using an 
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anti-HA specific antibody to detect GBA1 and GBA2 (Kremmer). Beta-tubulin was used as a loading 
control. (b) Lipids extracted from the cells were clicked to 3-azido-7-hydroxycoumarin and analysed by 
TLC at 404 nm. PacSph was partially metabolised to pacCer and pacPC. (c) Quantification of (b) 
expressed as % of total signal intensity. DAG: Diacylglycerol, GlcCer: Glucosylceramide, Cer: Ceramide, 
PE: Phosphatidylethanolamine, Deox-SA: Deoxysphinganine, PC: Phosphatidylcholine, SM: 
Sphingomyelin, pacSph: photoactivatable and clickable sphingosine. Data are presented as mean + 
SD. N numbers are indicated in brackets.  
3.16 Sphingosine – a “bioactive lipid” 
My results demonstrate that sphingosine binds to GBA2. However, sphingosine is also 
a “bioactive lipid” (Contreras et al., 2012). It either exerts its effect by directly binding 
to a protein and/or it indirectly changes the properties of cell membranes and, thereby, 
protein function. Sphingosine is a surface active agent (surfactant), which attains its 
function due to its amphipathic structure: The head group carries an amide and two 
hydroxyl groups, which represent the hydrophilic part, while the carbon tail is highly 
hydrophobic. Thus, sphingosine forms micelles above a critical micelle concentration 
(cmc) of 18 µM (Slavik, 1982). GBA2 activity is diminished in presence of detergents 
like Triton X-100 or sodium taurocholate (Körschen et al., 2013). Detergents solubilise 
membrane proteins by mimicking the lipid bilayer environment, but also severely 
change the properties of membranes themselves (le Maire et al., 2000). Their 
amphipathic nature enables them to incorporate into the lipid bilayer and, at 
concentrations around or greater than the cmc, to produce protein-detergent 
complexes as well as mixed micelles, consisting of detergent molecules and 
membrane lipids (le Maire et al., 2000). Why GBA2 activity is lost in presence of 
detergents is not known. Three scenarios could be envisioned: i) detergents solubilise 
a GBA2-binding protein that is necessary for the activity of the enzyme, just as GBA1 
needs saposin C to lift GlcCer from the luminal membrane of the lysosome to exert its 
activity (Alattia et al., 2006), or ii) detergents alter the membrane properties, e.g. the 
membrane curvature or integrity of distinct lipid platforms, preventing GBA2 from 
binding and sensing its substrate, or, finally, iii) detergents detach GBA2 from 
membranes. 
3.16.1 Establishing an immunoprecipitation protocol for GBA2 
Proteins interacting with GBA2 are not know. Thus, I set-out to first search for GBA2-
binding proteins. The method-of-choice to study protein-protein interaction is co-
immunoprecipitation, short co-IP (summarised in the Protein Interactions Handbook by 
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Thermo Fischer Scientific, 2010). Here, the protein of interest is isolated from a protein 
solution using a specific antibody that can be coupled to a matrix to “pull” the protein 
of interest out of the solution. Proteins strongly interacting with the protein of interest 
are isolated in a protein complex and can be identified by mass spectrometry. 
The basis for the co-IP is a GBA2-specific antibody. In the past, we have generated 
nine different monoclonal rat antibodies against four different mGBA2 peptides (Figure 
87 and Table 64) (Körschen et al., 2013). To immunoprecipitate GBA2 out of a protein 
solution, the anti-GBA2 antibody is coupled to a sepharose matrix. Sepharose 
(Separation-Pharmacia-Agarose) is the trade name for a cross-linked, beaded-form of 
agarose, a polysaccharide material extracted from seaweed (GE Healthcare). The link 
between the sepharose beads and the antibody is either protein A or G, two proteins 
that bind antibodies with high affinity (Bjorck&Kronvall, 1984). Both proteins bind to the 
IgG class of antibodies, but their binding properties differ among species and 
subclasses of IgG. Protein A prefers rabbit, pig, dog, and cat IgG, and protein G rather 
binds to human, mouse, and rat IgG. Thus, sepharose beads coupled to protein G 
were used (GE Healthcare).  
 
Figure 87: Topology of mouse GBA2. Monoclonal rat antibodies were generated against four different 
epitopes of mGBA2 (gray boxes, 1-4). Data published in Körschen et al. (Körschen et al., 2013). A 
polyclonal antibody against mGBA2 was produced in rabbit (Yildiz et al., 2006).   
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Table 64: Monoclonal rat antibodies generated against four different peptides of mGBA2. Data 
published in Körschen et al. (Körschen et al., 2013).  
Name Epitope/peptide Clone Species Isotype 
GBA2-1 1 3H8 Rat IgG2b 
GBA2-1 1 4A12 Rat IgG1 
GBA2-1 1 5A8/1 Rat IgG2b 
GBA2-1 1 8G4 Rat IgG2b 
GBA2-1 1 4F8 Rat IgG2c 
GBA2-2 2 4D7 Rat IgG2c 
GBA2-2 2 12F8 Rat IgG2c 
GBA2-2 2 2H1 Rat IgG2a 
GBA2-3 3 2F8 Rat IgG2b 
GBA2-4 4 5A8/4 Rat IgG2b 
 
In a first step, I tested, which of the aforementioned antibodies is the most specific one 
and shows the least cross reactivity to other proteins (Figure 88). Our monoclonal anti-
GBA2 antibodies are produced from hybridoma cells that are cell fusions of myeloma 
cells and B cells from rat spleen (Kohler&Milstein, 1975). There are five different 
antibody isotypes known, of which IgG is the most common one released by B cells. 
IgG can be further divided into four subclasses named IgG1, IgG2, IgG3, and IgG4, 
named in order of abundance in human serum with IgG1 being most abundant (Schur, 
1988). The four different subclasses differ in molecular mass, the amino acids present 
in the hinge region, and their antibody response to e.g. proteins or polysaccharides 
(Vidarsson et al., 2014).  
I tested all monoclonal rat antibodies besides 4A12, which had already been tested in 
a co-IP protocol, but failed in the quality control (Dr. D. N. Raju, unpublished data) and 
4F8, which does not detect GBA2 (unpublished data). Clones 8G4, 2H1, 2F8, and 
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5A8/4 were tested in a Western blot using hypotonic brain and testis lysates from 
control and GBA2-deficient mice (upper panel, Figure 88). As shown in Figure 88, all 
tested antibodies displayed a band slightly above the predicted molecular weight of 
103 kDa (NP_766280.2) in control samples, but not in samples from GBA2-deficient 
mice. Clone 8G4 showed additional, non–specific bands in control and GBA2-deficient 
samples at around 65 kDa and overall gave the highest background (upper panel, 
Figure 88). GBA2 detection by antibody clone 2H1 was very weak in both tested organs 
and there were non-specific bands in both, control and GBA2-deficient brains at around 
180 kDa. Clones 2F8 and 5A8/4 both showed some background in either brain or testis 
samples but overall, 2F8 gave very little background, but strong GBA2 band signals. 
Clones 3H8, 5A8/1, 4D7, and 12F8 were tested in a Western blot using hypotonic brain 
lysates from control and GBA2-deficient mice (lower panel, Figure 88). Clone 3H8 
showed nice bands in the control sample without any signal in the GBA2-deficient 
sample, but unfortunately predominant bands at around 50 kDa in lysates from both 
genotypes were observed (lower panel, Figure 88). This result was quite similar to 
clone 5A8/1, but the non-specific signal at 50 kDa was less pronounced (lower panel, 
Figure 88). Clones 4D7 and 12F8, however, did not label any protein (lower panel, 
Figure 88). Unfortunately, those antibodies with IgG subclasses that strongly bind to 
protein G (IgG2a: clone 2H1, IgG2c: clones 4F8, 4D7 and 12F8) did not or only poorly 
detect GBA2 in control brain lysates (Figure 88). Thus, I chose clone 2F8 for the 
experiment, even though protein G binding to IgG2b rat antibodies is supposed to be 
rather weak (Table 64 and Figure 88).   
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Figure 88: Test of monoclonal rat antibodies against mGBA2. Monoclonal antibodies summarised 
in Table 1 were tested for their specificity against mGBA2 in hypotonic brain and testis lysates from 
control and GBA2-deficient mice. A CHO cell lysate expressing mGBA1 and mGBA2 was used as 
positive control. WT: wild-type, KO: knockout.   
Next, anti-GBA2 antibody clone 2F8 was coupled to protein G sepharose and the 
efficiency of coupling was validated by Western blot analysis using a fluorescently-
labelled secondary anti-rat antibody (Figure 89). Figure 89 shows that less antibody 
was present in the supernatant after binding, demonstrating that some antibody had 
bound to the protein G coupled beads (2F8 antibody before and after, Figure 89). 
However, some antibody was lost during the following washing steps (W, Figure 89) 
and buffer exchange (ExB, exchange to boric acid, Figure 89), but after cross-linking 
the antibody to protein G via dimethylpimelimidate, there were no antibody signals 
detectable anymore on the Western blot, showing that the remaining antibody on the 
column was cross-linked (X, Figure 89). In a final step after exchanging the buffer to 
ethanolamine (ExE, Figure 89) and then to PBS (ExP, Figure 89), the column material 
was boiled to detect the antibody that is bound to the column. Indeed, antibody was 
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present, demonstrating that the 2F8 antibody was successfully cross-linked to the 
column (B, Figure 89, “2F8 column”).    
 
Figure 89: Coupling of monoclonal antibody clone 2F8 to protein G sepharose. Antibody clone 
2F8 was coupled to protein G sepharose by covalently cross-linking the antibody with the column 
material via demithylpimelimidate. After the cross-linking step, no antibody was washed off from the 
column; only when beads were boiled, the antibody was eluted. Eq: Equilibration step, pre: Previous, 
aft: After, W: Wash, ExB: Buffer exchange to boric acid, X: Cross-linking, ExE: Buffer exchange to 
ethanolamine, ExP: Buffer exchange to PBS, B: Beads, kDa: Kilo Dalton.   
The antibody to detect GBA2 after immunoprecipitation on the Western blot (“detection 
antibody”) needs to be preferably produced in a different animal species to avoid 
labelling of the heavy and light antibody chains of the 2F8 antibody used for 
immunoprecipitation. First, an anti-HA antibody produced in mouse (Sigma) was tested 
for detection on Western blot using lysates from control and mGBA2-HA over-
expressing CHO cells (#G4A11) (Dilution: Left: 1:5,000, right: 1:10,000, Figure 90). 
Unfortunately, the signals obtained from this antibody were very weak and also showed 
some non-specific background in the control cells (Figure 90).  
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Figure 90: Detection of GBA2 via an anti-HA antibody from mouse. Lysates from CHO control cells 
and cell stably over-expressing mGBA2 (15 µg/sample) and testis lysates from control and GBA2-
deficient mice (50 µg/sample) analysed by Western blot and the monoclonal rat antibody clone 2F8 (left) 
or an anti-HA antibody produced in mouse (Sigma, dilution on the left: 1:5,000, dilution on the right: 
1:10,000). Calnexin was used as loading control. Only very faint signals were detected using the anti-
HA antibody. WT: wild-type, KO: knockout, kDa: Kilo Dalton.    
I then tested a polyclonal anti-GBA2 antibody that was produced in rabbit (Yildiz et al., 
2006) on lysates from CHO control cells and different protein amounts of cells over-
expressing mGBA2-HA as well as on testis lysates from control and GBA2-deficient 
mice (Figure 91). The polyclonal anti-GBA2 antibody gave very nice signals in both, 
CHO cells and testis lysates without showing any signal in the GBA2-deficient sample 
(Figure 91). 
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Figure 91: Detection of GBA2 via a polyclonal anti-GBA2 antibody from rabbit. Lysates from CHO 
control cells and cell stably over-expressing mGBA2 (15 – 50 µg/sample) and testis lysates from control 
and GBA2-deficient mice (50 µg/sample) analysed by Western blot using and the anti-HA antibody from 
rat (left, Kremmer) or a polyclonal antibody produced in rabbit (Yildiz et al., 2006). Calnexin was used 
as loading control. The polyclonal anti-GBA2 antibody showed a clear staining in both, CHO cells and 
testis lysates, while not showing any signal in the GBA2-deficient sample. WT: wild-type, KO: knockout, 
kDa: Kilo Dalton.   
I started to establish the co-IP protocol using hypotonic lysates of CHO cells stably 
over-expressing mGBA2-HA (#G4A11) (Figure 92a). First, the protein lysate was 
incubated with protein G sepharose beads without the 2F8 antibody to remove proteins 
that non-specifically bind to the column material (Pre clearing step, Figure 92b). The 
pre-cleared protein lysate was then incubated with the 2F8 column material to allow 
antibody-GBA2 binding. On the next day, the non-bound proteins were collected (Flow-
through, Figure 92b) and the column was washed five times (Washes, Figure 92b) 
before proteins were eluted by adding SDS (E, Figure 92b). Likewise, proteins that had 
non-specifically bound to the empty column material (Pre-clearing step) were also 
eluted by SDS. The samples were analysed by Western blot using the polyclonal anti-
GBA2 antibody (Yildiz et al., 2006) (Figure 92b), which nicely labelled a band in protein 
lysates from CHO cells over-expressing mGBA2-HA (Figure 92b). There was no non-
specific binding to the protein G sepharose (Pre-clearing fraction, Figure 92b) but, 
unfortunately, GBA2 also did not bind to the 2F8 column (E, Figure 92b). Thus, almost 
all proteins from the input were recovered in the flow-through fraction (FT, Figure 92b).     
Results   173 
 
Figure 92: Immunoprecipitation of GBA2 in lysates from CHO cells stably over-expressing 
mGBA2 via anti-GBA2 antibody clone 2F8. Protein G sepharose beads covalently linked to 
monoclonal antibody clone 2F8 were incubated with hypotonic lysates of CHO cells stably over-
expressing mGBA2. Protein samples were subjected to Western blot analysis using a polyclonal 
antibody from rabbit against GBA2 (Yildiz et al., 2006). (a) Flow-chart of the experiment. (b) The anti-
GBA2 antibody showed that GBA2 did not bind to the column and was fully recovered in the flow-
through. There was no GBA2 band visible in the elution fraction. In: Input, Pre: Pre-incubation, FT: Flow-
through, E: Elution.          
To test whether presence of a detergent would favour specific binding of mGBA2-HA 
to 2F8, the same approach was repeated with total cell lysates (containing 1% Triton 
X-100) from CHO cells over-expressing mGBA2-HA (#G4A11) (Figure 93). Again, 
mGBA2-HA was still present in the column flow-through (FT, Figure 93), but the signal 
was weaker compared to the input (In, Figure 93), indicating that some GBA2 protein 
had bound to the column.  
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Figure 93: Immunoprecipitation of GBA2 from total protein lysates of CHO cells stably over-
expressing mGBA2 via anti-GBA2 antibody clone 2F8. Protein G sepharose beads covalently linked 
to monoclonal antibody clone 2F8 were incubated with total lysates from CHO cells stably over-
expressing mGBA2 containing Triton X-100 according to the text. Protein samples were subjected to 
Western blot analysis using a polyclonal antibody from rabbit against GBA2 (Yildiz et al., 2006). The 
anti-GBA2 antibody showed that GBA2 did not bind to the column even in presence of a detergent and 
was fully recovered in the flow-through. There was no GBA2 band visible in the elution fraction. In: Input, 
Pre: Pre-incubation, FT: Flow-through, E: Elution.      
Unfortunately, the elution fraction in both trials (Figure 92b and Figure 93) showed a 
high background staining that is probably due to cross-reactivity of the anti-rabbit 
secondary antibody with the 2F8 rat antibody being eluted from the column. To 
experimentally verify the cross-reactivity of the antibody, I ran pure 2F8 anti-GBA2 rat 
antibody on a SDS-PAGE, performed a Western blot, and incubated the blots with anti-
rabbit or anti-rat secondary antibodies, respectively (Figure 94). While the anti-rat 
antibody labelled the 2F8 antibody in a dose-dependent manner, the anti-rabbit 
antibody did not show any staining, meaning that the background on the previous 
Western blots was not due to cross-reactivity of the secondary antibody (Figure 94).   
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Figure 94: Analysis of the cross-reactivity of the anti-rabbit-IR800 secondary antibody. Western 
blot analysis of 0.4 – 20 µl pure clone 2F8 anti-GBA2 rat antibody and immunostaining with an anti-
rabbit or anti-rat secondary antibody. (a) The anti-rabbit secondary antibody did not recognise the 2F8 
antibody from rat, whereas (b) the anti-rat antibody labelled the 2F8 antibody in a dose-dependent 
manner. kDa: Kilo Dalton.  
To further test, where the strong background came from, I boiled and loaded pure 
protein G sepharose, the 2F8 column material, and an old elution fraction for 
comparison on a SDS gel, performed a Western blot, and incubated the blot with the 
polyclonal anti-GBA2 rabbit antibody (Figure 95). Here, the antibody did not show any 
non-specific binding to the pure column material, whereas the background bands 
appeared in the 2F8 column material, showing that the primary, polyclonal anti-GBA2 
antibody itself was responsible for the background signal (Figure 95). Thus, the 
combination of antibodies used so far did not allow to establish a GBA2 co-IP protocol.     
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Figure 95: Analysis of the cross-reactivity of the polyclonal anti-GBA2 rabbit antibody. Western 
blot analysis of pure 40 µl pure column material, 10 – 40 µl 2F8 column material, and an old elution 
fraction from 2F8 column material after boiling and immunostaining with the polyclonal anti-GBA2 
antibody from rabbit. The antibody did not bind non-specifically to the pure column material, whereas 
the background bands appeared in the 2F8 column material, showing that the primary, polyclonal anti-
GBA2 antibody itself was responsible for the background signal. kDa: Kilo Dalton.  
In a final approach, the co-IP strategy was changed as follows: protein G has high 
affinity for all mouse-derived antibodies; thus, the bead matrix was first coupled to an 
anti-rat-IgG2b antibody produced in mouse (green antibody in schematic, Figure 96a). 
Next, the monoclonal anti-GBA2 2F8 antibody from rat was bound to the column 
material via its interaction with the anti-rat-IgG2b antibody (black antibody in schematic, 
Figure 96a). The column was then incubated with a total brain lysate (NP-40/Igepal) 
from a control mouse overnight at 4 °C following the normal protocol (Figure 96). After 
performing an SDS-PAGE and Western blot, GBA2 was detected with the 2F8 
antibody, but three different HRP-coupled anti-rat secondary antibodies (Green: 
mouse-anti-rt-IgG2b, blue: goat-anti-rat-IgG, orange: mouse-anti-rat-kappa) to test, 
which secondary antibody shows the least background (Figure 96b-d). All three 
secondary anti-rat antibodies detected the heavy chains from the 2F8 column antibody 
in the elution fraction, with the anti-rt-IgG2b antibody showing the least background, 
but also no strong GBA2 band in the input lane (Figure 96b). The anti-rat-IgG2b 
antibody showed a very faint signal in the elution fractions, which could be at the same 
height as the input band. The anti-rat-IgG antibody clearly showed a GBA2 band in the 
input lane, but no signal at the same height in the elution fraction (Figure 96c). Lastly, 
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the anti-rat-kappa antibody gave the best result, while also detecting the heavy and 
light chain complexes of the column antibody (clone 2F8). However, there were bands 
visible in the elution fractions at the height of the mGBA2, indicating that this approach 
is suitable to immunoprecipitate GBA2 (Figure 96d). 
 
Figure 96: Immunoprecipitation of GBA2 using the same “column” and “detection” antibody. 
Incubation of a total brain lysate with protein G sepharose coupled to an anti-rat antibody produced in 
mouse and bound to the anti-GBA2 antibody clone 2F8 from rat. All fractions were analysed by Western 
blot using the GBA2-specific antibody clone 2F8. (a) Flow-chart of the experiment. (b) Decoration of 
antibody clone 2F8 with an HRP-coupled anti-rat-IgG2b secondary antibody. There were faint bands at 
around 120 kDa visible in the elution fraction. (c) Same as (b) using an anti-rat-IgG HRP-coupled 
secondary antibody. There was no GBA2 band visible in the elution. (d) As for (b) using an anti-rat-
kappa HRP-coupled secondary antibody. This antibody gave the clearest result with bands in the elution 
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fractions at around 120 kDa. In: Input, Pre: Pre-incubation, FT: Flow-through, C: Boiled column without 
protein lysate, E: Elution, B: Boiled beads, kDa: Kilo Dalton.      
To test whether these bands were indeed GBA2, the same approach was repeated 
using total brain lysates (NP-40/Igepal) from wild-type and GBA2-deficient mice 
(Figure 97). Although the detection of GBA2 worked in the input of the control, the 
results of the previous experiment could not be reproduced (Figure 97). Furthermore, 
there was a very faint band visible in the input and flow-through fraction of the GBA2-
deficient sample, suggesting that the animal was rather a heterozygous or wild-type 
animal or that there was non-specific binding of the antibody to a protein of a similar 
size, which would be due to a general detection problem using these antibodies 
(arrows, Figure 97b). Due to time limitations, the experiment was not further optimised. 
Thus, it is not clear yet whether a GBA2-binding protein is solubilised in presence of 
sphingosine, which would explain the reduction of GBA2 activity in presence of 
sphingoid bases. 
 
Figure 97: Immunoprecipitation of GBA2 from total brain lysates from control and GBA2-
deficient mice via anti-GBA2 antibody clone 2F8. Total brain lysates containing NP-40 were 
incubated with the 2F8 column material and processed as previously mentioned. Western blot analysis 
and immunostaining using the anti-GBA2 antibody clone 2F8 and the HRP-coupled secondary anti-rat-
kappa antibody to test the presence of GBA2 in (a) control and (b) GBA2-deficient brain lysates. (a) 
There were signals of different intensities visible in the input and flow-through fraction of the control 
sample, suggesting that some GBA2 had bound to the column. (b) There was also a very faint band 
visible in the input and flow-through fraction of the GBA2-deficient sample, suggesting that this animal 
was rather heterozygous. In both samples, no GBA2 bands was detectable in the elution fraction. In: 
Input, Pre: Pre-incubation, FT: Flow-through, C: Boiled column without protein lysate, E: Elution, B:  
Boiled beads, kDa: Kilo Dalton.  
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3.16.2 Recovery of GBA2 activity is similar at membranes derived from 
control and GBA1-deficient cells 
As previously stated, surfactants like sphingosine alter the membrane properties, e.g. 
by changing the membrane curvature or by modifying the composition of distinct lipid 
platforms, preventing GBA2 from binding and sensing its substrate (Contreras et al., 
2006). We have shown that the membrane surrounding is crucial for the activity of 
GBA2 (Körschen et al., 2013). When separating a protein lysate into a membrane and 
soluble fraction, GBA2 was partially recovered in the supernatant. However, GBA2 
activity was barely detectable in the supernatant. In Körschen et al., we demonstrated 
that addition of membranes from GBA2-deficient brain “rescued” the GBA2 activity in 
the soluble fraction, underlining the importance of membranes for the activity of GBA2 
(Körschen et al., 2013). Thus, I wondered whether a local increase of sphingosine in 
GBA1-deficient cells could alter the membrane properties and in turn, diminish GBA2 
activity at the membrane. 
To test this hypothesis, the recovery of GBA2 activity in supernatants from HEK293 
cells stably over-expressing mGBA2 was analysed by adding membranes from control, 
GBA1-deficient, or GBA2-deficient HAP1 cells (Figure 98). HEK293 cells stably over-
expressing mGBA2 were lysed and proteins were separated into a soluble and 
membrane fraction by ultracentrifugation. I followed the distribution of mGBA2 after 
ultracentrifugation by Western blot analysis: GBA2 was detected in both, the 
membrane and the soluble fraction (Figure 98a). The GBA2 activity measured in both 
fractions did not sum up to the total input activity, underlining that GBA2 activity is lost 
in absence of membranes (Figure 98b). Next, membranes from either control, GBA1-
deficient, or GBA2-deficient HAP1 cells were added in equal amounts to the 
supernatant of HEK293 cells stably over-expressing mGBA2 (Figure 98c). Of note, the 
endogenous GBA2 activity in HAP1 cells was negligible compared to over-expressed 
mGBA2 in the HEK293 cell supernatants. Addition of membranes slightly boosted the 
GBA2 activity from 19% (HEK293 supernatant only) to 29-30% (Figure 98c). There 
was no difference in activity between membranes from control, GBA1-deficient, or 
GBA2-deficient HAP1 cells, showing that GBA2 seems to exhibit equal activity at both, 
control and GBA1-deficient membranes (Figure 98c).        
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Figure 98: GBA2 activity in the absence or presence of membranes. HEK293 cell lysates stably 
over-expressing mGBA2 were subjected to ultracentrifugation to separate soluble GBA2 from 
membrane-associated GBA2. The distribution of GBA2 was analysed by Western blot using an anti-HA 
antibody (Kremmer). GBA2 activity was assayed in hypotonic lysates in presence of 1.67 mM 4-MUG. 
(a) GBA2 was found in both, the membrane fraction and the soluble fraction after ultracentrifugation. (b) 
GBA2 is less active in the absence of membranes. (c) To recover GBA2 activity, membrane fractions 
from HAP1 control cells and cells deficient for either GBA1 or GBA2 were added. All three HAP1 cell 
lines possessed very low endogenous GBA2 activity. Addition of membrane fractions resulted in an 
equal increase in GBA2 activity from 19% to 29-30%. 4-MUG: 4-Methylumbelliferyl beta-D-
glucopyranoside. Data are presented as mean + SD. N numbers are indicated in brackets. P values 
were determined using Student’s t-test (b) and One-way ANOVA (c).       
3.16.3 GBA2 is sensitive to lipids with detergent-like properties 
Besides being a membrane lipid, sphingosine also possesses sufficient aqueous 
solubility to move between membranes (Hannun&Obeid, 2008). Thus, Khan et al. have 
estimated that around 70% of intracellular sphingosine resides in membranes at 
physiological pH, whereas the remaining 30% are soluble (Khan et al., 1991). Higher 
cytoplasmic levels of sphingosine might not only incorporate into adjacent membranes 
and change its local properties, but could also be present in solution. As previously 
mentioned, Slavik and co-workers showed that sphingosine forms micelles above a 
cmc of 18 µM (Slavik, 1982). This concentration is very similar to the IC50 of 25.04 ± 
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0.2 µM of sphingosine inhibition of GBA2 in GBA2-expressing bacteria lysates (see 
Figure 52). As the effect that I saw was reversible (Figure 58) and non-competitive (see 
Figure 59 and Figure 60), I wondered whether the inhibition of GBA2 activity upon 
addition of sphingosine might be due to a detergent-like effect of sphingosine. Thus, 
sphingosine could also exert its surfactant activity by forming detergent-protein 
complexes with soluble GBA2 itself and, thereby, preventing it from being active at a 
membrane.  
To test this hypothesis, I searched for an amphipathic lipid that exerts similar surfactant 
properties as sphingosine, but is not involved in glycosphingolipid metabolism. C16 
carnitine (palmitoylcarnitine, 3-(palmitoyloxy)-4-(trimethylammonio) butanoate) is 
present in all animal species, many microorganisms, and also in some plants, and is 
required during fatty acid oxidation in mitochondria (Bremer, 1983; Fritz, 1955). To test 
whether the activity of GBA2 is also sensitive to a sphingosine-like molecule with a 
similar cmc, I analysed the effect of C16 carnitine on GBA2 activity in bacterial lysates 
(Figure 99). C16 carnitine is a long-chain fatty acyl ester with a cmc of 10 µM (Goni et 
al., 1996). Adams and co-workers have shown that this structural sphingosine 
analogue initiates changes in the structure and function of the cardiac sarcoplasmic 
reticulum and the sarcolemmal Na+-K+-ATPase, while functioning as a “natural 
occurring detergent” (Adams et al., 1979). Echabe et al. showed that C16 carnitine 
induced alterations in membrane fluidity of erythrocytes (Echabe et al., 1995). Requero 
and co-workers showed that C16 carnitine that is added to a liposome suspension 
becomes almost completely membrane-bound, while the concentration of free C16 
carnitine approaches the cmc (Requero et al., 1995). When analysing the GBA2 
activity in the presence of C16 carnitine, a dose-dependent inhibition of GBA2 activity 
with an IC50 of 31.31 ± 2.68 µM was determined (Figure 99). Thus, C16 carnitine as a 
surfactant might form protein-detergent complexes with GBA2 and, thereby, hinders it 
from being active at the membrane. Of note, as previously seen for 
sphingosine/sphinganine and GBA1 (compare Figure 52, Figure 53, and Figure 61), 
C16 carnitine did not evoke a full block of GBA2 activity even at high concentrations 
(Figure 99). Because of its lipid properties, C16 carnitine (and sphingosine, 
sphinganine) might cluster at higher concentrations and, therefore, loses its effect on 
GBA2.   
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Figure 99: Dose-response relationship of GBA2 to C16 carnitine. Analysis of the GBA2 activity in 
bacterial lysates over-expressing mGBA2 in presence of a serial dilution of C16 carnitine and 1.67 mM 
4-MUG at pH 6. Data were normalised to a non-treated control. (a) Structure of C16 carnitine. (b) The 
IC50 for C16 carnitine in bacterial lysates over-expressing mGBA2 was 31.31 ± 2.68 µM. Representative 
plot for n = 3 experiments, data are presented as mean of quadruples ± SD. 
3.16.4 Detergent-like properties of lipids detach GBA2 from membranes 
Previous experiments have shown that soluble GBA2 is equally active at membranes 
obtained from HAP1 control and GBA1-deficient cells, suggesting that there is no 
change in intra-membranous sphingosine levels or, if so, that this does not affect the 
activity of GBA2 (compare 3.16.2). As mentioned above, around 30% of sphingosine 
in the cell are soluble (Khan et al., 1991). Results from the dose-response analysis of 
GBA2 and C16 carnitine showed that lipids with similar chemical properties like 
sphingosine might form protein-lipid/detergent complexes, which could interfere with 
GBA2 finding/binding to its substrate at the membrane (compare 3.16.3). Thus, 
increased amounts of soluble sphingosine might detach GBA2 from the membrane in 
GBA1-deficient cells.  
To test this hypothesis, wild-type and GBA1-deficient HAP1 cells transiently 
expressing mGBA2 were lysed and proteins were separated into a soluble and 
membrane fraction by ultracentrifugation (3.16.2). mGBA2 was detected in both, the 
membrane and the soluble fraction, whereas the mGBA2 signal was a bit stronger in 
the soluble fraction of the GBA1-deficient samples compared to the wild-type control 
(Figure 100a). I quantified the band signals, normalised the signals from the soluble 
fraction to the input fraction, and compared the ratios between samples with a wild-
type and a GBA1-deficient background. Interestingly, there was significantly more 
mGBA2 present in the soluble fractions from GBA1-deficient cells compared to wild-
type cells compared to the respective input. This means that less GBA2 is bound to 
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the membrane, resulting in less active GBA2 present in GBA1-deficient cells (Figure 
100b). Of note, the input was similar in wild-type and GBA1-deficient samples (Figure 
100c). These results suggest that increased amounts of (soluble) sphingosine in 
GBA1-deficient cells form reversible lipid-protein complexes with GBA2, which 
disables the binding of GBA2 to the membrane and, thereby, reduces its enzymatic 
activity.           
          
 
Figure 100: GBA2 membrane-association in HAP1 control and GBA1-deficient cells. HAP1 cell 
lysates transiently expressing mGBA2 were subjected to ultracentrifugation to separate soluble GBA2 
from membrane-associated GBA2. The distribution of GBA2 was analysed by Western blot using an 
anti-HA antibody (Kremmer). CHO cells stably expressing mGBA2-HA were used as a positive control. 
(a) The GBA2 signal in the soluble fraction of the GBA1-deficient sample was slightly stronger than in 
the control sample. (b) Ratio of mGBA2 signals in the soluble compared to the input fraction in wild-type 
and GBA1-deficient samples. The amount of mGBA2 in the soluble fraction of GBA1-deficient HAP1 cell 
lysates was significantly increased compared to control cells. (c) The input signal intensity is similar in 
wild-type and GBA1-deficient samples. WT. Wild-type, KO. Knockout, kDa: Kilo Dalton, CHO: Chinese 
hamster ovary cells. Data are presented as mean + SD. N numbers are indicated in brackets. 
Representative Western blot for n = 3 experiments. P values were determined One-way ANOVA.               
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4 Discussion 
4.1 The effect of GBA1 on GBA2 activity 
In my PhD thesis, I have demonstrated that the GBA2 activity is reduced in genetic 
and pharmacologic models that lack active GBA1 in vitro and in vivo. Mistry et al. 
proposed that accumulating GlcCer and GlcSph spill over into the cytoplasm in GBA1-
deficient cells, which leads to a breakdown of these metabolites by GBA2 and an 
increase in cytotoxic sphingosine (Mistry et al., 2014). I could show that sphingosine 
directly binds to GBA2 and inhibits its activity.  
Based on the findings presented in this study, I developed the following model 
underlying the GBA1-dependent regulation of GBA2 activity in Gaucher cells (Figure 
101): In wild-type cells, GBA1 breaks GlcCer down to glucose and ceramide in the 
lysosome, whereas an acid ceramidase cleaves GlcCer to GlcSph and a fatty acid. 
GBA2 cleaves GlcCer to glucose and ceramide at the cis Golgi and the ER. In Gaucher 
cells, GBA1 is almost inactive, resulting in the accumulation of GlcCer and GlcSph in 
the lysosome. Both metabolites spill over into the cytoplasm, where they become a 
substrate for GBA2. Here, GBA2 breaks GlcCer and GlcSph down to release ceramide 
and sphingosine, whereas ceramide is further broken down to sphingosine and a fatty 
acid by a neutral ceramidase, resulting in the cytoplasmic accumulation of cytotoxic 
sphingosine. Application of NB-DNJ/Zavesca in Gaucher disease inhibits both, 
GlcCerS and GBA2, resulting in fewer production of GlcCer and reduction in 
cytoplasmic sphingosine levels. 
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Figure 101: The GBA1-dependent regulation of GBA2 activity in Gaucher disease. The model is 
decribed in the text. ER: Endoplasmic reticulum, GlcCer: Glucosylceramide, GBA1: acid beta-
glucosidase, GBA2: non-lysosomal beta-glucosidase, GlcSph: Glucosylsphingosine, FA: Fatty acid, 
GlcCerS: Glucosylceramide synthase, NB-DNJ: N-butyl-deoxynojirimycin.   
4.2 The GBA1-dependent control of GBA2 activity – a closer look 
4.2.1 Mimicking the effect of sphingosine on GBA2 activity 
To demonstrate that sphingosine is indeed the metabolite that regulates GBA2 activity, 
cytoplasmic sphingosine levels can be increased by either feeding cells with 
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sphingosine or over-expressing an enzyme that is involved in sphingosine metabolism. 
The former has already been tried in this study, where incubation of GBA1-deficient 
cells with 20 µM sphingosine resulted in a decrease in GBA2 activity (see Figure 41). 
The latter could be done by over-expression of neutral ceramidase (EC 3.5.1.23), 
which cleaves ceramide to release fatty acids and sphingosine (El Bawab et al., 2000).  
Besides the recent finding that sphingosine serum levels are elevated in GBA1-
deficient mice (Mistry et al., 2014), both, sphingosine and sphinganine, have previously 
been reported to be accumulating in different lysosomal storage disorders. However, 
the underlying molecular mechanisms are ill-defined. Sphinganine levels are increased 
in liver from CerS2-deficient mice (Pewzner-Jung et al., 2010). In CerS2-deficient liver, 
GBA2 was slightly less active compared to control livers, but the change was not 
significant (Figure 37). Thus, sphinganine levels were most likely not high enough to 
evoke an effect on GBA1 and/or GBA2 activity, e.g. because the total amount of 
sphinganine was diluted during sample preparation and performance of the activity 
assay. Sphingosine accumulates in the lysosomes of macrophages treated with 
U18666A, a drug that is used to pharmacologically induce a Niemann-Pick type C (NP-
C) phenotype in cells (Lloyd-Evans et al., 2008), but is also known to accumulate in 
brain, liver, and spleen from NP-C-deficient mice (te Vruchte et al., 2004). My data 
show that both, GBA1 and GBA2 activity, are significantly reduced in dermal fibroblasts 
from NP-C patients (Figure 36). Thus, it is difficult to distinguish between a GBA1-
dependent and -independent effect on GBA2 activity because GBA1 activity was also 
reduced. However, under acidic conditions, sphingosine is protonated (pKa of 8.9) 
(Kagedal et al., 2001) and cannot leave the lysosome unless actively shuttled by e.g. 
a transporter (Lloyd-Evans et al., 2008). Thus, it is unlikely that the GBA2 activity is 
reduced due to increased levels of sphingosine in NP-C cells. However, my data also 
show that GBA1 is sensitive to sphingosine (compare Figure 40 and Figure 61) 
(Erickson et al., 1985; Grabowski et al., 1985). Thus, the accumulation of sphingosine 
in lysosomes of NP-C cells could block GBA1, leading to accumulation of GlcCer and, 
thereby, to a reduction of GBA2 activity in a GBA1-dependent manner. Of note, during 
my binding studies with pacSph, GBA1 did not directly bind to sphingosine, in contrast 
to what Dr. P. Haberkant observed (personal communication, non-published data). 
This result is puzzling because sphingosine and sphinganine blocked GBA1 in a dose-
dependent manner (Figure 61).      
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4.3 Reversing the GBA1-dependent effect on GBA2 activity 
To restore GBA2 activity in a GBA1-dependent manner, I over-expressed mGBA1 in 
GBA1-deficient cells. However, GBA1 activity could not be fully restored. Accordingly, 
the GBA2 activity remained unchanged. Two main factors are known, which are crucial 
for the activity of GBA1: Its glycosylation pattern and the presence of saposin C, which 
catalyses the binding of GBA1 and GlcCer at the membrane (Alattia et al., 2006; 
Bergmann&Grabowski, 1989). Thus, heterologously expressed GBA1 might not be 
fully glycosylated, resulting in protein expression but very little activity.      
Another approach would be to feed recombinant GBA1 (imiglucerase or Cerezyme, 
Genzyme Corporation, Cambridge, MA, USA) to cells. Imiglucerase carries mannose-
type oligosaccharide side chains, which bind to mannose receptors present on the cell 
surface of e.g. macrophages and fibroblasts (Bergmann&Grabowski, 1989; Sheikh et 
al., 2000). Once internalised, imiglucerase reaches the lysosome via the endocytic 
pathway. Because of its high water solubility, I tested the activity of imiglucerase under 
our assay conditions. Imiglucerase (Cerezyme Finished Product, Part No 4285, 
obtained from E. Monlleó Mas, Institute of Advanced Chemistry of Catalonia, Spain) 
was dissolved to a concentration of 0.2 mg/ml in hypotonic buffer and analysed at pH 
4, 5, 6, and 7 to find its optimal pH value (Figure 102). The enzyme was only active at 
pH 5 and the activity was partially blocked by 25 µM CBE, but insensitive to 8.3 µM 
NB-DNJ (Figure 102). To study the GBA1-dependent effect on GBA2 activity in more 
detail, GBA1-deficient cells could be fed with imiglucerase to increase the amount of 
active GBA1 and, thereby, restore GlcCer and GlcSph levels to control levels.  
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Figure 102: Imiglucerase activity at different pH values. Imiglucerase was dissolved to 0.2 mg/ml in 
hypotonic buffer and analysed at pH 4, 5, 6, and 7 in presence of 1.67 mM 4-MUG. There was no CBE-
blockable activity detectable at pH 4, 6, and 7 but robust activity at pH 5, which was partially blockable 
by CBE. 4-MUG: 4-Methylumbelliferyl beta-D-glucopyranoside, CBE: Conduritol B epoxide. Data are 
presented as mean + SD of quadruples. The N number is indicated. 
4.4 Regulation of GBA2 
Results presented in this study show that sphingosine reversibly binds to an allosteric 
site of GBA2, which results in mixed-type enzyme inhibition (see 3.14.4). Even though 
GBA2 was first purified from human liver in 1997 and cloned in 2001, little is known 
about its functional domains and no crystal structure has been published so far (Matern 
et al., 2001; Matern et al., 1997). Thus, it is difficult to predict an allosteric site 
controlling lipid-dependent regulation of GBA2 activity. Data presented by others but 
also in this study (Figure 40 and Figure 61) show that GBA1 is also sensitive to 
sphingosine (Erickson&Radin, 1973; Grabowski et al., 1985). As previously mentioned, 
three domains are crucial for GBA1 activity, of which one interacts with sphingosine 
derivatives (Grabowski et al., 1986). This third domain was found to reversibly bind to 
sphingosine with an IC50 value of 40 µM (Grabowski et al., 1985). Interestingly, mutated 
GBA1 obtained from different Gaucher patients either showed similar behaviour 
towards sphingosine, or, in some cases, the sphingosine concentration had to be 
fivefold greater to achieve a half-maximal enzyme inhibition (Grabowski et al., 1985). 
Thus, point mutations, which result in an amino acid exchange in close proximity to the 
third domain of GBA1, seemed to reduce sphingosine binding (Grabowski et al., 1985). 
Likewise, point mutations could be introduced into the GBA2 gene to identify residues 
that are crucial for aglycon binding. Unfortunately, truncated or mutated forms of GBA2 
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are inactive and single point mutations already result in a complete loss of GBA2 
activity (Sultana et al., 2015) (personal observation in our lab). Recently, the crystal 
structure of a glycoside hydrolase family GH116 enzyme from the bacterium 
Thermoanaerobacterium xylanolyticum has been solved. The protein shares 40% 
sequence identity with the predicted catalytic domain of human GBA2, but does not 
cleave GlcCer (Charoenwattanasatien et al., 2016). Instead, the enzyme hydrolyses 
alkyl glycosides, including n-heptyl glucoside and n-octyl glucoside. Its structure 
supports the peripheral membrane localisation of GBA2 that we have also described 
previously (Körschen et al., 2013). Interestingly, loss-of-function mutations similar to 
those found in GBA2 also showed loss of activity, most likely due to reduced substrate 
binding and reduced enzyme stability (Charoenwattanasatien et al., 2016). Thus, a 
crystal structure of GBA2 is needed to study its regulatory domains in more detail. 
4.5 The function of GBA2 in the cell 
Since degradation of most GSLs occurs through GBA1 in the lysosomes, the cellular 
function of GBA2 is a matter of ongoing debate. GBA2 is associated with membranes 
at the cytosolic side of the cis Golgi and the ER, where it cleaves GlcCer to glucose 
and ceramide (Körschen et al., 2013). Thus, GBA2 is localised in close proximity to 
GlcCerS and the synthesis pathway of its substrate, GlcCer (Schweizer et al., 1994), 
suggesting that GBA2 could be a “fine-tuner” for intracellular GlcCer levels. However, 
the fact that the GBA2 activity remains unchanged in complete absence of GlcCer 
argues against GBA2 being a sensor for GlcCer levels at the Golgi and ER membrane 
(see Figure 39). 
To date, the function of GBA2 can only be described by the effect of its loss and the 
subsequent accumulation of GlcCer. Loss of GBA2 activity in pharmacologic and 
genetic models results in impaired male fertility caused by accumulation of GlcCer, 
which alters cytoskeletal dynamics during sperm development (Raju et al., 2015; van 
der Spoel et al., 2002; Yildiz et al., 2006). Thus, GBA2 might indeed primarily function 
as a regulator of GlcCer levels in membranes at the Golgi and the ER, which, in turn, 
could affect downstream signalling pathways. It is well known that membrane lipid 
composition determines its characteristics and directly controls protein function (van 
Meer et al., 2003). Depletion of cholesterol enhances auto-phosphorylation of the EGF 
receptor (epidermal growth factor receptor), leading to an increase in tyrosine kinase 
activity (Pike&Casey, 2002). Furthermore, it has been shown that GM3 can regulate 
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the transition from an inactive to an active EGF receptor independent from ligand 
binding (Coskun et al., 2011). 
In a previous study, we have shown that the accumulation of GlcCer in membranes 
derived from GBA2-deficient cells leads to more ordered lipid packaging, which 
seemed to affect the activity of proteins in or at the membrane (Raju et al., 2015). Since 
GBA2 is associated with the Golgi membrane, I wondered whether accumulation of its 
substrate, GlcCer, would also occur in Golgi membranes. Thus, I tried to establish an 
immunogold labelling protocol using an anti-GlcCer antibody that has previously been 
used to study the subcellular localisation of GlcCer (Brade et al., 2000; Vielhaber et 
al., 2001). Unfortunately, my experiments revealed that the anti-GlcCer antibody 
neither recognised GlcCer in control cells nor in DOPC liposomes containing GlcCer 
(see 3.15.1). Thus, I could not reveal, where GlcCer accumulates in GBA2-deficient 
cells.  
Sorli et al. have demonstrated that GBA2 is down-regulated in melanoma cells (Sorli 
et al., 2013). In turn, heterologous expression of GBA2 in melanoma cells led to 
degradation of GlcCer, accompanied by UPR-dependent apoptosis and reduced 
tumour growth (Sorli et al., 2013). In a different study, it was recognised that GlcCerS-
deficient cells (also used in Figure 39) were incapable of forming melanin, the pigment 
found in skin cells, even though all enzymes associated with pigmentation were 
present in these cells (Sprong et al., 2001). Interestingly, lack of GlcCer (and more 
complex GSLs) resulted in a mis-localisation of tyrosinase, an enzyme that is required 
in melanosomes, but was retained in the Golgi in GlcCerS-deficient cells. Heterologous 
expression of GlcCerS in GlcCerS-deficient cells restored pigmentation, whereas 
exogenous addition of GlcCer did not (Sprong et al., 2001). In total, these and other 
reports demonstrate that homeostasis of GSLs, and GlcCer in particular, is needed to 
maintain even basic cellular functions. Here, GBA2 as a non-lysosomal beta-
glucosidase has become a key enzyme in the field of GSL research (Aureli et al., 
2016).  
4.6 GBA2 in Gaucher disease 
Besides the present study, other reports have also analysed GBA2 activity in the 
context of Gaucher disease, showing an increase in GBA2 activity in brain from GBA1-
deficient mice and in fibroblasts from Gaucher disease patients (Aureli et al., 2012; 
Burke et al., 2013). These results are in contrast to my findings and the reason for this 
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discrepancy is not known. One explanation could be a difference in the experimental 
set-up and how GBA2 activity was measured. However, in none of the in vitro or in 
vivo models that I tested, GBA2 expression or activity was higher in the absence of 
GBA1, arguing against earlier findings described above. 
Analysis of the GBA2 activity in dermal fibroblasts from Gaucher type I, II, and III 
patients revealed that the GBA2 activity is similarly reduced in patients with a different 
genotypic and phenotypic background of the disease (Figure 14). From this I 
concluded that GBA2 does not play a role in genotype-phenotype correlation of 
Gaucher disease. However, even though the residual GBA2 activity might be equal in 
all tested patient cell lines, the effect of its partial loss might vary in the different 
phenotypes. As previously mentioned, type I Gaucher patients obtain a daily infusion 
of NB-DNJ/Zavesca (Actelion Pharmaceuticals, Basel, Switzerland) during substrate 
reduction therapy (SRT, also see 1.1.4.1.4) to block GlcCerS and subsequently reduce 
accumulation of GlcCer. According to dose-response analyses performed in our lab 
and also by others, treatment with NB-DNJ in the aforementioned concentration should 
completely inhibit GBA2 in Gaucher patients. According to my model presented above, 
the beneficial effect of NB-DNJ treatment might not only be due to a reduction in 
GlcCer, but also due to a reduction in GBA2 activity and, hence, the reduction of 
cytotoxic sphingosine levels (Figure 101). This hypothesis also matches the data 
generated by Mistry et al., who could reverse some of the symptoms previously seen 
in their type I Gaucher mouse by either applying NB-DNJ or genetically knocking out 
GBA2 (Mistry et al., 2014).  
On the other hand, SRT does not exert a beneficial effect in the treatment of type II 
Gaucher patients suffering from severe neurologic conditions. Of note, NB-
DNJ/Zavesca does not cross the blood-brain barrier (Coutinho et al., 2016). Still, the 
endogenous GBA2 activity is reduced in cells from type II Gaucher patients via the 
mechanism presented in this study. It has been shown that the GBA2 activity increases 
during neuronal differentiation, suggesting an important role for GBA2 during neuron 
development (Aureli et al., 2012). Furthermore, knock-down of GBA2 in zebrafish 
larvae resulted in abnormalities in motor behaviour and axonal outgrowth of motor 
neurons (Martin et al., 2013). GBA2 loss-of-function mutations have recently been 
connected to neuronal disorders such as hereditary spastic paraplegia and autosomal-
recessive cerebellar ataxia with spasticity, underlining the importance of GBA2 in 
neuron function (Citterio et al., 2014; Hammer et al., 2013; Martin et al., 2013; Sultana 
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et al., 2015; Votsi et al., 2014). Thus, the probably beneficial effect of reduced GBA2 
activity in type I Gaucher patients might be the opposite in type II and III patients 
suffering from neurologic symptoms. Here, a PDMP (1-phenyl-2-decanoylamino-3-
morpholino-1-propanol)-based compound capable of crossing the blood-brain barrier 
might be of great advantage to reduce accumulation of GlcCer without further reducing 
the activity of GBA2, since PDMP inhibits GlcCerS, but not GBA2 (Shayman&Larsen, 
2014). 
In conclusion, the present study reveals the regulation of GBA2 activity by sphingosine 
in Gaucher disease. Thus, my results add a new chapter to the understaning of the 
molecular mechanisms underlying Gaucher disease pathology, presenting new ideas 
for the therapy of this severe lysosomal storage disorder.  
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